



Comprehensive Formulary

(List of covered drugs)

MEDIDUAL

2024

January 1st - December 31st

This formulary was updated on 03/19/2024. For more recent information or other questions, please contact Leon Health's Member Services Department at the toll-free number (844) 969-5366, or our local number (305) 541-5366. (TTY users should call 711). Hours of operation are from 8 a.m. to 8 p.m., seven days a week from October 1st through March 31st, and Monday through Friday the rest of the year, or visit www.leonhealth.com.

Leon Health is an HMO plan with a Medicare Contract. Enrollment in Leon Health, Inc. depends on contract renewal.

H4286_FORMULARY002_2024_C

Leon Health, Inc.

Leon MediDual

2024 Formulary

List of Covered Drugs

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

Formulary ID 24548, Version 16

This formulary was updated on 03/19/2024. For more recent information or other questions, please contact Leon Health, Inc. Member Service at 844-9-MY-LEON (1-844-969-5366) or local at 305-541-LEON (305-541-5366) for additional information. (TTY users should call 711), Hours are from 8 a.m. to 8 p.m., seven days a week from October 1st through March 31st and Monday through Friday from April 1st through September 30th or visit www.leonhealth.com.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Leon Health, Inc. When it refers to “plan” or “our plan,” it means Leon Health, Inc. This document includes a list of the drugs (formulary) for our plan which is current as of 04/01/2024. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, each year, and from time to time during the year.

What is the Leon Health, Inc. Formulary?

A formulary is a list of covered drugs selected by Leon Health, Inc. in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Leon Health, Inc. will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Leon Health, Inc. network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand-name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand-name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand-name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can find information in the section below titled “How do I request an exception to the Leon Health, Inc.’s Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to the market to replace a brand-name drug currently on the formulary or add new restrictions to the brand-name drug or move it to a different cost-sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.
 - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Leon Health, Inc.’s Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2024 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2024 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs. The enclosed formulary is current as of April 2024. To get updated information about the drugs covered by Leon Health, Inc. please contact us. Our contact information appears on the front and back cover pages. If there are significant changes made to the printed drug list within the covered year, you may be notified by mail identifying the changes. Drug lists located on our website are reviewed and updated monthly. You can visit www.leonhealth.com.

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 10. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, cardiovascular agents. If you know what your drug is used for, look for the category name in the list that begins on page 8. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 158. The Index provides an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Leon Health, Inc. covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization (PA):** Leon Health, Inc. requires you [or your physician] to get prior authorization for certain drugs. This means that you will need to get approval from Leon Health, Inc. before you fill your prescriptions. If you don't get approval, Leon Health, Inc. may not cover the drug.
- **Quantity Limits (QL):** For certain drugs, Leon Health, Inc. limits the amount of the drug that Leon Health, Inc. will cover. For example, Leon Health, Inc. provides 30 tablets every 30 days per prescription for atorvastatin. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy (ST):** In some cases, Leon Health, Inc. requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Leon Health, Inc. may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Leon Health, Inc. will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 10. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior

authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Leon Health, Inc. to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, “How do I request an exception to the Leon Health, Inc.’s formulary?” on page 4 for information about how to request an exception.

What are over-the-counter (OTC) drugs?

OTC drugs are non-prescription drugs that are not normally covered by a Medicare Prescription Drug Plan. Leon Health, Inc. pays for certain OTC drugs. Leon Health, Inc. will provide these OTC drugs at no cost to you. The cost to Leon Health, Inc. of these OTC drugs will not count toward your total Part D drug costs (that is, the cost of the OTC drugs does not count for the coverage gap).

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered. If you learn that Leon Health, Inc. does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by Leon Health, Inc. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by Leon Health, Inc.
- You can ask Leon Health, Inc. to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Leon Health, Inc.’s Formulary?

You can ask Leon Health, Inc. to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, Leon Health, Inc. limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, Leon Health, Inc. will only approve your request for an exception if the alternative drugs included on the plan’s formulary, the lower cost-sharing drug or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects. You should contact us to ask us for an initial coverage decision for a formulary, tier, or utilization restriction exception. **When you request a formulary, tier, or utilization restriction exception you**

should submit a statement from your prescriber or physician supporting your request.

Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

Current members that need a one-time emergency fill or that are prescribed a non-formulary drug as a result of a level of care change will be placed in transition and we will allow a one-time 31-day supply (unless the prescription is written for fewer days). If you are admitted or readmitted into a Long-Term Care facility and you need a medication that is not on our drug list or has a limitation, you will be eligible to receive a 31-day emergency supply of that drug while you pursue a drug list exception or prior authorization.

For more information

For more detailed information about your Leon Health, Inc. prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Leon Health, Inc., please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

Leon Health, Inc. formulary provides coverage information about the drugs covered by Leon Health, Inc. If you have trouble finding your drug in the list, turn to the Index that begins on page 158. The first column of the chart lists the drug name. Brand-name drugs are capitalized (e.g., JUXTAPID) and generic drugs are listed in lower-case italics (e.g., gemfibrozil).

The information in the Requirements/Limits column tells you if Leon Health, Inc. has any special requirements for coverage of your drug.

Leon MediDual

| Tier | Preferred retail cost sharing (30-day supply) | Standard retail cost sharing (30-day supply) |
|-----------------------------------|---|--|
| Tier 1: Generic Drugs | \$0 copay | \$0 copay |
| Tier 2: Preferred Brand Drugs | \$0 copay | \$0 copay |
| Tier 3: Non-Preferred Brand Drugs | \$0 copay | \$0 copay |
| Tier 4: Specialty Tier | \$0 copay | \$0 copay |
| Tier 5: Supplemental Drugs | \$0 copay | \$10 copay |

You pay **\$0 - \$35** for a one-month supply of each covered insulin product regardless of the cost-sharing tier for preferred and standard retail pharmacies.

Leon Health, Inc. uses preferred network pharmacies. See your Provider and Pharmacy Directory or visit www.leonhealth.com to search for a preferred retail pharmacy near you.

Leon Health Inc.'s pharmacy network offers limited access to pharmacies with preferred cost sharing in Miami-Dade, FL. The lower costs advertised in our plan materials for these pharmacies may not be available at the pharmacy you use. For up-to-date information about our network pharmacies, including pharmacies with preferred cost sharing, please call 1-844-969-5366 (TTY: 711) or consult the online pharmacy directory at www.LeonHealth.com/.

Symbols and Abbreviations:

- EX - This prescription drug is not normally covered in a Medicare Prescription Drug Plan. The amount you pay when you fill a prescription for this drug does not count towards your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug.
- CB – Capped Benefit Limit (this drug has a specified limit amount per month and does not allow early refill).
- LA - This prescription may be available only at certain pharmacies. For more information consult your Pharmacy Directory or call Member Services at 1-844-969-5366 from 8 a.m. to 8 p.m., Monday through Friday, or visit www.leonhealth.com. TTY users should call 711.
- GC - We provide additional coverage of this prescription drug in the coverage gap. Please refer to our Evidence of Coverage for more information about this coverage.
- HI - This prescription drug may be covered under our medical benefit. For more information, call Member Services at 1-844-969-5366, from 8 a.m. to 8 p.m., Monday through Friday, or visit www.leonhealth.com. TTY users should call 711.
- PA NSO - New Starts Only (this would only apply to patients newly started on this drug).

- PA - This drug requires prior authorization.
- PA BvD - The decision process required to determine whether or not a specific prescription should be covered as a Part B or a Part D benefit.
- QL - This drug has quantity limits.
- ST - This drug has step therapy requirements.
- NDS - Non-Extended Days' Supply.

Table of Contents

| | |
|--|----|
| Analgesics | 10 |
| Anesthetics | 14 |
| Anti-Addiction/Substance Abuse Treatment Agents | 14 |
| Antianxiety Agents | 15 |
| Antibacterials | 16 |
| Anticancer Agents | 21 |
| Anticonvulsants | 31 |
| Antidementia Agents | 35 |
| Antidepressants | 35 |
| Antidiabetic Agents | 38 |
| Antifungals | 42 |
| Antigout Agents | 44 |
| Antihistamines | 44 |
| Anti-Infectives (Skin And Mucous Membrane) | 44 |
| Antimigraine Agents | 45 |
| Antimycobacterials | 46 |
| Antinausea Agents | 46 |
| Antiparasite Agents | 47 |
| Antiparkinsonian Agents | 48 |
| Antipsychotic Agents | 49 |
| Antivirals (Systemic) | 54 |
| Blood Products/Modifiers/Volume Expanders | 58 |
| Caloric Agents | 61 |
| Cardiovascular Agents | 63 |
| Central Nervous System Agents | 71 |
| Contraceptives | 75 |
| Cough And Cold Products | 81 |

| | |
|---|-----|
| Dental And Oral Agents | 81 |
| Dermatological Agents | 82 |
| Devices | 87 |
| Enzyme Replacement/Modifiers | 121 |
| Eye, Ear, Nose, Throat Agents | 122 |
| Gastrointestinal Agents | 125 |
| Genitourinary Agents | 128 |
| Heavy Metal Antagonists | 129 |
| Hormonal Agents, Stimulant/Replacement/Modifying | 129 |
| Immunological Agents | 134 |
| Inflammatory Bowel Disease Agents | 143 |
| Metabolic Bone Disease Agents | 144 |
| Miscellaneous Therapeutic Agents | 145 |
| Ophthalmic Agents | 147 |
| Replacement Preparations | 148 |
| Respiratory Tract Agents | 149 |
| Skeletal Muscle Relaxants | 153 |
| Sleep Disorder Agents | 154 |
| Vasodilating Agents | 154 |
| Vitamins And Minerals | 155 |

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| Analgesics | | |
| Analgesics, Miscellaneous | | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 1 | QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 1 | QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 1 | QL (180 per 30 days) |
| <i>ascomp with codeine oral capsule 30-50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>buprenorphine hcl injection solution 0.3 mg/ml</i> | 1 | |
| <i>buprenorphine hcl injection syringe 0.3 mg/ml</i> | 1 | |
| <i>buprenorphine transdermal patch weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour</i> | 1 | QL (4 per 28 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg, 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butalbital-aspirin-caffeine oral tablet 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>butorphanol nasal spray,non-aerosol 10 mg/ml</i> | 1 | QL (5 per 28 days) |
| <i>codeine sulfate oral tablet 30 mg, 60 mg</i> | 1 | QL (180 per 30 days) |
| <i>codeine-bitalbital-asa-caff oral capsule 30-50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| <i>endocet oral tablet 10-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> | 1 | QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> | 1 | QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 4 | PA; NDS; QL (120 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 1 | PA; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 1 | QL (10 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | 1 | QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 7.5-300 mg, 7.5-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 2.5-325 mg, 5-300 mg, 5-325 mg</i> | 1 | QL (240 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | 1 | QL (150 per 30 days) |
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | 1 | |
| <i>hydromorphone oral liquid 1 mg/ml</i> | 1 | QL (1200 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> | 1 | QL (180 per 30 days) |
| <i>methadone oral solution 10 mg/5 ml</i> | 1 | QL (600 per 30 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | 1 | QL (1200 per 30 days) |
| <i>methadone oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>methadone oral tablet 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>methadone oral tablet, soluble 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>methadose oral tablet, soluble 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 1 | PA; QL (180 per 30 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | 1 | QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 1 | QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 3 | NDS; QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 3 | NDS; QL (120 per 30 days) |
| <i>morphine oral tablet extended release 100 mg, 200 mg, 60 mg</i> | 1 | QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> | 1 | QL (90 per 30 days) |
| <i>oxycodone oral capsule 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxycodone oral concentrate 20 mg/ml</i> | 1 | PA; QL (120 per 30 days) |
| <i>oxycodone oral solution 5 mg/5 ml</i> | 1 | QL (1300 per 30 days) |
| <i>oxycodone oral tablet 10 mg, 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 20 mg, 30 mg</i> | 1 | QL (120 per 30 days) |
| <i>oxycodone oral tablet, oral only, ext. rel. 12 hr 10 mg, 20 mg</i> | 2 | QL (60 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> | 1 | QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> | 1 | QL (240 per 30 days) |
| OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 2 | QL (60 per 30 days) |
| <i>oxymorphone oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>oxymorphone oral tablet 5 mg</i> | 1 | QL (180 per 30 days) |
| <i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | QL (60 per 30 days) |
| <i>oxymorphone oral tablet extended release 12 hr 40 mg</i> | 4 | NDS; QL (60 per 30 days) |
| <i>tencon oral tablet 50-325 mg</i> | 1 | QL (180 per 30 days) |
| <i>tramadol oral tablet 50 mg</i> | 1 | QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 1 | QL (300 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 9 MG | 2 | QL (60 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 27 MG | 2 | QL (120 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG | 4 | NDS; QL (240 per 30 days) |
| <i>zebutal oral capsule 50-325-40 mg</i> | 1 | QL (180 per 30 days) |
| Nonsteroidal Anti-Inflammatory Agents | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 1 | QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 1 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | 1 | QL (60 per 30 days) |
| <i>diclofenac sodium oral tablet,delayed release (dr/ec) 25 mg</i> | 1 | QL (150 per 30 days) |
| <i>diclofenac sodium oral tablet,delayed release (dr/ec) 50 mg</i> | 1 | QL (120 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 75 mg</i> | 1 | QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | 1 | QL (300 per 30 days) |
| <i>diclofenac sodium topical gel 1 %</i> | 1 | QL (1000 per 30 days) |
| <i>diclofenac sodium topical gel 3 %</i> | 1 | PA; QL (100 per 28 days) |
| <i>diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %)</i> | 4 | PA; NDS; QL (224 per 28 days) |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 50-200 mg-mcg, 75-200 mg-mcg</i> | 1 | |
| <i>diflunisal oral tablet 500 mg</i> | 1 | |
| <i>ec-naproxen dr 500 mg tablet</i> | 1 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 1 | |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 1 | |
| <i>fenoprofen oral tablet 600 mg</i> | 1 | |
| <i>flurbiprofen oral tablet 100 mg</i> | 1 | |
| <i>ibu oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> | 1 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | |
| <i>ibuprofen-famotidine oral tablet 800-26.6 mg</i> | 1 | PA; QL (90 per 30 days) |
| <i>indomethacin oral capsule 25 mg</i> | 1 | QL (240 per 30 days) |
| <i>indomethacin oral capsule 50 mg</i> | 1 | QL (120 per 30 days) |
| <i>indomethacin oral capsule, extended release 75 mg</i> | 1 | QL (60 per 30 days) |
| <i>ketoprofen oral capsule 50 mg, 75 mg</i> | 1 | |
| <i>ketoprofen oral capsule, ext rel. pellets 24 hr 200 mg</i> | 1 | |
| <i>ketorolac injection solution 15 mg/ml</i> | 1 | QL (40 per 30 days) |
| <i>ketorolac injection solution 30 mg/ml, 30 mg/ml (1 ml)</i> | 1 | QL (20 per 30 days) |
| <i>ketorolac injection syringe 15 mg/ml</i> | 1 | QL (40 per 30 days) |
| <i>ketorolac injection syringe 30 mg/ml</i> | 1 | QL (20 per 30 days) |
| <i>ketorolac intramuscular solution 60 mg/2 ml</i> | 1 | QL (20 per 30 days) |
| <i>ketorolac intramuscular syringe 60 mg/2 ml</i> | 1 | QL (20 per 30 days) |
| <i>ketorolac oral tablet 10 mg</i> | 1 | QL (20 per 30 days) |
| <i>mefenamic acid oral capsule 250 mg</i> | 1 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg, 500 mg</i> | 1 | |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 1 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 1 | |
| Anesthetics | | |
| Local Anesthetics | | |
| <i>glydo mucous membrane jelly in applicator 2 %</i> | 1 | QL (30 per 30 days) |
| <i>lidocaine (pf) injection solution 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 40 mg/ml (4 %), 5 mg/ml (0.5 %)</i> | 1 | |
| <i>lidocaine hcl injection solution 10 mg/ml (1 %), 20 mg/ml (2 %), 5 mg/ml (0.5 %)</i> | 1 | |
| <i>lidocaine hcl mucous membrane jelly in applicator 2 %</i> | 1 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 1 | PA |
| <i>lidocaine topical adhesive patch, medicated 5 %</i> | 1 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 1 | PA; QL (90 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> | 1 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 1 | PA; QL (30 per 30 days) |
| ZTLIDO TOPICAL ADHESIVE PATCH, MEDICATED 1.8 % | 2 | PA; QL (90 per 30 days) |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| <i>acamprosate oral tablet, delayed release (dr/ec) 333 mg</i> | 1 | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 1 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 12-3 mg</i> | 1 | QL (60 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | 1 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 1 | QL (90 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------|
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 1 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 1 | |
| KLOXXADO NASAL SPRAY, NON-AEROSOL 8 MG/ACTUATION | 2 | QL (4 per 30 days) |
| <i>naloxone injection solution 0.4 mg/ml</i> | 1 | |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i> | 1 | |
| <i>naloxone nasal spray, non-aerosol 4 mg/actuation</i> | 1 | QL (4 per 30 days) |
| <i>naltrexone oral tablet 50 mg</i> | 1 | |
| NICOTROL INHALATION CARTRIDGE 10 MG | 3 | NDS; QL (2688 per 365 days) |
| SUBLOCADE SUBCUTANEOUS SOLUTION, EXTENDED REL SYRINGE 100 MG/0.5 ML | 4 | NDS; QL (0.5 per 30 days) |
| SUBLOCADE SUBCUTANEOUS SOLUTION, EXTENDED REL SYRINGE 300 MG/1.5 ML | 4 | NDS; QL (1.5 per 30 days) |
| <i>varenicline oral tablet 0.5 mg, 1 mg</i> | 1 | QL (336 per 365 days) |
| <i>varenicline oral tablets, dose pack 0.5 mg (11)- 1 mg (42)</i> | 1 | |
| Antianxiety Agents | | |
| Benzodiazepines | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg</i> | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 3 mg</i> | 1 | QL (90 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | 1 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 1 | QL (180 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | 1 | QL (10 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>diazepam injection syringe 5 mg/ml</i> | 1 | |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> | 1 | QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 1 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>estazolam oral tablet 1 mg</i> | 1 | QL (60 per 30 days) |
| <i>estazolam oral tablet 2 mg</i> | 1 | QL (30 per 30 days) |
| <i>lorazepam 2 mg/ml oral concent</i> | 1 | QL (150 per 30 days) |
| <i>lorazepam 4 mg/ml vial inner</i> | 1 | |
| <i>lorazepam injection solution 2 mg/ml</i> | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 4 mg/ml</i> | 3 | NDS; QL (2 per 30 days) |
| <i>lorazepam injection syringe 2 mg/ml</i> | 1 | QL (2 per 30 days) |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> | 1 | QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>midazolam oral syrup 2 mg/ml</i> | 1 | QL (10 per 30 days) |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 1 | QL (120 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | 1 | QL (30 per 30 days) |
| <i>triazolam oral tablet 0.125 mg</i> | 1 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.25 mg</i> | 1 | QL (60 per 30 days) |
| Antibacterials | | |
| Aminoglycosides | | |
| <i>gentamicin injection solution 40 mg/ml</i> | 1 | |
| <i>neomycin oral tablet 500 mg</i> | 1 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 4 | NDS |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG | 4 | LA; NDS; QL (224 per 28 days) |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> | 4 | PA BvD; NDS |
| <i>tobramycin inhalation solution for nebulization 300 mg/4 ml</i> | 4 | PA BvD; NDS |
| <i>tobramycin sulfate injection solution 40 mg/ml</i> | 1 | |
| Antibacterials, Miscellaneous | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> | 1 | |
| <i>clindamycin in 5 % dextrose intravenous piggyback 300 mg/50 ml</i> | 1 | PA BvD; HI |
| <i>clindamycin pediatric oral recon soln 75 mg/5 ml</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| <i>clindamycin ph 9 g/60 ml vial mdv 150 mg/ml</i> | 1 | PA BvD |
| <i>clindamycin phosphate injection solution 150 (mg/ml) (6 ml), 150 mg/ml</i> | 1 | PA BvD; HI |
| <i>clindamycin phosphate intravenous solution 600 mg/4 ml</i> | 1 | PA BvD; HI |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i> | 4 | PA BvD; HI; NDS |
| <i>daptomycin intravenous recon soln 500 mg</i> | 4 | NDS |
| FIRVANQ ORAL RECON SOLN 25 MG/ML | 3 | NDS |
| <i>fosfomycin tromethamine oral packet 3 gram</i> | 1 | |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> | 1 | PA BvD; HI |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> | 4 | NDS |
| <i>linezolid oral tablet 600 mg</i> | 1 | |
| <i>methenamine hippurate oral tablet 1 gram</i> | 1 | |
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> | 1 | PA BvD; HI |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> | 1 | QL (60 per 30 days) |
| <i>polymyxin b sulfate injection recon soln 500,000 unit</i> | 1 | PA BvD; HI |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | |
| <i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg</i> | 1 | |
| <i>vancomycin oral capsule 125 mg</i> | 1 | QL (56 per 14 days) |
| <i>vancomycin oral capsule 250 mg</i> | 1 | QL (112 per 14 days) |
| <i>vancomycin oral recon soln 25 mg/ml</i> | 3 | NDS |
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; NDS; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 4 | PA; NDS; QL (90 per 30 days) |
| Cephalosporins | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cefaclor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml</i> | 1 | |
| <i>cefaclor oral tablet extended release 12 hr 500 mg</i> | 1 | |
| <i>cefadroxil oral capsule 500 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 1 | |
| <i>cefadroxil oral tablet 1 gram</i> | 1 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | 1 | |
| <i>cefdinir oral capsule 300 mg</i> | 1 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 1 | |
| <i>cefixime oral capsule 400 mg</i> | 1 | |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 1 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 1 | PA BvD; HI |
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml</i> | 1 | |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 1 | |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i> | 1 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 1 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 1 | PA BvD; HI |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram</i> | 1 | PA BvD; HI |
| <i>cephalexin oral capsule 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>tazicef injection recon soln 1 gram, 2 gram, 6 gram</i> | 1 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 4 | PA BvD; HI; NDS |
| Macrolides | | |
| <i>azithromycin intravenous recon soln 500 mg</i> | 1 | PA BvD; HI |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i> | 1 | |
| DIFICID ORAL SUSPENSION FOR RECONSTITUTION 40 MG/ML | 4 | NDS; QL (136 per 10 days) |
| DIFICID ORAL TABLET 200 MG | 4 | NDS; QL (20 per 10 days) |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 1 | |
| Miscellaneous B-Lactam Antibiotics | | |
| <i>aztreonam injection recon soln 1 gram</i> | 1 | PA BvD; HI |
| <i>aztreonam injection recon soln 2 gram</i> | 4 | NDS |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 4 | PA; LA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> | 1 | |
| <i>imipenem-cilastatin intravenous recon soln 250 mg, 500 mg</i> | 1 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 1 | |
| Penicillins | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 1 | |
| <i>ampicillin oral capsule 500 mg</i> | 1 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | 1 | PA BvD; HI |
| <i>ampicillin sodium injection recon soln 2 gram, 250 mg, 500 mg</i> | 1 | PA BvD |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> | 1 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 3 | NDS |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>nafcillin 1 gm/ 50 ml inj 1 gram/50 ml</i> | 1 | PA BvD; HI |
| <i>nafcillin injection recon soln 1 gram</i> | 1 | PA BvD; HI |
| <i>nafcillin injection recon soln 10 gram</i> | 4 | PA BvD; HI; NDS |
| <i>nafcillin injection recon soln 2 gram</i> | 3 | NDS |
| <i>penicillin g potassium injection recon soln 20 million unit</i> | 1 | PA BvD; HI |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml</i> | 1 | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 1 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>pfizerpen-g injection recon soln 20 million unit</i> | 1 | PA BvD |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 1 | |
| Quinolones | | |
| <i>ciprofloxacin hcl oral tablet 100 mg, 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i> | 1 | PA BvD; HI |
| <i>ciprofloxacin oral suspension, microcapsule recon 250 mg/5 ml</i> | 1 | |
| <i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i> | 1 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin 400 mg/250 ml bag</i> | 3 | PA BvD; HI; NDS |
| <i>moxifloxacin oral tablet 400 mg</i> | 1 | |
| <i>moxifloxacin-sod.chloride(iso) intravenous piggyback 400 mg/250 ml</i> | 3 | PA BvD; HI; NDS |
| Sulfonamides | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | |
| <i>sulfatrim oral suspension 200-40 mg/5 ml</i> | 1 | |
| Tetracyclines | | |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i> | 1 | |
| <i>doxy-100 intravenous recon soln 100 mg</i> | 1 | PA BvD; HI |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> | 1 | PA BvD |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 1 | |
| <i>doxycycline hyclate oral tablet 100 mg, 150 mg, 20 mg, 50 mg, 75 mg</i> | 1 | |
| <i>doxycycline monohydrate oral capsule 100 mg, 150 mg, 50 mg, 75 mg</i> | 1 | |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> | 1 | |
| <i>doxycycline monohydrate oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 1 | |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 1 | |
| <i>minocycline oral tablet 100 mg, 50 mg, 75 mg</i> | 1 | |
| <i>mondoxyne nl oral capsule 100 mg, 75 mg</i> | 1 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>tigecycline intravenous recon soln 50 mg</i> | 4 | PA BvD; HI; NDS |
| Anticancer Agents | | |
| Anticancer Agents | | |
| <i>abiraterone oral tablet 250 mg, 500 mg</i> | 4 | PA NSO; NDS; QL (120 per 30 days) |
| <i>adrucil intravenous solution 2.5 gram/50 ml</i> | 1 | PA BvD |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 4 | PA NSO; LA; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)- 180 MG (23) | 4 | PA NSO; LA; NDS |
| <i>anastrozole oral tablet 1 mg</i> | 1 | |
| AUGTYRO ORAL CAPSULE 40 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> | 4 | NDS |
| BALVERSA ORAL TABLET 3 MG | 4 | PA NSO; LA; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 4 | PA NSO; LA; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 4 | PA NSO; LA; NDS; QL (28 per 28 days) |
| <i>bendamustine intravenous recon soln 100 mg, 25 mg</i> | 4 | PA NSO; NDS |
| BENDAMUSTINE INTRAVENOUS SOLUTION 25 MG/ML | 4 | PA NSO; NDS |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML | 4 | PA NSO; NDS |
| <i>bexarotene oral capsule 75 mg</i> | 4 | PA NSO; NDS |
| <i>bexarotene topical gel 1 %</i> | 4 | PA NSO; NDS |
| <i>bicalutamide oral tablet 50 mg</i> | 1 | |
| <i>bleomycin injection recon soln 15 unit, 30 unit</i> | 1 | |
| <i>bortezomib injection recon soln 1 mg, 2.5 mg</i> | 4 | PA NSO; NDS |
| BOSULIF ORAL CAPSULE 100 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 50 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| BRAFTOVI ORAL CAPSULE 75 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 60 MG/DAY (20 MG X 3/DAY) | 4 | PA NSO; LA; NDS |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 4 | PA NSO; LA; NDS; QL (112 per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 4 | PA NSO; LA; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 4 | PA NSO; LA; NDS; QL (63 per 28 days) |
| <i>cyclophosphamide intravenous solution 200 mg/ml</i> | 4 | PA BvD; NDS |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 3 | PA BvD; ST; NDS |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i> | 2 | PA BvD; ST |
| DAURISMO ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| <i>doxorubicin, peg-liposomal intravenous suspension 2 mg/ml</i> | 4 | PA BvD; NDS |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 3 | PA NSO; NDS |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 3 | PA NSO; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 3 | PA NSO; NDS |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 3 | PA NSO; NDS |
| EMCYT ORAL CAPSULE 140 MG | 4 | NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 4 | PA NSO; LA; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| <i>erlotinib oral tablet 100 mg, 25 mg</i> | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>erlotinib oral tablet 150 mg</i> | 4 | PA NSO; NDS; QL (90 per 30 days) |
| <i>everolimus (antineoplastic) oral tablet 10 mg</i> | 4 | PA NSO; NDS; QL (56 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | 4 | PA NSO; NDS; QL (28 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> | 4 | PA NSO; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> | 1 | |
| EXKIVITY ORAL CAPSULE 40 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG | 4 | PA NSO; NDS |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | 4 | PA NSO; NDS; QL (4 per 365 days) |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | 3 | PA NSO; NDS |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 4 | PA NSO; LA; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 4 | PA NSO; NDS; QL (84 per 21 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 4 | PA NSO; NDS; QL (21 per 21 days) |
| GAVRETO ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> | 3 | PA NSO; NDS |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG | 4 | NDS |
| <i>hydroxyurea oral capsule 500 mg</i> | 1 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 4 | PA NSO; LA; NDS; QL (21 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 4 | PA NSO; LA; NDS; QL (21 per 28 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous recon soln 1 gram</i> | 1 | |
| <i>imatinib oral tablet 100 mg</i> | 1 | PA NSO; QL (180 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> | 1 | PA NSO; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 4 | PA NSO; LA; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 4 | PA NSO; LA; NDS; QL (240 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 4 | PA NSO; LA; NDS; QL (28 per 28 days) |
| INLYTA ORAL TABLET 1 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 4 | PA NSO; LA; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| IRESSA ORAL TABLET 250 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| IWILFIN ORAL TABLET 192 MG | 4 | PA NSO; NDS |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 4 | PA NSO; NDS; QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 4 | PA NSO; NDS; QL (70 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 4 | PA NSO; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 4 | PA NSO; NDS; QL (21 per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 4 | PA NSO; NDS; QL (42 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 4 | PA NSO; NDS; QL (63 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 4 | PA NSO; LA; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> | 4 | PA NSO; LA; NDS |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> | 4 | PA NSO; LA; NDS; QL (28 per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 4 | PA NSO; LA; NDS |
| <i>letrozole oral tablet 2.5 mg</i> | 1 | |
| LEUKERAN ORAL TABLET 2 MG | 4 | NDS |
| <i>leuprolide (3 month) intramuscular suspension for reconstitution 22.5 mg</i> | 3 | PA NSO; NDS |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 4 | PA NSO; NDS |
| LONSURF ORAL TABLET 15-6.14 MG | 4 | PA NSO; LA; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 4 | PA NSO; LA; NDS; QL (80 per 28 days) |
| LORBRENA ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG, 320 MG | 4 | PA NSO; LA; NDS; QL (240 per 30 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 4 | PA NSO; NDS |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 4 | NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| LYTGOBI ORAL TABLET 4 MG, 4 MG (4X 4 MG TB), 4 MG (5X 4 MG TB) | 4 | PA NSO; NDS; QL (140 per 28 days) |
| MATULANE ORAL CAPSULE 50 MG | 4 | LA; NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 1 | |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 4 | NDS |
| MEKINIST ORAL TABLET 0.5 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| <i>mercaptopurine oral tablet 50 mg</i> | 1 | |
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 1 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 1 | |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 1 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 1 | ST |
| NERLYNX ORAL TABLET 40 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> | 4 | NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 4 | PA NSO; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 4 | PA NSO; LA; NDS |
| OGSIVEO ORAL TABLET 50 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ONUREG ORAL TABLET 200 MG, 300 MG | 4 | PA NSO; LA; NDS; QL (14 per 28 days) |
| ORSERDU ORAL TABLET 345 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| <i>pazopanib oral tablet 200 mg</i> | 4 | PA NSO; NDS; QL (120 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 4 | PA NSO; LA; NDS; QL (28 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 4 | PA NSO; LA; NDS; QL (56 per 28 days) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 4 | PA NSO; LA; NDS; QL (21 per 28 days) |
| PURIXAN ORAL SUSPENSION 20 MG/ML | 4 | LA; NDS |
| QINLOCK ORAL TABLET 50 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| RYDAPT ORAL CAPSULE 25 MG | 4 | PA NSO; NDS; QL (224 per 28 days) |
| SCSEMBLIX ORAL TABLET 20 MG, 40 MG | 4 | PA NSO; NDS |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 4 | NDS |
| <i>sorafenib oral tablet 200 mg</i> | 4 | PA NSO; NDS; QL (120 per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 70 MG, 80 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 4 | PA NSO; NDS; QL (90 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 4 | PA NSO; LA; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 4 | PA NSO; NDS; QL (28 per 28 days) |
| SYNRIBO SUBCUTANEOUS RECON SOLN 3.5 MG | 4 | PA NSO; NDS |
| TABLOID ORAL TABLET 40 MG | 3 | NDS |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 4 | PA NSO; LA; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 4 | NDS |
| TAGRISSO ORAL TABLET 40 MG, 80 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.35 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| TALZENNA ORAL CAPSULE 0.25 MG, 0.5 MG, 0.75 MG, 1 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 1 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 4 | PA NSO; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 4 | PA NSO; LA; NDS; QL (240 per 30 days) |
| TEPMETKO ORAL TABLET 225 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| TIBSOVO ORAL TABLET 250 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG | 3 | NDS |
| <i>toremifene oral tablet 60 mg</i> | 4 | NDS |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG, 3.75 MG | 3 | PA NSO; NDS |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 4 | NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 4 | PA NSO; NDS; QL (64 per 28 days) |
| TUKYSA ORAL TABLET 150 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 4 | PA NSO; LA; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 125 MG | 4 | NDS |
| TURALIO ORAL CAPSULE 200 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 4 | PA NSO; NDS; QL (56 per 28 days) |
| VENCLEXTA ORAL TABLET 10 MG | 2 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 4 | PA NSO; LA; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | PA NSO; LA; NDS; QL (56 per 28 days) |
| VITRAKVI ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 4 | PA NSO; LA; NDS; QL (300 per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| VOTRIENT ORAL TABLET 200 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| WELIREG ORAL TABLET 40 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| XALKORI ORAL PELLETT 150 MG | 4 | PA NSO; NDS; QL (180 per 30 days) |
| XALKORI ORAL PELLETT 20 MG | 4 | PA NSO; NDS; QL (240 per 30 days) |
| XALKORI ORAL PELLETT 50 MG | 4 | PA NSO; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 3 | ST; NDS |
| XOSPATA ORAL TABLET 40 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) | 4 | PA NSO; LA; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | 4 | PA NSO; LA; NDS; QL (4 per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 4 | PA NSO; LA; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 4 | PA NSO; LA; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| XTANDI ORAL TABLET 80 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| YONSA ORAL TABLET 125 MG | 4 | PA NSO; LA; NDS; QL (120 per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 4 | PA NSO; LA; NDS; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 4 | PA NSO; LA; NDS; QL (240 per 30 days) |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | 3 | PA NSO; NDS |
| ZOLINZA ORAL CAPSULE 100 MG | 4 | NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 4 | PA NSO; LA; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 4 | PA NSO; LA; NDS; QL (84 per 28 days) |
| Anticonvulsants | | |
| Anticonvulsants | | |
| APTIOM ORAL TABLET 200 MG, 400 MG | 4 | ST; NDS; QL (30 per 30 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | 4 | ST; NDS; QL (60 per 30 days) |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | 2 | QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 2 | QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 2 | QL (60 per 30 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | 1 | |
| <i>carbamazepine oral tablet 200 mg</i> | 1 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | 1 | |
| <i>carbamazepine oral tablet, chewable 100 mg</i> | 1 | |
| CELONTIN ORAL CAPSULE 300 MG | 3 | NDS |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 1 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | 1 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | 4 | PA NSO; LA; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------------|
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 4 | PA NSO; LA; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i> | 3 | NDS |
| DILANTIN ORAL CAPSULE 30 MG | 3 | NDS |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> | 1 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | 1 | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | 1 | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 4 | PA NSO; LA; NDS |
| <i>epitol oral tablet 200 mg</i> | 1 | |
| EPRONTIA ORAL SOLUTION 25 MG/ML | 3 | ST; NDS; QL (480 per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> | 1 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> | 1 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> | 4 | NDS |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 1 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 4 | PA NSO; LA; NDS |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 4 | ST; NDS; QL (720 per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 8 MG | 4 | ST; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 3 | ST; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 4 MG, 6 MG | 4 | ST; NDS; QL (60 per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> | 1 | QL (360 per 30 days) |
| <i>gabapentin oral capsule 400 mg</i> | 1 | QL (270 per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> | 1 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> | 1 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> | 1 | QL (120 per 30 days) |
| <i>lacosamide intravenous solution 200 mg/20 ml</i> | 1 | QL (200 per 5 days) |
| <i>lacosamide oral solution 10 mg/ml</i> | 3 | NDS; QL (1200 per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 1 | QL (60 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg (42) -100 mg (14)</i> | 1 | |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 1 | |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> | 1 | |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | 1 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> | 1 | |
| <i>methsuximide oral capsule 300 mg</i> | 3 | NDS |
| <i>NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML)</i> | 4 | NDS; QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> | 1 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 1 | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 1 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> | 1 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> | 1 | |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> | 1 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 1 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | 1 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg, 250 mg, 50 mg</i> | 1 | |
| <i>rufinamide oral suspension 40 mg/ml</i> | 4 | NDS |
| <i>rufinamide oral tablet 200 mg</i> | 1 | |
| <i>rufinamide oral tablet 400 mg</i> | 4 | NDS |
| <i>SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG</i> | 3 | ST; NDS; QL (60 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG, 750 MG | 3 | ST; NDS; QL (120 per 30 days) |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 4 | PA NSO; NDS; QL (60 per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 1 | |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> | 1 | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 1 | |
| <i>valproic acid oral capsule 250 mg</i> | 1 | |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 4 | NDS |
| <i>vigabatrin oral powder in packet 500 mg</i> | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i> | 4 | PA NSO; LA; NDS; QL (180 per 30 days) |
| <i>vigadrone oral tablet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigpoder oral powder in packet 500 mg</i> | 4 | PA NSO; NDS; QL (180 per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 4 | ST; NDS; QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 50 MG | 4 | ST; NDS; QL (30 per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 4 | ST; NDS; QL (60 per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 12.5 MG (14)- 25 MG (14) | 3 | ST; NDS |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 4 | ST; NDS |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------------|
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 4 | PA NSO; NDS; QL (1080 per 30 days) |
| Antidementia Agents | | |
| Antidementia Agents | | |
| <i>donepezil oral tablet 10 mg, 23 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>donepezil oral tablet, disintegrating 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 1 | |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 1 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 1 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 1 | QL (60 per 30 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i> | 1 | QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | 1 | QL (300 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> | 1 | QL (60 per 30 days) |
| NAMZARIC ORAL CAP, SPRINKLE, ER 24HR DOSE PACK 7/14/21/28 MG-10 MG | 3 | NDS |
| NAMZARIC ORAL CAPSULE, SPRINKLE, ER 24HR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 3 | NDS; QL (30 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 1 | QL (60 per 30 days) |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> | 1 | QL (30 per 30 days) |
| Antidepressants | | |
| Antidepressants | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>amitriptyline-chlordiazepoxide oral tablet 12.5-5 mg, 25-10 mg</i> | 1 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 1 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | 4 | ST; NDS |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 1 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> | 1 | |
| <i>citalopram oral solution 10 mg/5 ml</i> | 1 | QL (600 per 30 days) |
| <i>citalopram oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>citalopram oral tablet 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>desipramine oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> | 1 | QL (30 per 30 days) |
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | 1 | |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 60 MG | 3 | ST; NDS; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | 3 | ST; NDS; QL (30 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 60 mg</i> | 1 | QL (60 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 40 mg</i> | 1 | QL (30 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 4 | ST; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 1 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| FETZIMA ORAL CAPSULE, EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | 3 | ST; NDS |
| FETZIMA ORAL CAPSULE, EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 3 | ST; NDS; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 1 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg</i> | 1 | |
| MARPLAN ORAL TABLET 10 MG | 3 | NDS |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg, 7.5 mg</i> | 1 | |
| <i>mirtazapine oral tablet, disintegrating 15 mg, 30 mg, 45 mg</i> | 1 | |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 1 | |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 1 | |
| <i>paroxetine hcl oral suspension 10 mg/5 ml</i> | 1 | |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg</i> | 1 | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> | 1 | |
| <i>phenelzine oral tablet 15 mg</i> | 1 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>sertraline oral concentrate 20 mg/ml</i> | 1 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 28 MG | 3 | PA NSO; NDS |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3) | 4 | PA NSO; NDS |
| <i>tranylcypromine oral tablet 10 mg</i> | 1 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 2 | QL (30 per 30 days) |
| <i>venlafaxine besylate oral tablet extended release 24hr 112.5 mg</i> | 3 | NDS; QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg</i> | 1 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 37.5 mg, 75 mg</i> | 1 | QL (90 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | |
| <i>venlafaxine oral tablet extended release 24hr 150 mg, 225 mg, 37.5 mg</i> | 1 | QL (30 per 30 days) |
| <i>venlafaxine oral tablet extended release 24hr 75 mg</i> | 1 | QL (90 per 30 days) |
| VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23) | 2 | |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 4 | PA NSO; NDS; QL (28 per 14 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | 4 | PA NSO; NDS; QL (14 per 14 days) |
| Antidiabetic Agents | | |
| Antidiabetic Agents, Miscellaneous | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | QL (90 per 30 days) |
| <i>alogliptin oral tablet 12.5 mg, 25 mg, 6.25 mg</i> | 1 | |
| <i>alogliptin-metformin oral tablet 12.5-1,000 mg, 12.5-500 mg</i> | 1 | |
| <i>alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg</i> | 1 | |
| <i>dapaglifloz propaned-metformin oral tablet, ir - er, biphasic 24hr 10-1,000 mg</i> | 1 | QL (30 per 30 days) |
| <i>dapaglifloz propaned-metformin oral tablet, ir - er, biphasic 24hr 5-1,000 mg</i> | 1 | QL (60 per 30 days) |
| <i>dapagliflozin propanediol oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| FARXIGA ORAL TABLET 10 MG, 5 MG | 2 | QL (30 per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 2 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 2 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG | 2 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 2 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 2 | QL (30 per 30 days) |
| KORLYM ORAL TABLET 300 MG | 4 | PA; LA; NDS; QL (112 per 28 days) |
| <i>metformin oral solution 500 mg/5 ml</i> | 1 | QL (765 per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> | 1 | QL (75 per 30 days) |
| <i>metformin oral tablet 500 mg</i> | 1 | QL (150 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| <i>metformin oral tablet 850 mg</i> | 1 | QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 1 | QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 1 | QL (60 per 30 days) |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | QL (90 per 30 days) |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 2 | QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 1 | QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML) | 2 | QL (3 per 28 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 2 | PA; QL (3 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | QL (30 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-500 mg, 15-850 mg</i> | 1 | QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 1 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 1 | QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 2 | PA; QL (30 per 30 days) |
| SYMLINPEN 120 SUBCUTANEOUS PEN INJECTOR 2,700 MCG/2.7 ML | 4 | PA; NDS; QL (10.8 per 28 days) |
| SYMLINPEN 60 SUBCUTANEOUS PEN INJECTOR 1,500 MCG/1.5 ML | 4 | PA; NDS; QL (10.8 per 28 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG | 2 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 2 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 2 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG | 2 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 2 | QL (30 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------|
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | 2 | QL (60 per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 2 | PA; QL (2 per 28 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG | 2 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG, 5-500 MG | 2 | QL (60 per 30 days) |
| Insulins | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | QL (30 per 28 days) |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 2 | QL (30 per 28 days) |
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 2 | QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 2 | QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 2 | QL (24 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | 1 | QL (30 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | 1 | QL (40 per 28 days) |
| <i>insulin aspart u-100 subcutaneous cartridge 100 unit/ml</i> | 1 | QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 1 | QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous solution 100 unit/ml</i> | 1 | QL (40 per 28 days) |
| <i>insulin degludec subcutaneous insulin pen 100 unit/ml (3 ml), 200 unit/ml (3 ml)</i> | 2 | |
| <i>insulin degludec subcutaneous solution 100 unit/ml</i> | 2 | |
| <i>insulin glargine subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------|
| <i>insulin glargine subcutaneous solution 100 unit/ml</i> | 2 | |
| <i>insulin glargine u-300 conc subcutaneous insulin pen 300 unit/ml (1.5 ml)</i> | 2 | QL (13.5 per 28 days) |
| <i>insulin glargine u-300 conc subcutaneous insulin pen 300 unit/ml (3 ml)</i> | 2 | QL (18 per 28 days) |
| <i>insulin glargine-yfgn subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 2 | |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | 2 | |
| <i>insulin lispro protamin-lispro subcutaneous insulin pen 100 unit/ml (75-25)</i> | 2 | |
| <i>insulin lispro subcutaneous insulin pen 100 unit/ml</i> | 2 | |
| <i>insulin lispro subcutaneous insulin pen, half-unit 100 unit/ml</i> | 2 | |
| <i>insulin lispro subcutaneous solution 100 unit/ml</i> | 2 | |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | 2 | QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 2 | QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | QL (30 per 28 days) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 2 | QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | QL (30 per 28 days) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 2 | QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARGINE-YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML | 2 | QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARG-YFGN)PEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 2 | QL (30 per 28 days) |
| SOLIQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 2 | QL (30 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------|
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | 2 | QL (18 per 28 days) |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | 2 | QL (13.5 per 28 days) |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | 2 | QL (15 per 28 days) |
| Sulfonylureas | | |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>glipizide oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glipizide oral tablet extended release 24hr 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glipizide-metformin oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 1 | |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | |
| Antifungals | | |
| Antifungals | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 3 | PA BvD; HI; NDS |
| AMBISOME INTRAVENOUS SUSPENSION FOR RECONSTITUTION 50 MG | 4 | PA BvD; NDS |
| <i>amphotericin b injection recon soln 50 mg</i> | 1 | PA BvD; HI |
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> | 4 | PA BvD; NDS |
| <i>casprofungin intravenous recon soln 50 mg</i> | 4 | NDS |
| <i>casprofungin intravenous recon soln 70 mg</i> | 4 | PA BvD; HI; NDS |
| <i>ciclopirox topical cream 0.77 %</i> | 1 | QL (180 per 30 days) |
| <i>ciclopirox topical gel 0.77 %</i> | 1 | QL (300 per 30 days) |
| <i>ciclopirox topical shampoo 1 %</i> | 1 | |
| <i>ciclopirox topical solution 8 %</i> | 1 | QL (19.8 per 30 days) |
| <i>ciclopirox topical suspension 0.77 %</i> | 1 | QL (180 per 30 days) |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 1 | |
| <i>clotrimazole topical cream 1 %</i> | 1 | |
| <i>clotrimazole topical solution 1 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 1 | QL (90 per 30 days) |
| <i>clotrimazole-betamethasone topical lotion 1-0.05 %</i> | 1 | QL (90 per 30 days) |
| <i>econazole topical cream 1 %</i> | 1 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 1 | PA BvD; HI |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml</i> | 1 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 1 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 4 | NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 1 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 1 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 1 | |
| <i>itraconazole oral capsule 100 mg</i> | 1 | |
| <i>itraconazole oral solution 10 mg/ml</i> | 4 | PA; NDS |
| <i>ketoconazole oral tablet 200 mg</i> | 1 | |
| <i>ketoconazole topical cream 2 %</i> | 1 | QL (180 per 30 days) |
| <i>ketoconazole topical foam 2 %</i> | 1 | ST; QL (100 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | 1 | QL (360 per 30 days) |
| <i>miconazole-3 vaginal suppository 200 mg</i> | 1 | |
| NOXAFIL INTRAVENOUS SOLUTION 300 MG/16.7 ML | 4 | PA; NDS |
| NOXAFIL ORAL SUSP, DELAYED RELEASE FOR RECON 300 MG | 4 | PA; NDS |
| NOXAFIL ORAL SUSPENSION 200 MG/5 ML (40 MG/ML) | 4 | PA; NDS |
| <i>nyamyc topical powder 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | 1 | QL (900 per 30 days) |
| <i>nystatin oral tablet 500,000 unit</i> | 1 | |
| <i>nystatin topical cream 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin topical ointment 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin topical powder 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | 1 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>nystop topical powder 100,000 unit/gram</i> | 1 | QL (60 per 30 days) |
| <i>posaconazole oral suspension 200 mg/5 ml (40 mg/ml)</i> | 4 | PA; NDS |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i> | 4 | PA; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous recon soln 200 mg</i> | 4 | PA BvD; HI; NDS |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> | 4 | PA; NDS |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 1 | |
| Antigout Agents | | |
| Antigout Agents, Other | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | |
| <i>colchicine oral capsule 0.6 mg</i> | 1 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> | 1 | QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 1 | ST; QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 1 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 1 | |
| Antihistamines | | |
| Antihistamines | | |
| <i>carbinoxamine maleate oral liquid 4 mg/5 ml</i> | 1 | |
| <i>carbinoxamine maleate oral tablet 4 mg</i> | 1 | |
| <i>clemastine oral tablet 2.68 mg</i> | 1 | |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | 1 | |
| <i>cyproheptadine oral tablet 4 mg</i> | 1 | |
| <i>diphenhydramine hcl injection syringe 50 mg/ml</i> | 1 | |
| <i>diphenhydramine hcl oral elixir 12.5 mg/5 ml</i> | 1 | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | 1 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 1 | |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> | 1 | |
| <i>levocetirizine oral tablet 5 mg</i> | 1 | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | 1 | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> | 1 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 1 | |
| <i>terconazole vaginal suppository 80 mg</i> | 1 | |
| Antimigraine Agents | | |
| Antimigraine Agents | | |
| AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 225 MG/1.5 ML | 2 | PA; QL (1.5 per 30 days) |
| AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML | 2 | PA; QL (1.5 per 30 days) |
| <i>dihydroergotamine nasal spray,non-aerosol 0.5 mg/pump act. (4 mg/ml)</i> | 4 | NDS; QL (8 per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 2 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 2 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 2 | PA; QL (3 per 30 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | 1 | QL (9 per 30 days) |
| NURTEC ODT ORAL TABLET,DISINTEGRATING 75 MG | 2 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | 2 | PA; QL (30 per 30 days) |
| <i>rizatriptan oral tablet 10 mg, 5 mg</i> | 1 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet,disintegrating 10 mg, 5 mg</i> | 1 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation</i> | 1 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol 5 mg/actuation</i> | 1 | QL (18 per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> | 1 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> | 1 | QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml, 6 mg/0.5 ml</i> | 3 | NDS; QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml, 6 mg/0.5 ml</i> | 1 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | 1 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous syringe 6 mg/0.5 ml</i> | 1 | QL (4 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| <i>sumatriptan-naproxen oral tablet 85-500 mg</i> | 1 | QL (9 per 27 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 2 | PA; QL (16 per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | 1 | QL (6 per 30 days) |
| <i>zolmitriptan oral tablet, disintegrating 2.5 mg, 5 mg</i> | 1 | QL (6 per 30 days) |
| Antimycobacterials | | |
| Antimycobacterials | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 1 | |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | 1 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | 1 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |
| PRETOMANID ORAL TABLET 200 MG | 3 | NDS; QL (30 per 30 days) |
| PRIFTIN ORAL TABLET 150 MG | 3 | NDS |
| <i>pyrazinamide oral tablet 500 mg</i> | 1 | |
| <i>rifabutin oral capsule 150 mg</i> | 1 | |
| <i>rifampin intravenous recon soln 600 mg</i> | 1 | PA BvD; HI |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 1 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 4 | PA; LA; NDS |
| TRECTOR ORAL TABLET 250 MG | 3 | NDS |
| Antinausea Agents | | |
| Antinausea Agents | | |
| AKYNZEO (FOSNETUPITANT) INTRAVENOUS RECON SOLN 235-0.25 MG | 3 | NDS |
| AKYNZEO (FOSNETUPITANT) INTRAVENOUS SOLUTION 235 MG-0.25 MG /20 ML | 3 | NDS |
| AKYNZEO (NETUPITANT) ORAL CAPSULE 300-0.5 MG | 3 | PA BvD; NDS |
| <i>aprepitant oral capsule 125 mg</i> | 1 | PA BvD; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> | 1 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> | 1 | PA BvD; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> | 1 | PA BvD |
| <i>compro rectal suppository 25 mg</i> | 1 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 1 | PA; QL (60 per 30 days) |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.) | 4 | PA BvD; NDS; QL (6 per 28 days) |
| <i>fosaprepitant intravenous recon soln 150 mg</i> | 1 | QL (2 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>granisetron (pf) intravenous solution 1 mg/ml (1 ml), 100 mcg/ml</i> | 1 | |
| <i>granisetron hcl intravenous solution 1 mg/ml</i> | 1 | |
| <i>granisetron hcl oral tablet 1 mg</i> | 1 | PA BvD |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | 1 | |
| <i>ondansetron hcl (pf) injection solution 4 mg/2 ml</i> | 1 | |
| <i>ondansetron hcl (pf) injection syringe 4 mg/2 ml</i> | 1 | |
| <i>ondansetron hcl intravenous solution 2 mg/ml</i> | 1 | |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 1 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 1 | PA BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 1 | PA BvD |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>prochlorperazine rectal suppository 25 mg</i> | 1 | |
| <i>promethazine injection solution 25 mg/ml, 50 mg/ml</i> | 1 | |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>promethazine rectal suppository 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>promethegan rectal suppository 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i> | 1 | QL (10 per 30 days) |
| Antiparasite Agents | | |
| Antiparasite Agents | | |
| <i>albendazole oral tablet 200 mg</i> | 4 | NDS |
| <i>atovaquone oral suspension 750 mg/5 ml</i> | 1 | |
| <i>atovaquone-proguanil oral tablet 250-100 mg, 62.5-25 mg</i> | 1 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 1 | |
| COARTEM ORAL TABLET 20-120 MG | 3 | NDS |
| <i>hydroxychloroquine oral tablet 200 mg</i> | 1 | QL (90 per 30 days) |
| IMPAVIDO ORAL CAPSULE 50 MG | 4 | PA; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> | 1 | PA |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| KRINTAFEL ORAL TABLET 150 MG | 3 | NDS |
| <i>mefloquine oral tablet 250 mg</i> | 1 | |
| <i>nitazoxanide oral tablet 500 mg</i> | 4 | NDS |
| <i>paromomycin oral capsule 250 mg</i> | 1 | |
| <i>pentamidine inhalation recon soln 300 mg</i> | 1 | PA BvD |
| <i>pentamidine injection recon soln 300 mg</i> | 1 | PA BvD; HI |
| PRIMAQUINE ORAL TABLET 26.3 MG | 3 | NDS |
| <i>pyrimethamine oral tablet 25 mg</i> | 4 | PA; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> | 1 | PA; QL (42 per 7 days) |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| Antiparkinsonian Agents | | |
| Antiparkinsonian Agents | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 1 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 1 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 1 | |
| <i>apomorphine subcutaneous cartridge 10 mg/ml</i> | 4 | PA; NDS; QL (60 per 30 days) |
| <i>benztropine injection solution 1 mg/ml</i> | 1 | |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>bromocriptine oral capsule 5 mg</i> | 1 | |
| <i>bromocriptine oral tablet 2.5 mg</i> | 1 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 1 | |
| <i>carbidopa oral tablet 25 mg</i> | 1 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 1 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 1 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | |
| <i>entacapone oral tablet 200 mg</i> | 1 | |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 42 MG | 4 | PA; LA; NDS; QL (300 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 4 | PA; NDS; QL (150 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10-15-20-25-30 MG | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 2 | QL (30 per 30 days) |
| ONGENTYS ORAL CAPSULE 25 MG, 50 MG | 3 | PA; NDS; QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 258 MG | 3 | ST; LA; NDS; QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 322 MG/DAY(129 MG X1-193MG X1) | 3 | ST; LA; NDS; QL (60 per 30 days) |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> | 1 | |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 1 | |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i> | 1 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 1 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 1 | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | 1 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 1 | |
| XADAGO ORAL TABLET 100 MG, 50 MG | 4 | PA; NDS; QL (30 per 30 days) |
| Antipsychotic Agents | | |
| Antipsychotic Agents | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML, 960 MG/3.2 ML | 4 | NDS |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 4 | NDS; QL (1 per 28 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 4 | NDS; QL (1 per 28 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 1 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> | 1 | |
| <i>aripiprazole oral tablet 2 mg</i> | 1 | QL (60 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 10 mg</i> | 4 | ST; NDS; QL (90 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 15 mg</i> | 4 | ST; NDS; QL (60 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 675 MG/2.4 ML | 4 | NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML | 4 | NDS; QL (3.9 per 56 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML | 4 | NDS; QL (1.6 per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML | 4 | NDS; QL (2.4 per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML | 4 | NDS; QL (3.2 per 28 days) |
| <i>asenapine maleate sublingual tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 4 | ST; NDS; QL (30 per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 1 | |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 1 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg</i> | 1 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | 1 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet,disintegrating 200 mg</i> | 4 | ST; NDS; QL (120 per 30 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 4 | ST; NDS; QL (60 per 30 days) |
| FANAPT ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)- 4MG(2)-6MG(2) | 3 | ST; NDS |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 1 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 1 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 1 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 1 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 1 | |
| <i>haloperidol lactate intramuscular syringe 5 mg/ml</i> | 1 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 1 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 1 | |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 4 | NDS; QL (3.5 per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 4 | NDS; QL (5 per 180 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 4 | NDS; QL (0.75 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 4 | NDS; QL (1 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 4 | NDS; QL (1.5 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 2 | QL (0.25 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 4 | NDS; QL (0.5 per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 4 | NDS; QL (0.88 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 4 | NDS; QL (1.32 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 4 | NDS; QL (1.75 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 4 | NDS; QL (2.63 per 84 days) |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG | 3 | NDS; QL (30 per 30 days) |
| LATUDA ORAL TABLET 80 MG | 3 | NDS; QL (60 per 30 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 1 | |
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | 1 | QL (30 per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> | 1 | QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 4 | PA NSO; NDS; QL (30 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------------|
| <i>molindone oral tablet 10 mg</i> | 1 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 1 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 1 | QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 4 | PA NSO; LA; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>olanzapine oral tablet, disintegrating 10 mg, 15 mg, 20 mg, 5 mg</i> | 1 | |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i> | 1 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> | 1 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 1 | |
| PERSERIS ABDOMINAL SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 120 MG, 90 MG | 4 | NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 1 | |
| <i>quetiapine oral tablet 150 mg</i> | 1 | QL (30 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | 1 | |
| REXULTI ORAL TABLET 0.25 MG | 4 | NDS; QL (120 per 30 days) |
| REXULTI ORAL TABLET 0.5 MG | 4 | NDS; QL (60 per 30 days) |
| REXULTI ORAL TABLET 1 MG, 2 MG, 3 MG, 4 MG | 4 | NDS; QL (30 per 30 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 12.5 MG/2 ML | 3 | NDS; QL (2 per 28 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML | 4 | NDS; QL (2 per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> | 1 | |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>risperidone oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 4 | ST; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 100 MG/0.28 ML | 4 | NDS; QL (0.28 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 125 MG/0.35 ML | 4 | NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 150 MG/0.42 ML | 4 | NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 200 MG/0.56 ML | 4 | NDS; QL (0.56 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 250 MG/0.7 ML | 4 | NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 50 MG/0.14 ML | 4 | NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 75 MG/0.21 ML | 4 | NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 4 | ST; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 4 | ST; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE, DOSE PACK 1.5 MG (1)- 3 MG (6) | 3 | ST; NDS |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------|
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> | 1 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG, 300 MG | 4 | NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 4 | NDS; QL (1 per 28 days) |
| Antivirals (Systemic) | | |
| Antiretrovirals | | |
| <i>abacavir oral solution 20 mg/ml</i> | 1 | |
| <i>abacavir oral tablet 300 mg</i> | 1 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 1 | |
| APTIVUS ORAL CAPSULE 250 MG | 4 | NDS |
| <i>atazanavir oral capsule 150 mg, 200 mg, 300 mg</i> | 1 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 4 | NDS; QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML | 4 | NDS |
| <i>cabotegravir intramuscular suspension, extended release 400 mg/2 ml (200 mg/ml), 600 mg/3 ml (200 mg/ml)</i> | 4 | NDS; QL (24 per 365 days) |
| CIMDUO ORAL TABLET 300-300 MG | 4 | NDS |
| COMPLERA ORAL TABLET 200-25-300 MG | 4 | NDS |
| <i>darunavir oral tablet 600 mg, 800 mg</i> | 4 | NDS |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 4 | NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 4 | NDS |
| <i>didanosine oral capsule, delayed release(dr/ec) 250 mg, 400 mg</i> | 1 | |
| DOVATO ORAL TABLET 50-300 MG | 4 | NDS |
| EDURANT ORAL TABLET 25 MG | 4 | NDS |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | 1 | |
| <i>efavirenz oral tablet 600 mg</i> | 1 | |
| <i>efavirenz-emtricitabin-tenofovir oral tablet 600-200-300 mg</i> | 4 | NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------|
| <i>efavirenz-lamivu-tenofovir disoproxil fumarate oral tablet 400-300-300 mg, 600-300-300 mg</i> | 4 | NDS |
| <i>emtricitabine oral capsule 200 mg</i> | 1 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | 4 | NDS |
| <i>emtricitabine-tenofovir (tdf) oral tablet 200-300 mg</i> | 3 | NDS |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 3 | NDS |
| <i>etravirine oral tablet 100 mg, 200 mg</i> | 4 | NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 4 | NDS |
| <i>fosamprenavir oral tablet 700 mg</i> | 4 | NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 4 | NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 4 | NDS |
| INTELENCE ORAL TABLET 25 MG | 3 | NDS |
| ISENTRESS HD ORAL TABLET 600 MG | 4 | NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 4 | NDS |
| ISENTRESS ORAL TABLET 400 MG | 4 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | 4 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | 3 | NDS |
| JULUCA ORAL TABLET 50-25 MG | 4 | NDS |
| <i>lamivudine oral solution 10 mg/ml</i> | 1 | |
| <i>lamivudine oral tablet 100 mg, 150 mg, 300 mg</i> | 1 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 1 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 3 | NDS |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5 ml</i> | 1 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | 1 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | 3 | NDS; QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> | 4 | NDS |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 1 | |
| <i>nevirapine oral tablet 200 mg</i> | 1 | |
| <i>nevirapine oral tablet extended release 24 hr 100 mg, 400 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| NORVIR ORAL POWDER IN PACKET 100 MG | 3 | NDS |
| ODEFSEY ORAL TABLET 200-25-25 MG | 4 | NDS |
| PIFELTRO ORAL TABLET 100 MG | 4 | NDS |
| PREZCOBIX ORAL TABLET 800-150 MG-MG | 4 | NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 4 | NDS |
| PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG, 800 MG | 4 | NDS |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 4 | NDS |
| <i>rilpivirine intramuscular suspension, extended release 600 mg/2 ml (300 mg/ml), 900 mg/3 ml (300 mg/ml)</i> | 4 | NDS |
| <i>ritonavir oral tablet 100 mg</i> | 1 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 4 | NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 4 | NDS |
| SELZENTRY ORAL TABLET 25 MG | 2 | |
| SELZENTRY ORAL TABLET 75 MG | 4 | NDS |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 4 | NDS |
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK) | 4 | NDS |
| SYMITUZA ORAL TABLET 800-150-200-10 MG | 4 | NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 4 | NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 1 | |
| TIVICAY ORAL TABLET 10 MG | 3 | NDS |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 4 | NDS |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 4 | NDS |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 4 | NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 4 | NDS |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 4 | NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| VEMLIDY ORAL TABLET 25 MG | 4 | NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 4 | NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 4 | NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 4 | NDS |
| VOCABRIA ORAL TABLET 30 MG | 3 | NDS |
| <i>zidovudine oral capsule 100 mg</i> | 1 | |
| <i>zidovudine oral syrup 10 mg/ml</i> | 1 | |
| <i>zidovudine oral tablet 300 mg</i> | 1 | |
| Antivirals, Miscellaneous | | |
| <i>oseltamivir oral capsule 30 mg</i> | 1 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> | 1 | QL (48 per 180 days) |
| <i>oseltamivir oral capsule 75 mg</i> | 1 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> | 1 | QL (540 per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150-100 MG, 300 MG (150 MG X 2)-100 MG | 1 | |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 4 | PA; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 3 | NDS; QL (60 per 180 days) |
| <i>rimantadine oral tablet 100 mg</i> | 1 | |
| XOFLUZA ORAL TABLET 20 MG, 40 MG | 3 | NDS; QL (4 per 180 days) |
| XOFLUZA ORAL TABLET 80 MG | 3 | NDS; QL (2 per 180 days) |
| Hcv Antivirals | | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 4 | PA; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 4 | PA; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG, 400- 100 MG | 4 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 4 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45- 200 MG | 4 | PA; NDS; QL (56 per 28 days) |
| HARVONI ORAL TABLET 45-200 MG, 90- 400 MG | 4 | PA; NDS; QL (28 per 28 days) |
| <i>ledipasvir-sofosbuvir oral tablet 90-400 mg</i> | 4 | PA; NDS; QL (28 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| MAVYRET ORAL PELLETS IN PACKET 50-20 MG | 4 | PA; NDS; QL (84 per 28 days) |
| MAVYRET ORAL TABLET 100-40 MG | 4 | PA; NDS; QL (84 per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 4 | PA; NDS; QL (28 per 28 days) |
| Interferons | | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 4 | NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 4 | NDS |
| Nucleosides And Nucleotides | | |
| <i>acyclovir 1,000 mg/20 ml vial sdv 50 mg/ml</i> | 1 | PA BvD |
| <i>acyclovir oral capsule 200 mg</i> | 1 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> | 1 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 1 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 1 | PA BvD; HI |
| <i>adefovir oral tablet 10 mg</i> | 1 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 1 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 1 | |
| <i>lagevrio (eua) oral capsule 200 mg</i> | 1 | |
| <i>ribavirin oral capsule 200 mg</i> | 1 | |
| <i>ribavirin oral tablet 200 mg</i> | 1 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> | 1 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> | 4 | NDS |
| <i>valganciclovir oral tablet 450 mg</i> | 1 | |
| Blood Products/Modifiers/Volume Expanders | | |
| Anticoagulants | | |
| <i>dabigatran etexilate oral capsule 150 mg, 75 mg</i> | 1 | QL (60 per 30 days) |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 2 | |
| ELIQUIS ORAL TABLET 2.5 MG | 2 | QL (60 per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 2 | QL (74 per 30 days) |
| <i>enoxaparin subcutaneous solution 300 mg/3 ml</i> | 1 | QL (30 per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> | 1 | QL (60 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> | 1 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> | 1 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> | 1 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> | 1 | QL (36 per 30 days) |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i> | 4 | NDS; QL (24 per 30 days) |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> | 1 | QL (15 per 30 days) |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i> | 4 | NDS; QL (12 per 30 days) |
| <i>fondaparinux subcutaneous syringe 7.5 mg/0.6 ml</i> | 4 | NDS; QL (18 per 30 days) |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | 1 | PA BvD; HI |
| <i>heparin sodium 1,000 unit/ml vial sdv,outer</i> | 1 | PA BvD |
| <i>heparin sodium 10,000 unit/ml vial mdv,outer</i> | 1 | PA BvD |
| <i>heparin sodium 5,000 unit/ml vial suv, outer</i> | 1 | PA BvD |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | |
| PRADAXA ORAL CAPSULE 110 MG, 150 MG, 75 MG | 2 | |
| PRADAXA ORAL PELLETS IN PACKET 110 MG, 150 MG, 20 MG, 30 MG, 40 MG, 50 MG | 2 | |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)-20 MG (9) | 2 | |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION 1 MG/ML | 2 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG | 2 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 2 | QL (60 per 30 days) |
| Blood Formation Modifiers | | |
| BERINERT INTRAVENOUS KIT 500 UNIT (10 ML) | 4 | PA BvD; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) | 4 | PA BvD; LA; NDS |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| FYLNETRA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| GRANIX SUBCUTANEOUS SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 4 | PA; NDS |
| GRANIX SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 4 | PA; NDS |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 4 | PA; LA; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 4 | PA; LA; NDS; QL (20 per 30 days) |
| LEUKINE INJECTION RECON SOLN 250 MCG | 4 | NDS |
| NEULASTA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 4 | PA; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 4 | PA; NDS |
| NYVEPRIA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG | 4 | PA; LA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL POWDER IN PACKET 25 MG | 4 | PA; LA; NDS; QL (180 per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG | 4 | PA; LA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL TABLET 25 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| RELEUKO SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 2 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 2 | PA; QL (4 per 28 days) |
| UDENYCA AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 6 MG/0.6 ML | 4 | PA; NDS |
| UDENYCA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 4 | PA; NDS |
| ZIEXTENZO SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 4 | PA; NDS |
| Hematologic Agents, Miscellaneous | | |
| ADAKVEO INTRAVENOUS SOLUTION 10 MG/ML | 4 | PA; NDS |
| <i>anagrelide oral capsule 0.5 mg, 1 mg</i> | 1 | |
| CABLIVI INJECTION KIT 11 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 3 | NDS |
| SIKLOS ORAL TABLET 100 MG | 3 | PA; NDS |
| TAVALISSE ORAL TABLET 100 MG, 150 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| <i>tranexamic acid oral tablet 650 mg</i> | 1 | |
| Platelet-Aggregation Inhibitors | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 1 | QL (60 per 30 days) |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 2 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 1 | |
| <i>clopidogrel oral tablet 75 mg</i> | 1 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 1 | |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 1 | |
| <i>prasugrel oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| Caloric Agents | | |
| Caloric Agents | | |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 2.75%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 2.75 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 4.25%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 5%/D15W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| CLINIMIX E 5%/D20W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| <i>dextrose 10 % in water (d10w) intravenous parenteral solution 10 %</i> | 1 | PA BvD; HI |
| <i>dextrose 5 % in water (d5w) intravenous piggyback 5 %</i> | 1 | PA BvD; HI |
| <i>dextrose 5%-water iv soln single use</i> | 1 | PA BvD; HI |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 3 | PA BvD; HI; NDS |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 3 | PA BvD; HI; NDS |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 3 | PA BvD; HI; NDS |
| TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 3 | PA BvD; HI; NDS |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 3 | PA BvD; HI; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------------|
| Cardiovascular Agents | | |
| Alpha-Adrenergic Agents | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr</i> | 1 | QL (4 per 28 days) |
| <i>clonidine transdermal patch weekly 0.3 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 1 | |
| <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i> | 4 | PA; NDS; QL (180 per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>phenylephrine hcl injection solution 10 mg/ml</i> | 1 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 1 | |
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 1 | |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 1 | |
| EDARBI ORAL TABLET 40 MG, 80 MG | 2 | |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG | 2 | |
| ENTRESTO ORAL TABLET 24-26 MG | 2 | QL (180 per 30 days) |
| ENTRESTO ORAL TABLET 49-51 MG, 97-103 MG | 2 | QL (60 per 30 days) |
| <i>eprosartan oral tablet 600 mg</i> | 1 | |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 1 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 1 | |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 1 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>olmesartan-amlodipin-hcthiaid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 1 | |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------|
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 1 | |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 1 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 1 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 1 | |
| Angiotensin-Converting Enzyme Inhibitors | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 1 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | 1 | |
| <i>enalapril maleate oral solution 1 mg/ml</i> | 1 | ST; QL (1200 per 30 days) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 1 | |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 1 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 1 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>trandolapril-verapamil oral tablet, ir - er, biphasic 24hr 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 1 | |
| Antiarrhythmic Agents | | |
| <i>amiodarone oral tablet 100 mg, 200 mg, 400 mg</i> | 1 | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 1 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 1 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | |
| <i>lidocaine (pf) intravenous syringe 100 mg/5 ml (2 %), 50 mg/5 ml (1 %)</i> | 1 | |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | 1 | |
| MULTAQ ORAL TABLET 400 MG | 2 | |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> | 1 | |
| <i>procainamide intravenous syringe 100 mg/ml</i> | 1 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | 1 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 1 | |
| <i>quinidine gluconate oral tablet extended release 324 mg</i> | 1 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 1 | |
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 1 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 1 | |
| <i>betaxolol oral tablet 10 mg, 20 mg</i> | 1 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 1 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 1 | |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | 1 | |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 1 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | 1 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> | 1 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| Calcium-Channel Blocking Agents | | |
| <i>cartia xt oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | 1 | |
| <i>diltiazem hcl oral capsule, extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 1 | |
| <i>diltiazem hcl oral capsule, extended release 24 hr 360 mg, 420 mg</i> | 1 | |
| <i>diltiazem hcl oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | 1 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 1 | |
| <i>diltiazem hcl oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1 | |
| <i>dilt-xr oral capsule, ext. rel 24h degradable 120 mg, 180 mg, 240 mg</i> | 1 | |
| <i>matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>taztia xt oral capsule, extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> | 1 | |
| <i>tiadylt er oral capsule, extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 1 | |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | 1 | |
| <i>verapamil oral capsule, ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> | 1 | |
| <i>verapamil oral capsule, ext rel. pellets 24 hr 360 mg</i> | 3 | NDS |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 1 | |
| Cardiovascular Agents, Miscellaneous | | |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 2 | QL (600 per 30 days) |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 3 | NDS; QL (60 per 30 days) |
| <i>digitek oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 1 | |
| <i>digox oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 1 | |
| <i>digoxin injection solution 250 mcg/ml (0.25 mg/ml)</i> | 1 | |
| <i>digoxin injection syringe 250 mcg/ml (0.25 mg/ml)</i> | 1 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 1 | |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml</i> | 1 | QL (4 per 30 days) |
| <i>epinephrine injection solution 1 mg/ml</i> | 1 | |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> | 4 | PA; NDS; QL (18 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> | 4 | NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg</i> | 1 | QL (60 per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 500 mg</i> | 1 | QL (120 per 30 days) |
| <i>sajazir subcutaneous syringe 30 mg/3 ml</i> | 4 | PA; LA; NDS; QL (18 per 30 days) |
| SYMJEPI INJECTION SYRINGE 0.15 MG/0.3 ML, 0.3 MG/0.3 ML | 3 | NDS; QL (4 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 3 | PA; NDS; QL (30 per 30 days) |
| Dihydropyridines | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 1 | |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 1 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 1 | |
| <i>amlodipine-valsartan-hcthiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | 1 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 1 | |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 3 | ST; NDS; QL (300 per 30 days) |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | 1 | |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | 1 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg</i> | 1 | |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i> | 1 | |
| Diuretics | | |
| <i>amiloride oral tablet 5 mg</i> | 1 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 1 | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 1 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 1 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| JYNARQUE ORAL TABLET 15 MG, 30 MG | 4 | PA; LA; NDS; QL (120 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| JYNARQUE ORAL TABLETS, SEQUENTIAL 15 MG (AM)/ 15 MG (PM), 30 MG (AM)/ 15 MG (PM), 45 MG (AM)/ 15 MG (PM), 60 MG (AM)/ 30 MG (PM), 90 MG (AM)/ 30 MG (PM) | 4 | PA; LA; NDS; QL (56 per 28 days) |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | 1 | |
| <i>torse mide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |
| Dyslipidemics | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg</i> | 1 | |
| <i>amlodipine-atorvastatin oral tablet 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 1 | QL (30 per 30 days) |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| <i>cholestyramine (with sugar) oral powder in packet 4 gram</i> | 1 | |
| <i>cholestyramine light oral powder in packet 4 gram</i> | 1 | |
| <i>colesevelam oral powder in packet 3.75 gram</i> | 1 | |
| <i>colesevelam oral tablet 625 mg</i> | 1 | |
| <i>colestipol oral packet 5 gram</i> | 1 | |
| <i>colestipol oral tablet 1 gram</i> | 1 | |
| EZALLOR SPRINKLE ORAL CAPSULE, SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG | 3 | ST; NDS; QL (30 per 30 days) |
| <i>ezetimibe oral tablet 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 1 | QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> | 1 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 1 | |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg, 45 mg</i> | 1 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> | 1 | |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | |
| <i>icosapent ethyl oral capsule 0.5 gram</i> | 1 | QL (240 per 30 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> | 1 | QL (120 per 30 days) |
| JUXTAPID ORAL CAPSULE 10 MG, 5 MG | 4 | PA; LA; NDS; QL (28 per 28 days) |
| JUXTAPID ORAL CAPSULE 20 MG, 30 MG | 4 | PA; LA; NDS; QL (56 per 28 days) |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG | 3 | NDS; QL (30 per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| NEXLETOL ORAL TABLET 180 MG | 2 | QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 2 | QL (30 per 30 days) |
| <i>niacin oral tablet 500 mg</i> | 1 | |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i> | 1 | |
| <i>niacor oral tablet 500 mg</i> | 1 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> | 1 | QL (120 per 30 days) |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/ML | 2 | LA; QL (2 per 28 days) |
| <i>pravastatin oral tablet 10 mg, 80 mg</i> | 1 | |
| <i>pravastatin oral tablet 20 mg, 40 mg</i> | 1 | QL (30 per 30 days) |
| <i>prevalite oral powder in packet 4 gram</i> | 1 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 2 | QL (7 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 2 | QL (6 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 2 | QL (6 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | QL (30 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| Renin-Angiotensin-Aldosterone System Inhibitors | | |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> | 1 | |
| CAROSPIR ORAL SUSPENSION 25 MG/5 ML | 3 | ST; NDS; QL (600 per 30 days) |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 1 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG | 2 | PA; QL (30 per 30 days) |
| Vasodilators | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 1 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 1 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | |
| <i>isosorbide-hydralazine oral tablet 20-37.5 mg</i> | 1 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 1 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> | 1 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 1 | |
| Central Nervous System Agents | | |
| Central Nervous System Agents | | |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| AUBAGIO ORAL TABLET 14 MG, 7 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 4 | PA; LA; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | 4 | PA; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 24 MG | 4 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 4 | PA; NDS; QL (210 per 30 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 6 MG (14)-12 MG (14)-24 MG (14) | 4 | PA; NDS; QL (42 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|------------------------------|
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 4 | PA; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 4 | PA; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 4 | PA; NDS; QL (15 per 30 days) |
| <i>caffeine citrate intravenous solution 60 mg/3 ml (20 mg/ml)</i> | 1 | PA BvD |
| <i>caffeine citrate oral solution 60 mg/3 ml (20 mg/ml)</i> | 1 | |
| <i>clonidine hcl oral tablet extended release 12 hr 0.1 mg</i> | 1 | |
| COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML | 4 | PA; NDS; QL (30 per 30 days) |
| COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML | 4 | PA; NDS; QL (12 per 28 days) |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> | 1 | PA; QL (60 per 30 days) |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | QL (60 per 30 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 10 mg, 15 mg, 5 mg</i> | 1 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | 1 | QL (180 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg, 5 mg</i> | 1 | QL (90 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20 mg, 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 15 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 20 mg, 25 mg, 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | QL (60 per 30 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg</i> | 4 | PA; NDS; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 240 mg</i> | 4 | PA; NDS; QL (60 per 30 days) |
| ENSPRYNG SUBCUTANEOUS SYRINGE 120 MG/ML | 4 | PA; LA; NDS |
| <i> fingolimod oral capsule 0.5 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| GILENYA ORAL CAPSULE 0.25 MG | 4 | PA; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> | 4 | PA; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> | 4 | PA; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | |
| INGREZZA INITIATION PACK ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | 4 | PA; LA; NDS |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 4 | PA; LA; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | |
| <i>lithium carbonate oral tablet extended release 300 mg, 450 mg</i> | 1 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG | 4 | PA; LA; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 4 | PA; LA; NDS; QL (112 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| MAYZENT ORAL TABLET 1 MG, 2 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) | 3 | PA; LA; NDS |
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) | 4 | PA; LA; NDS |
| <i>metadate er oral tablet extended release 20 mg</i> | 1 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> | 1 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 20 mg, 40 mg, 60 mg</i> | 1 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> | 1 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg, 20 mg</i> | 1 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 18 mg (bx rating), 27 mg, 27 mg (bx rating), 54 mg, 54 mg (bx rating)</i> | 1 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg, 36 mg (bx rating)</i> | 1 | QL (60 per 30 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | 4 | PA; LA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML | 4 | PA; LA; NDS |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | 4 | PA; LA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML | 4 | PA; LA; NDS |
| RADICAVA INTRAVENOUS SOLUTION 30 MG/100 ML | 4 | PA; NDS; QL (2800 per 28 days) |
| <i>riluzole oral tablet 50 mg</i> | 1 | QL (60 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 2 | QL (60 per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) | 2 | |
| TASCENSO ODT ORAL TABLET,DISINTEGRATING 0.25 MG, 0.5 MG | 4 | PA; NDS; QL (30 per 30 days) |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> | 4 | PA; LA; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 4 | PA; LA; NDS; QL (120 per 30 days) |
| Contraceptives | | |
| Contraceptives | | |
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg-35 mcg</i> | 1 | |
| <i>amethia oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>apri oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | 1 | |
| <i>ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 1 | |
| <i>aurovela 1/20 (21) oral tablet 1-20 mg-mcg</i> | 1 | |
| <i>aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>ayuna oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--------------------------|
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 1 | |
| <i>camila oral tablet 0.35 mg</i> | 1 | |
| <i>camrese oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>caziant (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | 1 | |
| <i>chateal eq (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>cryelle (28) oral tablet 0.3-30 mg-mcg</i> | 1 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg-35 mcg</i> | 1 | |
| <i>daysee oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>deblitane oral tablet 0.35 mg</i> | 1 | |
| <i>desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 1 | |
| <i>elinest oral tablet 0.3-30 mg-mcg</i> | 1 | |
| ELLA ORAL TABLET 30 MG | 3 | NDS; QL (6 per 365 days) |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |
| <i>enilloring vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>errin oral tablet 0.35 mg</i> | 1 | |
| <i>estarylla oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 1 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>gemmily oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>hailey oral tablet 1.5-30 mg-mcg</i> | 1 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24 hr</i> | 1 | QL (1 per 28 days) |
| <i>heather oral tablet 0.35 mg</i> | 1 | |
| <i>iclevia oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> | 1 | |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>jaimiess oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>jencycla oral tablet 0.35 mg</i> | 1 | |
| <i>jolessa oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>juleber oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 1 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> | 1 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>kalliga oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>kelnor 1-50 (28) oral tablet 1-50 mg-mcg</i> | 1 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>l norgest/e.estradiol-e.estradiol oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7), 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 1 | |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | 1 | |
| <i>larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>leena 28 oral tablet 0.5/1/0.5-35 mg-mcg</i> | 1 | |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>levonorgest-eth.estradiol-iron oral tablet 0.1 mg-0.02 mg (21)/iron (7)</i> | 1 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-0.03 mg</i> | 1 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>lojaimiess oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | 1 | |
| <i>lo-zumandimine (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>lutera (28) oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>lyleq oral tablet 0.35 mg</i> | 1 | |
| <i>lyza oral tablet 0.35 mg</i> | 1 | |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>merzee oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>microgestin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>microgestin 1/20 (21) oral tablet 1-20 mg-mcg</i> | 1 | |
| <i>microgestin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>microgestin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>mili oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>mono-linyah oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>necon 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 1 | |
| <i>nikki (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>nora-be oral tablet 0.35 mg</i> | 1 | |
| <i>norelgestromin-ethin.estradiol transdermal patch weekly 150-35 mcg/24 hr</i> | 1 | QL (3 per 28 days) |
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> | 1 | |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i> | 1 | |
| <i>norethindrone-e.estradiol-iron oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9), 1.5 mg-30 mcg (21)/75 mg (7)</i> | 1 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg (28), 0.25-35 mg-mcg</i> | 1 | |
| <i>nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 1 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | 1 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg-35 mcg</i> | 1 | |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 1 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>ocella oral tablet 3-0.03 mg</i> | 1 | |
| <i>philith oral tablet 0.4-35 mg-mcg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>pimtreea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>pirmella oral tablet 0.5/0.75/1 mg- 35 mcg, 1-35 mg-mcg</i> | 1 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | 1 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 1 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | 1 | |
| <i>simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>simpesse oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 1 | QL (91 per 84 days) |
| SLYND ORAL TABLET 4 MG (28) | 3 | NDS |
| <i>sprintec (28) oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>syeda oral tablet 3-0.03 mg</i> | 1 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>taysofy oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | 1 | |
| <i>tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 1 | |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 1 | |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 1 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 1 | |
| <i>tulana oral tablet 0.35 mg</i> | 1 | |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i> | 1 | |
| <i>tyblume oral tablet, chewable 0.1 mg- 20 mcg</i> | 3 | NDS |
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | 1 | |
| <i>vestura (28) oral tablet 3-0.02 mg</i> | 1 | |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | 1 | |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 1 | |
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i> | 1 | |
| <i>vylibra oral tablet 0.25-35 mg-mcg</i> | 1 | |
| <i>wera (28) oral tablet 0.5-35 mg-mcg</i> | 1 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | 1 | QL (3 per 28 days) |
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | 1 | QL (3 per 28 days) |
| <i>zarah oral tablet 3-0.03 mg</i> | 1 | |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | 1 | |
| <i>zumandimine (28) oral tablet 3-0.03 mg</i> | 1 | |
| Cough And Cold Products | | |
| Cough And Cold Products | | |
| <i>benzonatate oral capsule 100 mg, 200 mg</i> | 5 | EX |
| Dental And Oral Agents | | |
| Dental And Oral Agents | | |
| <i>cevimeline oral capsule 30 mg</i> | 1 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>fluoride (sodium) dental solution 0.2 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------|
| KOURZEQ DENTAL PASTE 0.1 % | 1 | |
| <i>oralone dental paste 0.1 %</i> | 1 | |
| <i>paroex oral rinse mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>periogard mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 1 | |
| <i>sodium fluoride-pot nitrate dental paste 1.1-5 %</i> | 1 | |
| <i>triamcinolone acetonide dental paste 0.1 %</i> | 1 | |
| Dermatological Agents | | |
| Dermatological Agents, Other | | |
| <i>accutane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 1 | |
| <i>acyclovir topical cream 5 %</i> | 1 | QL (5 per 4 days) |
| <i>acyclovir topical ointment 5 %</i> | 1 | QL (30 per 30 days) |
| ALCOHOL 70% SWABS | 1 | |
| ALCOHOL PADS TOPICAL PADS, MEDICATED | 1 | |
| ALCOHOL PREP SWABS TOPICAL PADS, MEDICATED | 1 | |
| <i>ammonium lactate topical cream 12 %</i> | 1 | |
| <i>ammonium lactate topical lotion 12 %</i> | 1 | |
| <i>amnestem oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | |
| BD SINGLE USE SWAB | 1 | |
| <i>calcipotriene scalp solution 0.005 %</i> | 1 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> | 1 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | 1 | QL (120 per 30 days) |
| CARETOUCH ALCOHOL 70% PREP PAD | 1 | |
| <i>claravis oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| CURITY ALCOHOL PREPS 2 PLY,MEDIUM | 1 | |
| DROPSAFE ALCOHOL 70% PREP PADS | 1 | |
| EASY COMFORT ALCOHOL 70% PAD | 1 | |
| EASY TOUCH ALCOHOL 70% PADS GAMMA-STERILIZED | 1 | |
| <i>fluorouracil topical cream 0.5 %</i> | 4 | NDS |
| <i>fluorouracil topical cream 5 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>fluorouracil topical solution 2 %, 5 %</i> | 1 | |
| HEB INCONTROL ALCOHOL 70% PADS | 1 | |
| <i>imiquimod topical cream in packet 5 %</i> | 1 | QL (24 per 30 days) |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| IV ANTISEPTIC WIPES | 1 | |
| KENDALL ALCOHOL 70% PREP PAD | 1 | |
| KLISYRI TOPICAL OINTMENT IN PACKET 1 % | 2 | QL (5 per 5 days) |
| <i>methoxsalen oral capsule, liqd-filled, rapid rel 10 mg</i> | 4 | NDS |
| PANRETIN TOPICAL GEL 0.1 % | 4 | NDS; QL (180 per 30 days) |
| <i>penciclovir topical cream 1 %</i> | 1 | |
| <i>podofilox topical solution 0.5 %</i> | 1 | |
| PRO COMFORT ALCOHOL 70% PADS | 1 | |
| PURE COMFORT ALCOHOL 70% PADS | 1 | |
| RA ISOPROPYL ALCOHOL 70% WIPES | 1 | |
| REGRANEX TOPICAL GEL 0.01 % | 4 | PA; NDS; QL (30 per 30 days) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 3 | NDS; QL (180 per 30 days) |
| SURE COMFORT ALCOHOL PREP PADS | 1 | |
| SURE-PREP ALCOHOL PREP PADS | 1 | |
| TRUE COMFORT ALCOHOL 70% PADS | 1 | |
| TRUE COMFORT PRO ALCOHOL PADS | 1 | |
| ULTILET ALCOHOL STERL SWAB | 1 | |
| VALCHLOR TOPICAL GEL 0.016 % | 4 | LA; NDS |
| WEBCOL ALCOHOL PREPS 20'S,LARGE | 1 | |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 1 | |
| Dermatological Antibacterials | | |
| <i>clindamycin phosphate topical foam 1 %</i> | 1 | QL (100 per 30 days) |
| <i>clindamycin phosphate topical solution 1 %</i> | 1 | QL (180 per 30 days) |
| <i>clindamycin phosphate topical swab 1 %</i> | 1 | |
| <i>clindamycin-benzoyl peroxide topical gel 1-5 %, 1.2 %(1 % base) -5 %</i> | 1 | |
| <i>ery pads topical swab 2 %</i> | 1 | |
| <i>erythromycin with ethanol topical gel 2 %</i> | 1 | QL (180 per 30 days) |
| <i>erythromycin with ethanol topical solution 2 %</i> | 1 | QL (180 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| <i>erythromycin-benzoyl peroxide topical gel 3-5 %</i> | 1 | |
| <i>gentamicin topical cream 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>metronidazole topical cream 0.75 %</i> | 1 | |
| <i>metronidazole topical gel 0.75 %, 1 %</i> | 1 | |
| <i>metronidazole topical lotion 0.75 %</i> | 1 | |
| <i>mupirocin topical ointment 2 %</i> | 1 | QL (220 per 30 days) |
| <i>neucac topical gel 1.2 %(1 % base) -5 %</i> | 1 | |
| <i>rosadan topical cream 0.75 %</i> | 1 | |
| <i>selenium sulfide topical lotion 2.5 %</i> | 1 | |
| <i>silver sulfadiazine topical cream 1 %</i> | 1 | |
| <i>ssd topical cream 1 %</i> | 1 | |
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> | 1 | |
| Dermatological Anti-Inflammatory Agents | | |
| <i>ala-cort topical cream 1 %</i> | 1 | |
| <i>ala-scalp topical lotion 2 %</i> | 1 | |
| <i>alclometasone topical cream 0.05 %</i> | 1 | |
| <i>alclometasone topical ointment 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 1 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 1 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | 1 | |
| <i>betamethasone valerate topical foam 0.12 %</i> | 1 | |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 1 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 1 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 1 | |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 1 | |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 1 | |
| <i>betamethasone, augmented topical ointment 0.05 %</i> | 1 | |
| <i>clobetasol scalp solution 0.05 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>clobetasol topical cream 0.05 %</i> | 1 | |
| <i>clobetasol topical foam 0.05 %</i> | 1 | |
| <i>clobetasol topical gel 0.05 %</i> | 1 | |
| <i>clobetasol topical lotion 0.05 %</i> | 1 | |
| <i>clobetasol topical ointment 0.05 %</i> | 1 | |
| <i>clobetasol topical shampoo 0.05 %</i> | 1 | |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 1 | |
| <i>clobetasol-emollient topical foam 0.05 %</i> | 1 | |
| <i>desonide topical cream 0.05 %</i> | 1 | |
| <i>desonide topical lotion 0.05 %</i> | 1 | |
| <i>desonide topical ointment 0.05 %</i> | 1 | |
| <i>desoximetasone topical cream 0.05 %, 0.25 %</i> | 1 | QL (120 per 30 days) |
| <i>desoximetasone topical gel 0.05 %</i> | 1 | QL (120 per 30 days) |
| <i>desoximetasone topical ointment 0.05 %, 0.25 %</i> | 1 | QL (120 per 30 days) |
| <i>diflorasone topical ointment 0.05 %</i> | 1 | QL (180 per 30 days) |
| EUCRISA TOPICAL OINTMENT 2 % | 2 | |
| <i>fluocinolone topical cream 0.01 %, 0.025 %</i> | 1 | |
| <i>fluocinolone topical ointment 0.025 %</i> | 1 | |
| <i>fluocinonide topical cream 0.05 %</i> | 1 | |
| <i>fluocinonide topical gel 0.05 %</i> | 1 | |
| <i>fluocinonide topical ointment 0.05 %</i> | 1 | |
| <i>fluocinonide topical solution 0.05 %</i> | 1 | |
| <i>fluocinonide-emollient topical cream 0.05 %</i> | 1 | |
| <i>fluticasone propionate topical cream 0.05 %</i> | 1 | |
| <i>fluticasone propionate topical ointment 0.005 %</i> | 1 | |
| <i>halobetasol propionate topical cream 0.05 %</i> | 1 | |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 1 | |
| <i>hydrocortisone 2.5% cream</i> | 1 | |
| <i>hydrocortisone butyrate topical cream 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical lotion 0.1 %</i> | 1 | QL (236 per 30 days) |
| <i>hydrocortisone butyrate topical ointment 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical solution 0.1 %</i> | 1 | QL (120 per 30 days) |
| <i>hydrocortisone topical cream 1 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------|
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> | 1 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | 1 | |
| <i>hydrocortisone topical ointment 1 %, 2.5 %</i> | 1 | |
| <i>hydrocortisone valerate topical cream 0.2 %</i> | 1 | |
| <i>hydrocortisone valerate topical ointment 0.2 %</i> | 1 | |
| <i>hydrocortisone-min oil-wht pet topical ointment 1 %</i> | 1 | |
| <i>mometasone topical cream 0.1 %</i> | 1 | |
| <i>mometasone topical ointment 0.1 %</i> | 1 | |
| <i>mometasone topical solution 0.1 %</i> | 1 | |
| <i>pimecrolimus topical cream 1 %</i> | 1 | QL (100 per 30 days) |
| <i>prednicarbate topical ointment 0.1 %</i> | 1 | |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i> | 1 | |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> | 1 | |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> | 1 | |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | 1 | QL (100 per 30 days) |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.1 %, 0.5 %</i> | 1 | |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | 1 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.05 %, 0.1 %, 0.5 %</i> | 1 | |
| <i>trianex topical ointment 0.05 %</i> | 1 | |
| <i>triderm topical cream 0.1 %, 0.5 %</i> | 1 | |
| Dermatological Retinoids | | |
| <i>adapalene topical cream 0.1 %</i> | 1 | |
| <i>adapalene topical gel 0.1 %</i> | 1 | |
| ALTRENO TOPICAL LOTION 0.05 % | 3 | PA; NDS |
| <i>avita topical cream 0.025 %</i> | 1 | PA |
| <i>avita topical gel 0.025 %</i> | 1 | PA |
| <i>tazarotene topical cream 0.1 %</i> | 1 | |
| TAZORAC TOPICAL CREAM 0.05 % | 3 | NDS |
| <i>tretinoin topical cream 0.025 %, 0.05 %, 0.1 %</i> | 1 | PA |
| <i>tretinoin topical gel 0.01 %, 0.025 %, 0.05 %</i> | 1 | PA |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Scabicides And Pediculicides | | |
| <i>malathion topical lotion 0.5 %</i> | 1 | |
| <i>permethrin topical cream 5 %</i> | 1 | |
| Devices | | |
| Devices | | |
| 1ST TIER UNIFINE PENTP 5MM 31G 31 GAUGE X 3/16" | 1 | |
| 1ST TIER UNIFINE PNTIP 4MM 32G 32 GAUGE X 5/32" | 1 | |
| 1ST TIER UNIFINE PNTIP 6MM 31G 31 GAUGE X 1/4" | 1 | |
| 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT 31 GAUGE X 5/16" | 1 | |
| 1ST TIER UNIFINE PNTTP 29GX1/2" 29 GAUGE X 1/2" | 1 | |
| 1ST TIER UNIFINE PNTTP 31GX3/16 31 GAUGE X 3/16" | 1 | |
| 1ST TIER UNIFINE PNTTP 32GX5/32 32 GAUGE X 5/32" | 1 | |
| ABOUTTIME PEN NEEDLE 30G X 8MM 30 GAUGE X 5/16" | 1 | |
| ABOUTTIME PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" | 1 | |
| ABOUTTIME PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" | 1 | |
| ABOUTTIME PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | 1 | |
| ADVOCATE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| ADVOCATE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ADVOCATE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| ADVOCATE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| ADVOCATE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| ADVOCATE INS SYR 0.3 ML 29GX1/2 0.3 ML 29 GAUGE X 1/2" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ADVOCATE INS SYR 0.5 ML 29GX1/2 0.5 ML 29 GAUGE X 1/2" | 1 | |
| ADVOCATE INS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| ADVOCATE INS SYR 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16 | 1 | |
| ADVOCATE PEN NDL 12.7MM 29G 29 GAUGE X 1/2" | 1 | |
| ADVOCATE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | 1 | |
| ADVOCATE PEN NEEDLES 5MM 31G 31 GAUGE X 3/16" | 1 | |
| ADVOCATE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | 1 | |
| AQINJECT PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | |
| AQINJECT PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | |
| ASSURE ID DUO PRO NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| ASSURE ID DUO-SHIELD 30GX3/16" 30 GAUGE X 3/16" | 1 | |
| ASSURE ID DUO-SHIELD 30GX5/16" 30 GAUGE X 5/16" | 1 | |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 1 | |
| ASSURE ID PEN NEEDLE 30GX3/16" 30 GAUGE X 3/16" | 1 | |
| ASSURE ID PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 1 | |
| ASSURE ID PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| ASSURE ID PRO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 1 | |
| ASSURE ID SYR 0.5 ML 29GX1/2" (RX) 0.5 ML 29 GAUGE X 1/2" | 1 | |
| ASSURE ID SYR 0.5 ML 31GX15/64" 0.5 ML 31 GAUGE X 15/64" | 1 | |
| ASSURE ID SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| BD AUTOSHIELD DUO NDL 5MMX30G 30 GAUGE X 3/16" | 1 | |
| BD ECLIPSE 30GX1/2" SYRINGE 1 ML 30 GAUGE X 1/2" | 1 | |
| BD ECLIPSE NEEDLE 30GX1/2" (OTC) 30 X 1/2 " | 1 | |
| BD INS SYR 0.3 ML 8MMX31G(1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | |
| BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN) 1/2 ML 31 GAUGE X 15/64" | 1 | |
| BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE 1 ML 30 GAUGE X 1/2" | 1 | |
| BD INSULIN SYR 1 ML 25GX1" 1 ML 25 X 1" | 1 | |
| BD INSULIN SYR 1 ML 25GX5/8" 1 ML 25 GAUGE X 5/8" | 1 | |
| BD INSULIN SYR 1 ML 26GX1/2" 1 ML 26 X 1/2" | 1 | |
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE 1 ML 27 GAUGE X 5/8" | 1 | |
| BD INSULIN SYR 1 ML 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | 1 | |
| BD INSULIN SYRINGE 1 ML W/O NEEDLE | 1 | |
| BD LUER-LOK SYRINGE 1 ML | 1 | |
| BD NANO 2 GEN PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| BD SAFETGLD INS 0.3 ML 29G 13MM 0.3 ML 29 GAUGE X 1/2" | 1 | |
| BD SAFETGLD INS 0.5 ML 13MMX29G 0.5 ML 29 GAUGE X 1/2" | 1 | |
| BD SAFETYGLD INS 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 1 | |
| BD SAFETYGLD INS 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | 1 | |
| BD SAFETYGLD INS 1 ML 29G 13MM 1 ML 29 GAUGE X 1/2" | 1 | |
| BD SAFETYGLID INS 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 1 | |
| BD SAFETYGLIDE SYRINGE 27GX5/8 1 ML 27 GAUGE X 5/8" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| BD SAFTYGLD INS 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | 1 | |
| BD SAFTYGLD INS 0.5 ML 29G 13MM 0.5 ML 29 GAUGE X 1/2" | 1 | |
| BD SAFTYGLD INS 0.5 ML 6MMX31G 0.5 ML 31 GAUGE X 15/64" | 1 | |
| BD UF MICRO PEN NEEDLE 6MMX32G 32 GAUGE X 1/4" | 1 | |
| BD UF MINI PEN NEEDLE 5MMX31G 31 GAUGE X 3/16" | 1 | |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" | 1 | |
| BD UF ORIG PEN NDL 12.7MMX29G 29 GAUGE X 1/2" | 1 | |
| BD UF SHORT PEN NEEDLE 8MMX31G 31 GAUGE X 5/16" | 1 | |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | 1 | |
| BD VEO INS SYRING 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 1 | |
| BD VEO INS SYRN 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | 1 | |
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" | 1 | |
| BORDERED GAUZE 2"X2" 2 X 2 " | 1 | |
| CAREFINE PEN NEEDLE 12.7MM 29G 29 GAUGE X 1/2" | 1 | |
| CAREFINE PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | 1 | |
| CAREFINE PEN NEEDLE 5MM 32G 32 GAUGE X 3/16" | 1 | |
| CAREFINE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | |
| CAREFINE PEN NEEDLE 8MM 30G 30 GAUGE X 5/16" | 1 | |
| CAREFINE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | 1 | |
| CAREFINE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | 1 | |
| CAREONE SYR 0.3 ML 31GX5/16" SHORT, HRI 0.3 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| CARETOUCH PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | |
| CARETOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| CARETOUCH PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| CARETOUCH PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| CARETOUCH PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | 1 | |
| CARETOUCH PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| CARETOUCH SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| CARETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| CARETOUCH SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| CARETOUCH SYR 1 ML 28GX5/16" 1 ML 28 X 5/16" | 1 | |
| CARETOUCH SYR 1 ML 29GX5/16" 1 ML 29 GAUGE X 5/16 | 1 | |
| CARETOUCH SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | |
| CARETOUCH SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | |
| CLICKFINE 31G X 5/16" NEEDLES 8MM, UNIVERSAL 31 GAUGE X 5/16" | 1 | |
| CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE 32 GAUGE X 5/32" | 1 | |
| CLICKFINE UNIVERSAL 31G X 1/4" 6MM, STORE BRAND 31 GAUGE X 1/4" | 1 | |
| COMFORT EZ INS 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | 1 | |
| COMFORT EZ INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| COMFORT EZ INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | |
| COMFORT EZ INSULIN SYR 0.3 ML 0.3 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| COMFORT EZ INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 1 | |
| COMFORT EZ PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | 1 | |
| COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO 32 GAUGE X 5/32" | 1 | |
| COMFORT EZ PEN NEEDLES 4MM 33G 33 GAUGE X 5/32" | 1 | |
| COMFORT EZ PEN NEEDLES 5MM 31G MINI 31 GAUGE X 3/16" | 1 | |
| COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI 32 GAUGE X 3/16" | 1 | |
| COMFORT EZ PEN NEEDLES 5MM 33G 33 GAUGE X 3/16" | 1 | |
| COMFORT EZ PEN NEEDLES 6MM 31G 31 GAUGE X 1/4" | 1 | |
| COMFORT EZ PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | 1 | |
| COMFORT EZ PEN NEEDLES 6MM 33G 33 GAUGE X 1/4" | 1 | |
| COMFORT EZ PEN NEEDLES 8MM 31G SHORT 31 GAUGE X 5/16" | 1 | |
| COMFORT EZ PEN NEEDLES 8MM 32G 32 GAUGE X 5/16" | 1 | |
| COMFORT EZ PEN NEEDLES 8MM 33G 33 GAUGE X 5/16" | 1 | |
| COMFORT EZ PRO PEN NDL 30G 8MM 30 GAUGE X 5/16" | 1 | |
| COMFORT EZ PRO PEN NDL 31G 4MM 31 GAUGE X 5/32" | 1 | |
| COMFORT EZ PRO PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| COMFORT EZ SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | |
| COMFORT EZ SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | |
| COMFORT EZ SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| COMFORT EZ SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| COMFORT EZ SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | |
| COMFORT EZ SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| COMFORT EZ SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| COMFORT EZ SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | |
| COMFORT POINT PEN NDL 31GX1/3" 31 GAUGE X 1/3" | 1 | |
| COMFORT POINT PEN NDL 31GX1/6" 31 GAUGE X 1/6" | 1 | |
| COMFORT TOUCH PEN NDL 31G 4MM 31 GAUGE X 5/32" | 1 | |
| COMFORT TOUCH PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| COMFORT TOUCH PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | |
| COMFORT TOUCH PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | |
| COMFORT TOUCH PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| COMFORT TOUCH PEN NDL 32G 5MM 32 GAUGE X 3/16" | 1 | |
| COMFORT TOUCH PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | |
| COMFORT TOUCH PEN NDL 32G 8MM 32 GAUGE X 5/16" | 1 | |
| COMFORT TOUCH PEN NDL 33G 4MM 33 GAUGE X 5/32" | 1 | |
| COMFORT TOUCH PEN NDL 33G 6MM 33 GAUGE X 1/4" | 1 | |
| COMFORT TOUCH PEN NDL 33GX5MM 33 GAUGE X 3/16" | 1 | |
| CURAD GAUZE PADS 2" X 2" 2 X 2 " | 1 | |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG 2 X 2 " | 1 | |
| CURITY GUAZE PADS 1'S(12 PLY) 2 X 2 " | 1 | |
| DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII 2 X 2 " | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY 2 X 2 " | 1 | |
| DERMACEA NON-WOVEN 2"X2" SPNGE 2 X 2 " | 1 | |
| DROPLET 0.5 ML 29GX12.5MM(1/2) 0.5 ML 29 GAUGE X 1/2" | 1 | |
| DROPLET 0.5 ML 30GX12.5MM(1/2) 0.5 ML 30 GAUGE X 1/2" | 1 | |
| DROPLET INS 0.3 ML 29GX12.5MM 0.3 ML 29 GAUGE X 1/2" | 1 | |
| DROPLET INS 0.3 ML 30GX12.5MM 0.3 ML 30 GAUGE X 1/2" | 1 | |
| DROPLET INS 0.5 ML 30GX6MM(1/2) 0.5ML 30 GAUGE X 15/64" | 1 | |
| DROPLET INS 0.5 ML 30GX8MM(1/2) 0.5 ML 30 GAUGE X 5/16" | 1 | |
| DROPLET INS 0.5 ML 31GX6MM(1/2) 0.5 ML 31 GAUGE X 15/64" | 1 | |
| DROPLET INS 0.5 ML 31GX8MM(1/2) 0.5 ML 31 GAUGE X 5/16" | 1 | |
| DROPLET INS SYR 0.3 ML 30GX6MM 0.3 ML 30 GAUGE X 15/64" | 1 | |
| DROPLET INS SYR 0.3 ML 30GX8MM 0.3 ML 30 GAUGE X 5/16" | 1 | |
| DROPLET INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | 1 | |
| DROPLET INS SYR 0.3 ML 31GX8MM 0.3 ML 31 GAUGE X 5/16" | 1 | |
| DROPLET INS SYR 1 ML 29GX12.5MM 1 ML 29 GAUGE X 1/2" | 1 | |
| DROPLET INS SYR 1 ML 30GX12.5MM 1 ML 30 GAUGE X 1/2" | 1 | |
| DROPLET INS SYR 1 ML 30GX6MM 1 ML 30 GAUGE X 15/64" | 1 | |
| DROPLET INS SYR 1 ML 30GX8MM 1 ML 30 GAUGE X 5/16 | 1 | |
| DROPLET INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | 1 | |
| DROPLET INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| DROPLET MICRON 34G X 9/64" 34 GAUGE X 9/64" | 1 | |
| DROPLET PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | |
| DROPLET PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | 1 | |
| DROPLET PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 1 | |
| DROPLET PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| DROPLET PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| DROPLET PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| DROPLET PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | |
| DROPLET PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | 1 | |
| DROPLET PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" | 1 | |
| DROPLET PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| DROPSAFE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 15/64" | 1 | |
| DROPSAFE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 1 | |
| DROPSAFE INS SYR 0.5 ML 31G 6MM 0.5 ML 31 GAUGE X 15/64" | 1 | |
| DROPSAFE INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | 1 | |
| DROPSAFE INSUL SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | 1 | |
| DROPSAFE INSUL SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16" | 1 | |
| DROPSAFE INSULN 1 ML 29G 12.5MM 1 ML 29 GAUGE X 1/2" | 1 | |
| DROPSAFE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| DROPSAFE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| DROPSAFE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| DRUG MART ULTRA COMFORT SYR 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | 1 | |
| EASY CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | |
| EASY CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| EASY COMFORT 0.3 ML 31G 1/2" 0.3 ML 31 X 1/2" | 1 | |
| EASY COMFORT 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| EASY COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | 1 | |
| EASY COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |
| EASY COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| EASY COMFORT 0.5 ML 32GX5/16" 1/2 ML 32 GAUGE X 5/16" | 1 | |
| EASY COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 5/16" | 1 | |
| EASY COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | |
| EASY COMFORT 1 ML 32GX5/16" 1 ML 32 GAUGE X 5/16" | 1 | |
| EASY COMFORT INSULIN 1 ML SYR 1 ML 30 GAUGE X 5/16 | 1 | |
| EASY COMFORT PEN NDL 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| EASY COMFORT PEN NDL 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| EASY COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| EASY COMFORT PEN NDL 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| EASY COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| EASY COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | 1 | |
| EASY COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | 1 | |
| EASY COMFORT SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| EASY GLIDE INS 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | 1 | |
| EASY GLIDE INS 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" | 1 | |
| EASY GLIDE INS 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | 1 | |
| EASY GLIDE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | 1 | |
| EASY TOUCH 0.3 ML SYR 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | 1 | |
| EASY TOUCH 0.5 ML SYR 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | 1 | |
| EASY TOUCH 0.5 ML SYR 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH 0.5 ML SYR 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |
| EASY TOUCH 0.5 ML SYR 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 1 | |
| EASY TOUCH 1 ML SYR 27GX1/2" 1 ML 27 GAUGE X 1/2" | 1 | |
| EASY TOUCH 1 ML SYR 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH 1 ML SYR 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| EASY TOUCH FLIPLOK 1 ML 27GX0.5 1 ML 27 GAUGE X 1/2" | 1 | |
| EASY TOUCH INSULIN 1 ML 29GX1/2 1 ML 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH INSULIN 1 ML 30GX1/2 1 ML 30 GAUGE X 1/2" | 1 | |
| EASY TOUCH INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| EASY TOUCH INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 1 | |
| EASY TOUCH INSULIN SYR 1 ML 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | |
| EASY TOUCH INSULIN SYR 1 ML RETRACTABLE 1 ML 30 GAUGE X 1/2" | 1 | |
| EASY TOUCH INSULN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH INSULN 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 1 | |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 1 | |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 1 | |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 1 | |
| EASY TOUCH LUER LOK INSUL 1 ML | 1 | |
| EASY TOUCH PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH PEN NEEDLE 30GX5/16 30 GAUGE X 5/16" | 1 | |
| EASY TOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| EASY TOUCH PEN NEEDLE 31GX3/16 31 GAUGE X 3/16" | 1 | |
| EASY TOUCH PEN NEEDLE 31GX5/16 31 GAUGE X 5/16" | 1 | |
| EASY TOUCH PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | |
| EASY TOUCH PEN NEEDLE 32GX3/16 32 GAUGE X 3/16" | 1 | |
| EASY TOUCH PEN NEEDLE 32GX5/32 32 GAUGE X 5/32" | 1 | |
| EASY TOUCH SAF PEN NDL 29G 5MM 29 GAUGE X 3/16" | 1 | |
| EASY TOUCH SAF PEN NDL 29G 8MM 29 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| EASY TOUCH SAF PEN NDL 30G 5MM 30 GAUGE X 3/16" | 1 | |
| EASY TOUCH SAF PEN NDL 30G 8MM 30 GAUGE X 5/16" | 1 | |
| EASY TOUCH SYR 0.5 ML 28G 12.7MM 1/2 ML 28 GAUGE X 1/2" | 1 | |
| EASY TOUCH SYR 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH SYR 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" | 1 | |
| EASY TOUCH SYR 1 ML 28G 12.7MM 1 ML 28 GAUGE X 1/2" | 1 | |
| EASY TOUCH SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | 1 | |
| EASY TOUCH UNI-SLIP SYR 1 ML | 1 | |
| EASYTOUCH SAF PEN NDL 30G 6MM 30 GAUGE X 1/4" | 1 | |
| EMBRACE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | |
| EMBRACE PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 1 | |
| EMBRACE PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 1 | |
| EMBRACE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | |
| EMBRACE PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | 1 | |
| EMBRACE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | |
| EMBRACE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | |
| EQL INSULIN 0.3 ML SYRINGE SHORT NEEDLE 0.3 ML 30 | 1 | |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 1/2 ML 30 GAUGE | 1 | |
| EQL INSULIN 1 ML SYRINGE SHORT NEEDLE 1 ML 30 GAUGE X 7/16" | 1 | |
| EXEL INSULIN SYRINGE 27G-1 ML 1 ML 27 GAUGE X 1/2" | 1 | |
| FIFTY50 INS 0.5 ML 31GX5/16" SHORT NEEDLE 0.5 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| FIFTY50 INS SYR 1 ML 31GX5/16" SHORT NEEDLE (OTC) 1 ML 31 GAUGE X 5/16 | 1 | |
| FIFTY50 PEN 31G X 3/16" NEEDLE (OTC) 31 GAUGE X 3/16" | 1 | |
| FP INSULIN 1 ML SYRINGE 1 ML 28 GAUGE | 1 | |
| FREESTYLE PREC 0.5 ML 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 1 | |
| FREESTYLE PREC 0.5 ML 31GX5/16 0.5 ML 31 GAUGE X 5/16" | 1 | |
| FREESTYLE PREC 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | |
| FREESTYLE PREC 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | 1 | |
| GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT 0.3 ML 29 GAUGE X 1/2" | 1 | |
| GNP ULTRA COMFORT 0.5 ML SYR 1/2 ML 29 , 1/2 ML 30 GAUGE | 1 | |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE, 1 ML 29 GAUGE, 1 ML 30 GAUGE X 7/16" | 1 | |
| GNP ULTRA COMFORT 3/10 ML SYR 0.3 ML 30 | 1 | |
| HEALTHWISE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| HEALTHWISE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| HEALTHWISE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| HEALTHWISE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| HEALTHWISE INS 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | 1 | |
| HEALTHWISE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | |
| HEALTHWISE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | |
| HEALTHWISE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| HEALTHWISE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | |
| HEALTHY ACCENTS PENTIP 4MM 32G 32 GAUGE X 5/32" | 1 | |
| HEALTHY ACCENTS PENTIP 5MM 31G 31 GAUGE X 3/16" | 1 | |
| HEALTHY ACCENTS PENTIP 6MM 31G 31 GAUGE X 1/4" | 1 | |
| HEALTHY ACCENTS PENTIP 8MM 31G 31 GAUGE X 5/16" | 1 | |
| HEALTHY ACCENTS PENTIP 12MM 29G 29 GAUGE X 1/2" | 1 | |
| INCONTROL PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | 1 | |
| INCONTROL PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | 1 | |
| INCONTROL PEN NEEDLE 5MM 31G 31 GAUGE X 3/16" | 1 | |
| INCONTROL PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | |
| INCONTROL PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | 1 | |
| INPEN (FOR HUMALOG) BLUE SUBCUTANEOUS INSULIN PEN | 2 | |
| INPEN (NOVOLOG OR FIASP) BLUE SUBCUTANEOUS INSULIN PEN | 2 | |
| INSULIN SYR 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| INSULIN SYR 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | 1 | |
| INSULIN SYRIN 0.3 ML 30GX1/2" SHORT NEEDLE 0.3 ML 30 GAUGE X 1/2" | 1 | |
| INSULIN SYRIN 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | |
| INSULIN SYRIN 0.5 ML 29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | 1 | |
| INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC) 0.5 ML 30 GAUGE X 1/2" | 1 | |
| INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC) 0.5 ML 30 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| INSULIN SYRINGE 0.5 ML 27G 1/2" INNER 1/2 ML 27 GAUGE X 1/2" | 1 | |
| INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE | 1 | |
| INSULIN SYRINGE 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | 1 | |
| INSULIN SYRINGE 0.5 ML 1/2 ML 29 | 1 | |
| INSULIN SYRINGE 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | 1 | |
| INSULIN SYRINGE 1 ML 1 ML 29 GAUGE | 1 | |
| INSULIN SYRINGE 1 ML 30GX1/2" (RX) 1 ML 30 GAUGE X 1/2" | 1 | |
| INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (OTC) 1 ML 30 GAUGE X 5/16 | 1 | |
| INSULIN SYRINGE 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | 1 | |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE | 1 | |
| INSUPEN 30G ULTRAFIN NEEDLE 30 GAUGE X 5/16" | 1 | |
| INSUPEN 31G ULTRAFIN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" | 1 | |
| INSUPEN 32G 6MM PEN NEEDLE 32 GAUGE X 1/4" | 1 | |
| INSUPEN 32G 8MM PEN NEEDLE 32 GAUGE X 5/16" | 1 | |
| INSUPEN PEN NEEDLE 29GX12MM 29 GAUGE X 1/2" | 1 | |
| INSUPEN PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| INSUPEN PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | 1 | |
| INSUPEN PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | 1 | |
| LISCO SPONGES 100/BAG 2 X 2 " | 1 | |
| LITE TOUCH 31GX1/4" PEN NEEDLE 31 GAUGE X 1/4" | 1 | |
| LITE TOUCH INSULIN 0.5 ML SYR 1/2 ML 28 GAUGE, 1/2 ML 29 , 1/2 ML 30 GAUGE | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| LITE TOUCH INSULIN 1 ML SYR 1 ML 28 GAUGE, 1 ML 29 GAUGE, 1 ML 30 GAUGE X 7/16" | 1 | |
| LITE TOUCH INSULIN SYR 1 ML 1 ML 31 GAUGE X 5/16" | 1 | |
| LITE TOUCH PEN NEEDLE 29G 29 GAUGE X 1/2" | 1 | |
| LITE TOUCH PEN NEEDLE 31G 31 GAUGE X 3/16", 31 GAUGE X 5/16" | 1 | |
| LITETOUCH INS 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | |
| LITETOUCH INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| LITETOUCH INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| LITETOUCH INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| LITETOUCH SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | |
| LITETOUCH SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| LITETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| LITETOUCH SYRIN 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | |
| LITETOUCH SYRIN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| LITETOUCH SYRIN 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | |
| MAGELLAN INSUL SYRINGE 0.3 ML 0.3 ML 30 X 5/16" | 1 | |
| MAGELLAN INSUL SYRINGE 0.5 ML 0.5 ML 30 GAUGE X 5/16" | 1 | |
| MAGELLAN INSULIN SYR 0.3 ML 0.3 ML 29 GAUGE X 1/2" | 1 | |
| MAGELLAN INSULIN SYR 0.5 ML 0.5 ML 29 GAUGE X 1/2" | 1 | |
| MAGELLAN INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | 1 | |
| MAXICOMFORT II PEN NDL 31GX6MM 31 GAUGE X 1/4" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| MAXICOMFORT INS 0.5 ML 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | 1 | |
| MAXI-COMFORT INS 0.5 ML 28G 1/2 ML 28 GAUGE X 1/2" | 1 | |
| MAXICOMFORT INS 1 ML 27GX1/2" 1 ML 27 GAUGE X 1/2" | 1 | |
| MAXI-COMFORT INS 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | |
| MAXICOMFORT PEN NDL 29G X 5MM 29 GAUGE X 3/16" | 1 | |
| MAXICOMFORT PEN NDL 29G X 8MM 29 GAUGE X 5/16" | 1 | |
| MICRODOT PEN NEEDLE 31GX6MM 31 GAUGE X 1/4" | 1 | |
| MICRODOT PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | 1 | |
| MICRODOT PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | 1 | |
| MINI PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | |
| MINI PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | 1 | |
| MINI PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | 1 | |
| MINI PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | 1 | |
| MINI PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | 1 | |
| MINI PEN NEEDLE 33G 5MM 33 GAUGE X 3/16" | 1 | |
| MINI PEN NEEDLE 33G 6MM 33 GAUGE X 1/4" | 1 | |
| MINI ULTRA-THIN II PEN NDL 31G STERILE 31 GAUGE X 3/16" | 1 | |
| MONOJECT 0.5 ML SYRN 28GX1/2" 1/2 ML 28 GAUGE | 1 | |
| MONOJECT 1 ML SYRN 27X1/2" 1 ML 27 GAUGE X 1/2" | 1 | |
| MONOJECT 1 ML SYRN 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| MONOJECT INSUL SYR U100 (OTC) 0.3 ML 29 GAUGE X 1/2" | 1 | |
| MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | 1 | |
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC) 1/2 ML 28 GAUGE X 1/2" | 1 | |
| MONOJECT INSUL SYR U100 1 ML 1 ML 25 GAUGE X 5/8" | 1 | |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC) 1 ML 29 GAUGE X 1/2" | 1 | |
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC) | 1 | |
| MONOJECT INSULIN SYR 0.3 ML (OTC) 0.3 ML 30 GAUGE X 5/16" | 1 | |
| MONOJECT INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16" | 1 | |
| MONOJECT INSULIN SYR 0.5 ML (OTC) 0.5 ML 30 GAUGE X 5/16" | 1 | |
| MONOJECT INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16" | 1 | |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC) 1 ML 30 GAUGE X 5/16" | 1 | |
| MONOJECT INSULIN SYR U-100 0.5 ML 29 GAUGE X 1/2", 29 GAUGE X 1/2" | 1 | |
| MONOJECT SYRINGE 0.3 ML 0.3 ML 31 GAUGE X 5/16" | 1 | |
| MONOJECT SYRINGE 0.5 ML 0.5 ML 31 GAUGE X 5/16" | 1 | |
| MONOJECT SYRINGE 1 ML 1 ML 31 GAUGE X 5/16" | 1 | |
| NOVOFINE 30 NEEDLE | 1 | |
| NOVOFINE 32G NEEDLES 32 GAUGE X 1/4" | 1 | |
| NOVOFINE PLUS PEN NDL 32GX1/6" 32 GAUGE X 1/6" | 1 | |
| NOVOTWIST NEEDLE 32G 5MM 32 GAUGE X 1/5" | 1 | |
| OMNIPOD 5 G6 INTRO KIT (GEN 5) SUBCUTANEOUS CARTRIDGE | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| OMNIPOD 5 G6 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 2 | |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 2 | |
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 2 | |
| OMNIPOD DASH PDM KIT (GEN 4) | 2 | |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 2 | |
| PC UNIFINE PENTIPS 8MM NEEDLE SHORT 31 GAUGE X 5/16" | 1 | |
| PEN NEEDLE 30G 5MM OUTER 30 GAUGE X 3/16" | 1 | |
| PEN NEEDLE 30G 8MM INNER 30 GAUGE X 5/16" | 1 | |
| PEN NEEDLE 30G X 5/16" 30 GAUGE X 5/16" | 1 | |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2" | 1 | |
| PEN NEEDLES 12MM 29G 29GX12MM,STRL 29 GAUGE X 1/2" | 1 | |
| PEN NEEDLES 4MM 32G 32 GAUGE X 5/32" | 1 | |
| PEN NEEDLES 6MM 31G 31GX6MM, STRL 31 GAUGE X 1/4" | 1 | |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) 31 GAUGE X 5/16" | 1 | |
| PENTIPS PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | |
| PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM 31 GAUGE X 3/16" | 1 | |
| PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM 31 GAUGE X 5/16" | 1 | |
| PENTIPS PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | 1 | |
| PENTIPS PEN NEEDLE 32GX5/32" 4MM 32 GAUGE X 5/32" | 1 | |
| PENTIPS PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| PIP PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" | 1 | |
| PIP PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | 1 | |
| PREVENT PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| PREVENT PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| PRO COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |
| PRO COMFORT 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| PRO COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| PRO COMFORT 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| PRO COMFORT 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | |
| PRO COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| PRO COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| PRO COMFORT PEN NDL 32G X 1/4" 32 GAUGE X 1/4" | 1 | |
| PRO COMFORT PEN NDL 4MM 32G 32 GAUGE X 5/32" | 1 | |
| PRO COMFORT PEN NDL 5MM 32G 32 GAUGE X 3/16" | 1 | |
| PRODIGY INS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | |
| PRODIGY SYRNG 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| PRODIGY SYRNGE 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| PURE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| PURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | |
| PURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| PURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| PURE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | 1 | |
| PURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | |
| PURE COMFORT PEN NDL 32G 8MM 32 GAUGE X 5/16" | 1 | |
| RAYA SURE PEN NEEDLE 29G 12MM 29 GAUGE X 15/32" | 1 | |
| RAYA SURE PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" | 1 | |
| RAYA SURE PEN NEEDLE 31G 5MM 31 GAUGE X 13/64" | 1 | |
| RAYA SURE PEN NEEDLE 31G 6MM 31 GAUGE X 15/64" | 1 | |
| RELION INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | 1 | |
| RELION INS SYR 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" | 1 | |
| RELION INS SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 1 | |
| RELI-ON INSULIN 0.5 ML SYR 1/2 ML 29 | 1 | |
| RELI-ON INSULIN 1 ML SYR 1 ML 29 GAUGE X 7/16" | 1 | |
| RELION MINI PEN 31G X 1/4" NDL 31 GAUGE X 1/4" | 1 | |
| RELION NEEDLES NEEDLE 31 GAUGE X 1/4" | 1 | |
| RELION PEN NEEDLES NEEDLE 32 GAUGE X 5/32" | 1 | |
| SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10 0.3 ML 30 GAUGE X 5/16" | 1 | |
| SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10 0.5 ML 29 GAUGE X 1/2" | 1 | |
| SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10 0.5 ML 30 GAUGE X 5/16" | 1 | |
| SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10 1 ML 28 GAUGE X 1/2" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10 1 ML 29 GAUGE X 1/2" | 1 | |
| SAFETY PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" | 1 | |
| SAFETY PEN NEEDLE 5MM X 31G 31 GAUGE X 3/16" | 1 | |
| SAFETY SYRINGE 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |
| SECURESAFE PEN NDL 30GX5/16" OUTER 30 GAUGE X 5/16" | 1 | |
| SECURESAFE SYR 0.5 ML 29G 1/2" OUTER 0.5 ML 29 GAUGE X 1/2" | 1 | |
| SECURESAFE SYRNG 1 ML 29G 1/2" OUTER 1 ML 29 GAUGE X 1/2" | 1 | |
| SKY SAFETY PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 1 | |
| SKY SAFETY PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 1 | |
| SM ULT CFT 0.3 ML 31GX5/16(1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | |
| STERILE PADS 2" X 2" 2 X 2 " | 1 | |
| SURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | |
| SURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| NEEDLES, INSULIN DISP., SAFETY | 1 | |
| SURE COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | 1 | |
| SURE COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | |
| SURE COMFORT 3/10 ML SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | 1 | |
| SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SURE COMFORT 30G PEN NEEDLE 30 GAUGE X 5/16" | 1 | |
| SURE COMFORT INS 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | 1 | |
| SURE COMFORT INS 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | 1 | |
| SURE COMFORT INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | 1 | |
| SURE COMFORT PEN NDL 29GX1/2" 12.7MM 29 GAUGE X 1/2" | 1 | |
| SURE COMFORT PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| SURE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | |
| SURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| SURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | |
| SURE-FINE PEN NEEDLES 12.7MM 29 GAUGE X 1/2" | 1 | |
| SURE-FINE PEN NEEDLES 5MM 31 GAUGE X 3/16" | 1 | |
| SURE-FINE PEN NEEDLES 8MM 31 GAUGE X 5/16" | 1 | |
| SURE-JECT INSU SYR U100 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | 1 | |
| SURE-JECT INSU SYR U100 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | 1 | |
| SURE-JECT INSU SYR U100 1 ML 1 ML 28 GAUGE X 1/2" | 1 | |
| SURE-JECT INSUL SYR U100 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | 1 | |
| SURE-JECT INSULIN SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 | 1 | |
| TECHLITE 0.3 ML 29GX12MM (1/2) 0.3 ML 29 GAUGE X 1/2" | 1 | |
| TECHLITE 0.3 ML 30GX12MM (1/2) 0.3 ML 30 GAUGE X 1/2" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TECHLITE 0.3 ML 30GX8MM (1/2) 0.3 ML 30 GAUGE X 5/16" | 1 | |
| TECHLITE 0.3 ML 31GX6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | 1 | |
| TECHLITE 0.3 ML 31GX8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | |
| TECHLITE 0.5 ML 29GX12MM (1/2) 0.5 ML 29 GAUGE X 1/2" | 1 | |
| TECHLITE 0.5 ML 30GX12MM (1/2) 0.5 ML 30 GAUGE X 1/2" | 1 | |
| TECHLITE 0.5 ML 30GX8MM (1/2) 0.5 ML 30 GAUGE X 5/16" | 1 | |
| TECHLITE 0.5 ML 31GX6MM (1/2) 0.5 ML 31 GAUGE X 15/64" | 1 | |
| TECHLITE 0.5 ML 31GX8MM (1/2) 0.5 ML 31 GAUGE X 5/16" | 1 | |
| TECHLITE INS SYR 1 ML 29GX12MM 1 ML 29 GAUGE X 1/2" | 1 | |
| TECHLITE INS SYR 1 ML 30GX12MM 1 ML 30 GAUGE X 1/2" | 1 | |
| TECHLITE INS SYR 1 ML 30GX8MM 1 ML 30 GAUGE X 5/16 | 1 | |
| TECHLITE INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | 1 | |
| TECHLITE INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | 1 | |
| TECHLITE PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | 1 | |
| TECHLITE PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | 1 | |
| TECHLITE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |
| TECHLITE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| TECHLITE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| TECHLITE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | |
| TECHLITE PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TECHLITE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| TERUMO INS SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | |
| TERUMO INS SYRINGE U100-1 ML 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" | 1 | |
| TERUMO INS SYRINGE U100-1 ML 1 ML 30 GAUGE X 3/8" | 1 | |
| TERUMO INS SYRINGE U100-1/2 ML 1/2 ML 30 X 3/8" | 1 | |
| TERUMO INS SYRINGE U100-1/3 ML 0.3 ML 30 X 3/8" | 1 | |
| TERUMO INS SYRNG U100-1/2 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" | 1 | |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8", 0.3 ML 31 X 3/8" | 1 | |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 X 3/8", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" | 1 | |
| THINPRO INS SYRIN U100-1 ML 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8", 1 ML 31 X 3/8" | 1 | |
| TOPCARE CLICKFINE 31G X 1/4" 31 GAUGE X 1/4" | 1 | |
| TOPCARE CLICKFINE 31G X 5/16" 31 GAUGE X 5/16" | 1 | |
| TOPCARE ULTRA COMFORT SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | |
| TRUE CMFRT PRO 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| TRUE CMFRT PRO 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| TRUE CMFRT PRO 0.5 ML 32G 5/16" 1/2 ML 32 GAUGE X 5/16" | 1 | |
| TRUE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| TRUE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | |
| TRUE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| TRUE COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| TRUE COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| TRUE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | |
| TRUE COMFORT PEN NDL 31GX5MM 31 GAUGE X 3/16" | 1 | |
| TRUE COMFORT PEN NDL 31GX6MM 31 GAUGE X 1/4" | 1 | |
| TRUE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | 1 | |
| TRUE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | 1 | |
| TRUE COMFORT PEN NDL 32GX4MM 32 GAUGE X 5/32" | 1 | |
| TRUE COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | 1 | |
| TRUE COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | 1 | |
| TRUE COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | 1 | |
| TRUE COMFORT PRO 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| TRUE COMFORT PRO 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | 1 | |
| TRUE COMFORT PRO 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| TRUE COMFORT PRO 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 1 | |
| TRUE COMFRT PRO 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TRUEPLUS PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | |
| TRUEPLUS PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | |
| TRUEPLUS PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | |
| TRUEPLUS PEN NEEDLE 31G X 1/4" 31 GAUGE X 1/4" | 1 | |
| TRUEPLUS PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| TRUEPLUS SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | |
| TRUEPLUS SYR 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| TRUEPLUS SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| TRUEPLUS SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | 1 | |
| TRUEPLUS SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| TRUEPLUS SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| TRUEPLUS SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| TRUEPLUS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | 1 | |
| TRUEPLUS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| TRUEPLUS SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" | 1 | |
| TRUEPLUS SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| ULTICAR INS 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | 1 | |
| ULTICARE INS 0.3 ML 31GX1/4" 0.3 ML 31 GAUGE X 1/4" | 1 | |
| ULTICARE INS 0.5 ML 31GX1/4" 1/2 ML 31 GAUGE X 1/4" | 1 | |
| ULTICARE INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ULTICARE INS SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| ULTICARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| ULTICARE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | 1 | |
| ULTICARE PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | 1 | |
| ULTICARE PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | 1 | |
| ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM 32 GAUGE X 5/32" | 1 | |
| ULTICARE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | 1 | |
| ULTICARE SAFE PEN NDL 30G 8MM 30 GAUGE X 5/16" | 1 | |
| ULTICARE SAFE PEN NDL 5MM 30G 30 GAUGE X 3/16" | 1 | |
| ULTICARE SYR 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | 1 | |
| ULTICARE SYR 0.3 ML 31GX5/16" SHORT NDL 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ULTICARE SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |
| ULTICARE SYR 0.5 ML 31GX5/16" SHORT NDL 0.5 ML 31 GAUGE X 5/16" | 1 | |
| ULTICARE SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| ULTIGUARD SAFE 1 ML 30G 12.7MM 1 ML 30 X 1/2" | 1 | |
| ULTIGUARD SAFE PACK 29G 12.7MM 29 GAUGE X 1/2" | 1 | |
| ULTIGUARD SAFE PACK 32G 4MM 32 GAUGE X 5/32" | 1 | |
| ULTIGUARD SAFE0.3 ML 30G 12.7MM 0.3 ML 30 X 1/2" | 1 | |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM 1/2 ML 30 X 1/2" | 1 | |
| ULTIGUARD SAFEPACK 1 ML 31G 8MM 1 ML 31 X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ULTIGUARD SAFEPAK 31G 5MM 31 GAUGE X 3/16" | 1 | |
| ULTIGUARD SAFEPAK 31G 6MM 31 GAUGE X 1/4" | 1 | |
| ULTIGUARD SAFEPAK 31G 8MM 31 GAUGE X 5/16" | 1 | |
| ULTIGUARD SAFEPAK 32G 6MM 32 GAUGE X 1/4" | 1 | |
| ULTIGUARD SAFEPAK 0.3 ML 31G 8MM 0.3 ML 31 X 5/16" | 1 | |
| ULTIGUARD SAFEPAK 0.5 ML 31G 8MM 1/2 ML 31 X 5/16" | 1 | |
| ULTILET INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ULTILET INSULIN SYRINGE 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | 1 | |
| ULTILET INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 1 | |
| ULTILET PEN NEEDLE 29 GAUGE | 1 | |
| ULTILET PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | 1 | |
| ULTRA COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | 1 | |
| ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G 1/2 ML 28 GAUGE X 1/2" | 1 | |
| ULTRA COMFORT 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| ULTRA COMFORT 0.5 ML SYRINGE 1/2 ML 28 GAUGE | 1 | |
| ULTRA COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | 1 | |
| ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2" | 1 | |
| ULTRA FLO 0.3 ML 30G 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | 1 | |
| ULTRA FLO 0.3 ML 30G 5/16"(1/2) 0.3 ML 30 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| ULTRA FLO 0.3 ML 31G 5/16"(1/2) 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ULTRA FLO PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | |
| ULTRA FLO PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 1 | |
| ULTRA FLO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | |
| ULTRA FLO PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | 1 | |
| ULTRA FLO PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | 1 | |
| ULTRA FLO SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | 1 | |
| ULTRA FLO SYR 0.3 ML 30G 5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| ULTRA FLO SYR 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ULTRA FLO SYR 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| ULTRA THIN PEN NDL 32G X 4MM 32 GAUGE X 5/32" | 1 | |
| ULTRACARE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | 1 | |
| ULTRACARE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ULTRACARE INS 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | 1 | |
| ULTRACARE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | 1 | |
| ULTRACARE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| ULTRACARE INS 1 ML 30G X 5/16" 1 ML 30 GAUGE X 5/16" | 1 | |
| ULTRACARE INS 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 1 | |
| ULTRACARE INS 1 ML 31G X 5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| ULTRACARE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ULTRACARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | 1 | |
| ULTRACARE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 1 | |
| ULTRACARE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | 1 | |
| ULTRACARE PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | 1 | |
| ULTRACARE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| ULTRACARE PEN NEEDLE 33GX5/32" 33 GAUGE X 5/32" | 1 | |
| ULTRA-THIN II 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| ULTRA-THIN II INS 0.3 ML 30G 0.3 ML 30 GAUGE X 5/16" | 1 | |
| ULTRA-THIN II INS 0.3 ML 31G 0.3 ML 31 GAUGE X 5/16" | 1 | |
| ULTRA-THIN II INS 0.5 ML 29G 0.5 ML 29 GAUGE X 1/2" | 1 | |
| ULTRA-THIN II INS 0.5 ML 30G 0.5 ML 30 GAUGE X 5/16" | 1 | |
| ULTRA-THIN II INS 0.5 ML 31G 0.5 ML 31 GAUGE X 5/16" | 1 | |
| ULTRA-THIN II INS SYR 1 ML 29G 1 ML 29 GAUGE X 1/2" | 1 | |
| ULTRA-THIN II INS SYR 1 ML 30G 1 ML 30 GAUGE X 5/16" | 1 | |
| ULTRA-THIN II PEN NDL 29GX1/2" 29 GAUGE X 1/2" | 1 | |
| ULTRA-THIN II PEN NDL 31GX5/16 31 GAUGE X 5/16" | 1 | |
| UNIFINE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | 1 | |
| UNIFINE PENTIPS 12MM 29G 29GX12MM, STRL 29 GAUGE X 1/2" | 1 | |
| UNIFINE PENTIPS 31GX3/16" 31GX5MM,STRL,MINI 31 GAUGE X 3/16" | 1 | |
| UNIFINE PENTIPS 32GX1/4" 32 GAUGE X 1/4" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| UNIFINE PENTIPS 32GX5/32" 32GX4MM, STRL, NANO 32 GAUGE X 5/32" | 1 | |
| UNIFINE PENTIPS 33GX5/32" 33 GAUGE X 5/32" | 1 | |
| UNIFINE PENTIPS 6MM 31G 31 GAUGE X 1/4" | 1 | |
| UNIFINE PENTIPS MAX 30GX3/16" 30 GAUGE X 3/16" | 1 | |
| UNIFINE PENTIPS NEEDLES 29G 29 GAUGE | 1 | |
| UNIFINE PENTIPS PLUS 29GX1/2" 12MM 29 GAUGE X 1/2" | 1 | |
| UNIFINE PENTIPS PLUS 30GX3/16" 30 GAUGE X 3/16" | 1 | |
| UNIFINE PENTIPS PLUS 31GX1/4" ULTRA SHORT, 6MM 31 GAUGE X 1/4" | 1 | |
| UNIFINE PENTIPS PLUS 31GX3/16" MINI 31 GAUGE X 3/16" | 1 | |
| UNIFINE PENTIPS PLUS 31GX5/16" SHORT 31 GAUGE X 5/16" | 1 | |
| UNIFINE PENTIPS PLUS 32GX5/32" 32 GAUGE X 5/32" | 1 | |
| UNIFINE PENTIPS PLUS 33GX5/32" 33 GAUGE X 5/32" | 1 | |
| UNIFINE PROTECT 30G 5MM 30 GAUGE X 3/16" | 1 | |
| UNIFINE PROTECT 30G 8MM 30 GAUGE X 5/16" | 1 | |
| UNIFINE PROTECT 32G 4MM 32 GAUGE X 5/32" | 1 | |
| UNIFINE SAFECONTROL 30GX3/16" 30 GAUGE X 3/16" | 1 | |
| UNIFINE SAFECONTROL 30GX5/16" 30 GAUGE X 5/16" | 1 | |
| UNIFINE SAFECONTROL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| UNIFINE ULTRA PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| UNIFINE ULTRA PEN NDL 31G 6MM 31 GAUGE X 1/4" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| UNIFINE ULTRA PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | |
| UNIFINE ULTRA PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| VANISHPOINT 0.5 ML 30GX1/2" SY OUTER 0.5 ML 30 GAUGE X 1/2" | 1 | |
| VANISHPOINT INS 1 ML 30GX3/16" 1 ML 30 GAUGE X 3/16" | 1 | |
| VANISHPOINT U-100 29X1/2 SYR 1 ML 29 GAUGE X 1/2" | 1 | |
| VERIFINE INS SYR 1 ML 29G 1/2" 1 ML 29 GAUGE X 1/2" | 1 | |
| VERIFINE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | 1 | |
| VERIFINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | 1 | |
| VERIFINE PEN NEEDLE 31G X 6MM 31 GAUGE X 1/4" | 1 | |
| VERIFINE PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" | 1 | |
| VERIFINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | 1 | |
| VERIFINE PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | 1 | |
| VERIFINE PEN NEEDLE 32G X 5MM 32 GAUGE X 3/16" | 1 | |
| VERIFINE PLUS PEN NDL 31G 5MM 31 GAUGE X 3/16" | 1 | |
| VERIFINE PLUS PEN NDL 31G 8MM 31 GAUGE X 5/16" | 1 | |
| VERIFINE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | 1 | |
| VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER 32 GAUGE X 5/32" | 1 | |
| VERIFINE SYRING 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | 1 | |
| VERIFINE SYRING 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 1 | |
| VERIFINE SYRNG 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| VERIFINE SYRNG 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 1 | |
| VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY 2 X 2 " | 1 | |
| V-GO 20 DEVICE | 2 | |
| V-GO 30 DEVICE | 2 | |
| V-GO 40 DEVICE | 2 | |
| Enzyme Replacement/Modifiers | | |
| Enzyme Replacement/Modifiers | | |
| ALDURAZYME INTRAVENOUS SOLUTION 2.9 MG/5 ML | 4 | NDS |
| CERDELGA ORAL CAPSULE 84 MG | 4 | PA; LA; NDS |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000-180,000 UNIT, 6,000-19,000 -30,000 UNIT | 2 | |
| GALAFOLD ORAL CAPSULE 123 MG | 4 | PA; LA; NDS; QL (14 per 28 days) |
| <i>javygtor oral tablet,soluble 100 mg</i> | 4 | PA; LA; NDS |
| <i>miglustat oral capsule 100 mg</i> | 4 | PA; LA; NDS; QL (90 per 30 days) |
| <i>nitisinone oral capsule 10 mg, 2 mg, 5 mg</i> | 4 | PA; NDS |
| <i>nitisinone oral capsule 20 mg</i> | 4 | NDS |
| ORFADIN ORAL CAPSULE 20 MG | 4 | PA; LA; NDS |
| ORFADIN ORAL SUSPENSION 4 MG/ML | 4 | PA; LA; NDS |
| PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML | 4 | PA; LA; NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 4 | PA BvD; NDS |
| REVCOVI INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) | 4 | PA; LA; NDS |
| <i>sapropterin oral tablet,soluble 100 mg</i> | 4 | PA; NDS |
| <i>yargesa oral capsule 100 mg</i> | 4 | PA; NDS; QL (90 per 30 days) |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000-105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600-252,600 UNIT | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| Eye, Ear, Nose, Throat Agents | | |
| Eye, Ear, Nose, Throat Agents, Miscellaneous | | |
| <i>alcaine ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>atropine ophthalmic (eye) drops 1 %</i> | 3 | NDS |
| <i>azelastine nasal aerosol,spray 137 mcg (0.1 %)</i> | 1 | QL (30 per 25 days) |
| <i>azelastine nasal spray,non-aerosol 205.5 mcg (0.15 %)</i> | 1 | QL (30 per 25 days) |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 1 | |
| <i>bepotastine besilate ophthalmic (eye) drops 1.5 %</i> | 1 | ST |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 1 | |
| <i>cyclopentolate ophthalmic (eye) drops 1 %</i> | 1 | |
| CYSTADROPS OPHTHALMIC (EYE) DROPS 0.37 % | 4 | PA; LA; NDS; QL (20 per 28 days) |
| CYSTARAN OPHTHALMIC (EYE) DROPS 0.44 % | 4 | PA; LA; NDS; QL (60 per 28 days) |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 1 | |
| <i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i> | 1 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | 1 | QL (15 per 10 days) |
| <i>levofloxacin ophthalmic (eye) drops 1.5 %</i> | 1 | |
| <i>olopatadine nasal spray,non-aerosol 0.6 %</i> | 1 | QL (30.5 per 30 days) |
| <i>olopatadine ophthalmic (eye) drops 0.1 %, 0.2 %</i> | 1 | |
| <i>proparacaine ophthalmic (eye) drops 0.5 %</i> | 1 | |
| Eye, Ear, Nose, Throat Anti-Infectives Agents | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 1 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 1 | |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 1 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 %</i> | 1 | QL (7.5 per 7 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 1 | QL (3.5 per 4 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | 1 | |
| <i>levofloxacin ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> | 1 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 3 | NDS |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | 1 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 1 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> | 1 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | 1 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 1 | |
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 1 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 1 | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 1 | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | 1 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 1 | |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 1 | |
| <i>polycin ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 1 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | 1 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 1 | |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | 1 | |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | 1 | |
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % | 3 | NDS |
| ZYLET OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % | 2 | |
| Eye, Ear, Nose, Throat Anti-Inflammatory Agents | | |
| ALREX OPHTHALMIC (EYE) DROPS,SUSPENSION 0.2 % | 2 | ST; QL (10 per 25 days) |
| <i>bromfenac ophthalmic (eye) drops 0.09 %</i> | 1 | |
| BROMSITE OPHTHALMIC (EYE) DROPS 0.075 % | 2 | |
| CEQUA OPHTHALMIC (EYE) DROPPERETTE 0.09 % | 3 | NDS |
| <i>cyclosporine ophthalmic (eye) dropperette 0.05 %</i> | 1 | QL (60 per 30 days) |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 %</i> | 1 | |
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i> | 1 | |
| <i>difluprednate ophthalmic (eye) drops 0.05 %</i> | 1 | |
| EYSUVIS OPHTHALMIC (EYE) DROPS,SUSPENSION 0.25 % | 2 | QL (8.3 per 14 days) |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i> | 1 | QL (50 per 25 days) |
| <i>fluocinolone acetonide oil otic (ear) drops 0.01 %</i> | 1 | |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i> | 2 | |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | 1 | |
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> | 1 | QL (16 per 30 days) |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| INVELTYS OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 2 | QL (5.6 per 14 days) |
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> | 1 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 2 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | 2 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,gel 0.5 %</i> | 1 | QL (10 per 13 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.5 %</i> | 1 | QL (15 per 19 days) |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> | 1 | QL (34 per 30 days) |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> | 2 | |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | 1 | |
| PROLENSA OPHTHALMIC (EYE) DROPS 0.07 % | 2 | |
| XHANCE NASAL AEROSOL BREATH ACTIVATED 93 MCG/ACTUATION | 2 | ST; QL (32 per 30 days) |
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % | 3 | NDS; QL (60 per 30 days) |

Gastrointestinal Agents

Antiulcer Agents And Acid Suppressants

| | | |
|--|---|-------------------------|
| <i>amoxicil-clarithromy-lansopraz oral combo pack 500-500-30 mg</i> | 1 | |
| <i>cimetidine hcl oral solution 300 mg/5 ml</i> | 1 | |
| <i>cimetidine oral tablet 200 mg, 300 mg, 400 mg, 800 mg</i> | 1 | |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 20 mg</i> | 1 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 10 mg, 20 mg</i> | 1 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 40 mg</i> | 1 | ST; QL (60 per 30 days) |
| <i>famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> | 1 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 1 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 1 | |
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>omeprazole-sodium bicarbonate oral capsule 20-1.1 mg-gram, 40-1.1 mg-gram</i> | 1 | ST; QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg</i> | 1 | QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 40 mg</i> | 1 | QL (60 per 30 days) |
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> | 1 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gram</i> | 1 | |
| Gastrointestinal Agents, Other | | |
| BYLVAY ORAL CAPSULE 1,200 MCG | 4 | NDS |
| BYLVAY ORAL PELLETT 200 MCG, 600 MCG | 4 | NDS |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> | 4 | PA; LA; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> | 1 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> | 1 | |
| <i>dicyclomine oral capsule 10 mg</i> | 1 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 1 | |
| <i>dicyclomine oral tablet 20 mg</i> | 1 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | 1 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 1 | |
| <i>enulose oral solution 10 gram/15 ml</i> | 1 | |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | 4 | PA; LA; NDS |
| <i>generlac oral solution 10 gram/15 ml</i> | 1 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>lactulose oral solution 10 gram/15 ml</i> | 1 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | NDS; QL (30 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| LOKELMA ORAL POWDER IN PACKET 10 GRAM | 2 | QL (34 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 5 GRAM | 2 | QL (30 per 30 days) |
| <i>loperamide oral capsule 2 mg</i> | 1 | |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | 2 | QL (60 per 30 days) |
| <i>methscopolamine oral tablet 2.5 mg, 5 mg</i> | 1 | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 1 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 2 | QL (30 per 30 days) |
| OICALIVA ORAL TABLET 10 MG, 5 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| RAVICTI ORAL LIQUID 1.1 GRAM/ML | 4 | PA; LA; NDS |
| RELISTOR ORAL TABLET 150 MG | 4 | PA; NDS; QL (90 per 30 days) |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML | 4 | PA; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML | 4 | PA; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML | 4 | PA; NDS; QL (11.2 per 28 days) |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | 4 | NDS |
| <i>sodium polystyrene sulfonate oral powder</i> | 1 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 1 | |
| <i>ursodiol oral capsule 300 mg</i> | 1 | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 1 | |
| VELTASSA ORAL POWDER IN PACKET 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 2 | QL (30 per 30 days) |
| XERMELO ORAL TABLET 250 MG | 4 | PA; LA; NDS; QL (84 per 28 days) |
| Laxatives | | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/160 ML | 2 | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/175 ML | 3 | NDS |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 - 5.84 gram</i> | 1 | |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 - 5.86 gram</i> | 1 | |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> | 1 | |
| <i>peg-electrolyte soln oral recon soln 420 gram</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram, 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 2 | |
| SUPREP BOWEL PREP KIT ORAL RECON SOLN 17.5-3.13-1.6 GRAM | 3 | NDS |
| SUTAB ORAL TABLET 1.479-0.188- 0.225 GRAM | 2 | |
| Phosphate Binders | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 1 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 1 | |
| <i>lanthanum oral tablet,chewable 1,000 mg, 500 mg, 750 mg</i> | 4 | NDS |
| PHOSLYRA ORAL SOLUTION 667 MG (169 MG CALCIUM)/5 ML | 3 | NDS |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> | 3 | NDS |
| <i>sevelamer carbonate oral tablet 800 mg</i> | 1 | |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | 1 | |
| VELPHORO ORAL TABLET,CHEWABLE 500 MG | 2 | |
| Genitourinary Agents | | |
| Antispasmodics, Urinary | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 1 | |
| <i>fesoterodine oral tablet extended release 24 hr 4 mg, 8 mg</i> | 1 | |
| <i>flavoxate oral tablet 100 mg</i> | 1 | |
| MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON 8 MG/ML | 2 | QL (300 per 30 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG | 2 | QL (30 per 30 days) |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 1 | |
| <i>oxybutynin chloride oral tablet 2.5 mg, 5 mg</i> | 1 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg</i> | 1 | |
| <i>solifenacin oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>tolterodine oral capsule,extended release 24hr 2 mg, 4 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------|
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | 1 | |
| <i>tropium oral capsule, extended release 24hr 60 mg</i> | 1 | |
| <i>tropium oral tablet 20 mg</i> | 1 | |
| Genitourinary Agents, Miscellaneous | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> | 1 | |
| <i>dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg</i> | 1 | |
| ENTADFI ORAL CAPSULE 5-5 MG | 3 | PA; NDS; QL (30 per 30 days) |
| <i>finasteride oral tablet 5 mg</i> | 1 | |
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 1 | |
| <i>tamsulosin oral capsule 0.4 mg</i> | 1 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| <i>tiopronin oral tablet 100 mg</i> | 4 | NDS |
| Heavy Metal Antagonists | | |
| Heavy Metal Antagonists | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> | 4 | PA; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg</i> | 4 | PA; NDS |
| <i>deferasirox oral tablet 90 mg</i> | 1 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg</i> | 3 | PA; NDS |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> | 4 | PA; NDS |
| <i>deferiprone oral tablet 1,000 mg, 500 mg</i> | 4 | PA; LA; NDS |
| <i>deferoxamine injection recon soln 500 mg</i> | 4 | PA; NDS |
| FERRIPROX (2 TIMES A DAY) ORAL TABLET, MODIFIED RELEASE 1,000 MG | 4 | PA; LA; NDS |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 4 | PA; LA; NDS |
| <i>penicillamine oral tablet 250 mg</i> | 4 | PA; NDS |
| <i>trientine oral capsule 250 mg</i> | 4 | PA; NDS; QL (240 per 30 days) |
| Hormonal Agents, Stimulant/Replacement/Modifying | | |
| Androgens | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 1 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | 1 | |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 1 | QL (5 per 28 days) |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> | 1 | QL (300 per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | 1 | QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i> | 1 | QL (300 per 30 days) |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml)</i> | 1 | QL (180 per 30 days) |
| XYOSTED SUBCUTANEOUS AUTO-INJECTOR 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML | 2 | PA; QL (2 per 28 days) |
| Estrogens And Antiestrogens | | |
| <i>amabelz oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 1 | |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| DUAVEE ORAL TABLET 0.45-20 MG | 2 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (8 per 28 days) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> | 1 | |
| <i>estradiol vaginal tablet 10 mcg</i> | 1 | QL (18 per 28 days) |
| <i>estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml, 40 mg/ml</i> | 1 | |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 1 | |
| FEMRING VAGINAL RING 0.05 MG/24 HR, 0.1 MG/24 HR | 3 | NDS; QL (1 per 84 days) |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 1 | |
| <i>jinteli oral tablet 1-5 mg-mcg</i> | 1 | |
| <i>lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 1 | QL (8 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>mimvey oral tablet 1-0.5 mg</i> | 1 | |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 1 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 2 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | 2 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) | 2 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 2 | |
| <i>raloxifene oral tablet 60 mg</i> | 1 | |
| <i>yuvaferm vaginal tablet 10 mcg</i> | 1 | QL (18 per 28 days) |
| Glucocorticoids/Mineralocorticoids | | |
| <i>betamethasone acet,sod phos injection suspension 6 mg/ml</i> | 1 | |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | 1 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 1 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 1 | |
| HEMADY ORAL TABLET 20 MG | 3 | NDS |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| <i>methylprednisolone acetate injection suspension 40 mg/ml, 80 mg/ml</i> | 1 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 1 | |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i> | 1 | |
| <i>methylprednisolone sodium succ intravenous recon soln 1,000 mg</i> | 1 | |
| MILLIPRED DP ORAL TABLETS,DOSE PACK 5 MG (21 TABS), 5 MG (48 TABS) | 1 | |
| MILLIPRED ORAL TABLET 5 MG | 1 | |
| <i>prednisolone 15 mg/5 ml soln d/f 15 mg/5 ml (3 mg/ml)</i> | 1 | PA BvD |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 1 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | 1 | PA BvD |
| PREDNISONO INTENSOL ORAL CONCENTRATE 5 MG/ML | 1 | |
| <i>prednisone oral solution 5 mg/5 ml</i> | 1 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablets, dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 1 | |
| <i>triamcinolone acetonide injection suspension 40 mg/ml</i> | 1 | |
| Pituitary | | |
| ACTHAR INJECTION GEL 80 UNIT/ML | 4 | PA; LA; NDS; QL (35 per 28 days) |
| CORTROPHIN GEL INJECTION GEL 80 UNIT/ML | 4 | PA; LA; NDS; QL (35 per 28 days) |
| <i>desmopressin 10 mcg/0.1 ml spr 10 mcg/spray (0.1 ml)</i> | 1 | |
| <i>desmopressin ac 4 mcg/ml ampul p/f, outer, sdv</i> | 4 | NDS |
| <i>desmopressin injection solution 4 mcg/ml</i> | 1 | |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i> | 1 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> | 1 | |
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 4 | LA; NDS |
| <i>lanreotide subcutaneous syringe 120 mg/0.5 ml</i> | 4 | PA NSO; NDS; QL (0.5 per 28 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG, 7.5 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 4 | NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG | 4 | PA NSO; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED) | 4 | NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT 45 MG | 4 | NDS |
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 4 | PA; NDS |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 500 mcg/ml</i> | 4 | NDS |
| <i>octreotide acetate injection solution 100 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 1 | |
| <i>octreotide acetate injection syringe 100 mcg/ml (1 ml), 50 mcg/ml (1 ml)</i> | 1 | |
| <i>octreotide acetate injection syringe 500 mcg/ml (1 ml)</i> | 4 | NDS |
| ORGOVYX ORAL TABLET 120 MG | 4 | PA NSO; LA; NDS |
| ORILISSA ORAL TABLET 150 MG | 4 | PA; NDS; QL (28 per 28 days) |
| ORILISSA ORAL TABLET 200 MG | 4 | PA; NDS; QL (56 per 28 days) |
| SAIZEN SUBCUTANEOUS RECON SOLN 5 MG | 4 | PA; NDS |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 4 | PA; LA; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 4 | PA; LA; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML | 4 | PA NSO; NDS; QL (0.5 per 28 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 4 | PA; LA; NDS |
| SYNAREL NASAL SPRAY, NON-AEROSOL 2 MG/ML | 4 | PA; NDS |
| ZOMACTON SUBCUTANEOUS RECON SOLN 5 MG | 4 | PA; NDS |
| Progestins | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 3 | NDS; QL (0.65 per 90 days) |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> | 1 | QL (1 per 84 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> | 1 | QL (1 per 84 days) |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml)</i> | 1 | |
| <i>norethindrone acetate oral tablet 5 mg</i> | 1 | |
| <i>progesterone intramuscular oil 50 mg/ml</i> | 1 | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | 1 | |
| Thyroid And Antithyroid Agents | | |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 1 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 1 | |
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 2 | |
| Immunological Agents | | |
| Immunological Agents | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 4 | PA; NDS |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 4 | PA; NDS |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 4 | PA; NDS |
| <i>adalimumab-fkjp subcutaneous pen injector kit 40 mg/0.8 ml</i> | 4 | PA; NDS |
| <i>adalimumab-fkjp subcutaneous syringe kit 20 mg/0.4 ml, 40 mg/0.8 ml</i> | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------------------|
| AMJEVITA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.4 ML, 40 MG/0.8 ML, 80 MG/0.8 ML | 4 | PA; NDS |
| AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML | 4 | PA; NDS |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 4 | LA; NDS |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG, 5 MG | 3 | PA BvD; NDS |
| AVSOLA INTRAVENOUS RECON SOLN 100 MG | 4 | PA; NDS |
| <i>azathioprine oral tablet 100 mg, 50 mg, 75 mg</i> | 1 | PA BvD |
| <i>azathioprine sodium injection recon soln 100 mg</i> | 1 | PA BvD |
| BENLYSTA INTRAVENOUS RECON SOLN 120 MG, 400 MG | 4 | PA; NDS |
| BENLYSTA SUBCUTANEOUS AUTO- INJECTOR 200 MG/ML | 4 | PA; LA; NDS; QL (8 per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 4 | PA; LA; NDS; QL (8 per 28 days) |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 4 | PA NSO; LA; NDS; QL (2 per 28 days) |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) | 4 | PA; NDS |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 4 | PA; NDS |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 4 | PA; LA; NDS |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 4 | PA; LA; NDS |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 4 | PA; NDS |
| COSENTYX UNOREADY PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML (150 MG/ML) | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| <i>cyclosporine intravenous solution 250 mg/5 ml</i> | 1 | PA BvD |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | PA BvD |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 1 | PA BvD |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 1 | PA BvD |
| CYLTEZO(CF) PEN CROHN'S-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| CYLTEZO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML | 4 | PA; NDS |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML | 4 | PA; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML | 4 | PA; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 4 | PA; NDS |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) | 4 | PA; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 4 | PA; NDS |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 4 | PA; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 4 | PA; NDS |
| <i>everolimus (immunosuppressive) oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg</i> | 4 | PA BvD; NDS |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 % | 4 | PA BvD; NDS |
| GAMMAGARD LIQUID INJECTION SOLUTION 10 % | 4 | PA BvD; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 4 | PA BvD; NDS |
| GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 % | 4 | PA BvD; LA; NDS |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 4 | PA BvD; LA; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 4 | PA BvD; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> | 1 | PA BvD |
| <i>gengraf oral solution 100 mg/ml</i> | 1 | PA BvD |
| HADLIMA PUSHTOUCH SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.8 ML | 4 | PA; NDS |
| HADLIMA SUBCUTANEOUS SYRINGE 40 MG/0.8 ML | 4 | PA; NDS |
| HADLIMA(CF) PUSHTOUCH SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.4 ML | 4 | PA; NDS |
| HADLIMA(CF) SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 4 | PA; NDS |
| HULIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HULIO(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.4 ML, 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML | 4 | PA; LA; NDS |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML-40 MG/0.4 ML | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 4 | PA; NDS |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 4 | PA; NDS |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 4 | PA; NDS |
| HYRIMOZ PEN CROHN'S-UC STARTER SUBCUTANEOUS PEN INJECTOR 80 MG/0.8 ML | 4 | PA; NDS |
| HYRIMOZ PEN PSORIASIS STARTER SUBCUTANEOUS PEN INJECTOR 80MG/0.8ML(X1)- 40 MG/0.4ML(X2) | 4 | PA; NDS |
| HYRIMOZ(CF) PEDI CROHN STARTER SUBCUTANEOUS SYRINGE 80 MG/0.8 ML- 40 MG/0.4 ML | 4 | PA; NDS |
| HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML | 4 | PA; NDS |
| HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 4 | PA; NDS |
| ILUMYA SUBCUTANEOUS SYRINGE 100 MG/ML | 4 | PA; NDS |
| <i>infliximab intravenous recon soln 100 mg</i> | 4 | PA; NDS |
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML | 4 | PA; NDS |
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML | 4 | PA; NDS |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 4 | PA; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>mycophenolate mofetil (hcl) intravenous recon soln 500 mg</i> | 1 | PA BvD |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 1 | PA BvD |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i> | 4 | PA BvD; NDS |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 1 | PA BvD |
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec) 180 mg, 360 mg</i> | 3 | PA BvD; NDS |
| OCTAGAM INTRAVENOUS SOLUTION 10 %, 5 % | 4 | PA BvD; NDS |
| OLUMIANT ORAL TABLET 1 MG, 2 MG, 4 MG | 4 | PA; NDS |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO-INJECTOR 125 MG/ML | 4 | PA; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 4 | PA; NDS |
| OTEZLA ORAL TABLET 30 MG | 4 | PA; LA; NDS |
| OTEZLA STARTER ORAL TABLETS, DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG (19) | 4 | PA; LA; NDS |
| PRIVIGEN INTRAVENOUS SOLUTION 10 % | 4 | PA BvD; NDS |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 3 | PA BvD; ST; NDS |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML | 2 | |
| REZUROCK ORAL TABLET 200 MG | 4 | PA NSO; LA; NDS |
| RIDAURA ORAL CAPSULE 3 MG | 4 | NDS |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 4 | PA; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | 4 | PA BvD; NDS |
| <i>sirolimus oral tablet 0.5 mg, 1 mg</i> | 1 | PA BvD |
| <i>sirolimus oral tablet 2 mg</i> | 3 | PA BvD; NDS |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML | 4 | PA; NDS |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 4 | PA; NDS |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 4 | PA; NDS |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) | 4 | PA; NDS |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 4 | PA; LA; NDS |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML | 4 | PA; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | 1 | PA BvD |
| TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML | 4 | PA; LA; NDS |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML | 4 | PA; LA; NDS |
| TREMFYA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 4 | PA; NDS |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML | 4 | PA; NDS |
| XELJANZ ORAL SOLUTION 1 MG/ML | 4 | PA; NDS |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 4 | PA; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 4 | PA; NDS |
| YUSIMRY(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.8 ML | 4 | PA; NDS |
| Vaccines | | |
| ABRYSVO INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 2 | |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 2 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 2 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 2 | |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 2 | |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------|
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 2 | |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML | 2 | |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML | 2 | |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 2 | PA BvD |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 2 | PA BvD |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 2 | PA BvD |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 2 | QL (1.5 per 365 days) |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 2 | QL (1.5 per 365 days) |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML | 2 | |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 2 | PA BvD |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 2 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 2 | PA BvD |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML | 2 | |
| IPOXIN INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 2 | |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 2 | |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 2 | |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 2 | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 2 | |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 2 | |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 2 | |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 2 | |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 2 | |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 3 | NDS |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU -10 MCG/0.5ML | 2 | |
| PREHEVBRIO (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML | 2 | PA BvD |
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML | 2 | |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3- 3.99 TCID50/0.5 | 2 | |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML, 15 LF-48 MCG- 5 LF UNIT/0.5ML (58 UNT/ML) | 2 | |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 2 | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 2 | PA BvD |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 2 | PA BvD |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 2 | PA BvD |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 2 | |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------|
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 2 | |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 2 | QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 2 | |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 2 | |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 2 | |
| TETANUS,DIPHThERIA TOX PED(PF) INTRAMUSCULAR SUSPENSION 5-25 LF UNIT/0.5 ML | 2 | |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML | 2 | QL (1.5 per 365 days) |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 2 | |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 2 | |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 2 | |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | 2 | |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML, 50 UNIT/ML | 2 | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML, 50 UNIT/ML | 2 | |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 2 | QL (2 per 365 days) |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 2 | |
| Inflammatory Bowel Disease Agents | | |
| Inflammatory Bowel Disease Agents | | |
| <i>alosetron oral tablet 0.5 mg</i> | 1 | |
| <i>alosetron oral tablet 1 mg</i> | 4 | NDS |
| <i>balsalazide oral capsule 750 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 3 | NDS |
| <i>budesonide rectal foam 2 mg/actuation</i> | 1 | |
| DIPENTUM ORAL CAPSULE 250 MG | 4 | ST; NDS |
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> | 1 | |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> | 1 | |
| <i>mesalamine oral capsule, extended release 500 mg</i> | 1 | |
| <i>mesalamine oral capsule, extended release 24hr 0.375 gram</i> | 1 | |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i> | 1 | QL (120 per 30 days) |
| <i>mesalamine oral tablet, delayed release (dr/ec) 800 mg</i> | 1 | |
| <i>mesalamine rectal enema 4 gram/60 ml</i> | 1 | |
| <i>mesalamine rectal suppository 1,000 mg</i> | 1 | |
| <i>sulfasalazine oral tablet 500 mg</i> | 1 | |
| <i>sulfasalazine oral tablet, delayed release (dr/ec) 500 mg</i> | 3 | NDS |
| UCERIS RECTAL FOAM 2 MG/ACTUATION | 3 | NDS |
| Metabolic Bone Disease Agents | | |
| Metabolic Bone Disease Agents | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 1 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg, 70 mg</i> | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) injection solution 200 unit/ml</i> | 4 | NDS |
| <i>calcitonin (salmon) nasal spray, non-aerosol 200 unit/actuation</i> | 1 | QL (3.7 per 28 days) |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 1 | |
| <i>calcitriol oral solution 1 mcg/ml</i> | 1 | |
| <i>cinacalcet oral tablet 30 mg</i> | 1 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 60 mg</i> | 2 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> | 2 | QL (120 per 30 days) |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 1 | |
| EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2) | 4 | PA; NDS; QL (2.34 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML) | 2 | QL (2.4 per 28 days) |
| <i>ibandronate intravenous solution 3 mg/3 ml</i> | 1 | QL (3 per 84 days) |
| <i>ibandronate intravenous syringe 3 mg/3 ml</i> | 1 | QL (3 per 84 days) |
| <i>ibandronate oral tablet 150 mg</i> | 1 | QL (1 per 28 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE | 4 | PA; LA; NDS; QL (2 per 28 days) |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 1 | |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML | 2 | QL (1 per 180 days) |
| RAYALDEE ORAL CAPSULE, EXTENDED RELEASE 24 HR 30 MCG | 2 | QL (60 per 30 days) |
| <i>risedronate oral tablet 150 mg</i> | 1 | QL (1 per 28 days) |
| <i>risedronate oral tablet 30 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>risedronate oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i> | 1 | QL (4 per 28 days) |
| <i>risedronate oral tablet, delayed release (dr/ec) 35 mg</i> | 1 | QL (4 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 2 | QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 4 | PA; NDS |
| <i>zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml</i> | 1 | QL (100 per 300 days) |
| Miscellaneous Therapeutic Agents | | |
| Miscellaneous Therapeutic Agents | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 4 | PA; LA; NDS |
| <i>betaine oral powder 1 gram/scoop</i> | 4 | PA; LA; NDS |
| <i>buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | |
| COSENTYX INTRAVENOUS SOLUTION 25 MG/ML | 4 | PA; NDS |
| DAYBUE ORAL SOLUTION 200 MG/ML | 4 | PA; NDS |
| <i>diazoxide oral suspension 50 mg/ml</i> | 4 | NDS |
| ELMIRON ORAL CAPSULE 100 MG | 3 | NDS; QL (90 per 30 days) |
| ENDARI ORAL POWDER IN PACKET 5 GRAM | 4 | PA; LA; NDS; QL (180 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---|
| EVRYSDI ORAL RECON SOLN 0.75 MG/ML | 4 | PA; LA; NDS |
| FILSPARI ORAL TABLET 200 MG, 400 MG | 4 | NDS |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 2 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML | 2 | |
| GVOKE PFS 2-PACK SYRINGE SUBCUTANEOUS SYRINGE 0.5 MG/0.1 ML | 2 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 2 | |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 1 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> | 1 | |
| <i>levocarnitine oral tablet 330 mg</i> | 3 | NDS |
| <i>levoleucovorin calcium intravenous recon soln 50 mg</i> | 4 | NDS |
| MESNEX ORAL TABLET 400 MG | 4 | NDS |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> | 1 | |
| <i>pyridostigmine bromide oral tablet 30 mg, 60 mg</i> | 1 | |
| <i>pyridostigmine bromide oral tablet extended release 180 mg</i> | 1 | |
| RECTIV RECTAL OINTMENT 0.4 % (W/W) | 3 | NDS; QL (30 per 30 days) |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) | 4 | PA; LA; NDS; QL (4 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML | 4 | PA; NDS; QL (2 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML) | 4 | PA; LA; NDS; QL (4 per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 4 | PA NSO; LA; NDS; QL (56 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 3 | NDS; QL (30 per 30 days) |
| VOWST ORAL CAPSULE | 4 | NDS; QL (12 per 30 days) |
| ZEGALOGUE AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 0.6 MG/0.6 ML | 2 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------|
| ZEGALOGUE SYRINGE SUBCUTANEOUS SYRINGE 0.6 MG/0.6 ML | 2 | |
| Ophthalmic Agents | | |
| Antiglaucoma Agents | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 1 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 1 | |
| ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 % | 2 | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 1 | |
| <i>bimatoprost ophthalmic (eye) drops 0.03 %</i> | 1 | QL (2.5 per 25 days) |
| <i>brimonidine ophthalmic (eye) drops 0.1 %, 0.15 %, 0.2 %</i> | 1 | |
| <i>brimonidine-timolol ophthalmic (eye) drops 0.2-0.5 %</i> | 1 | |
| <i>brinzolamide ophthalmic (eye) drops,suspension 1 %</i> | 1 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 1 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | 1 | |
| <i>dorzolamide-timolol (pf) ophthalmic (eye) dropperette 2-0.5 %</i> | 1 | |
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml</i> | 1 | |
| <i>latanoprost ophthalmic (eye) drops 0.005 %</i> | 1 | QL (2.5 per 25 days) |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 1 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 2 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 1 | |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | 1 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 2 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 2 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 2 | |
| <i>tafluprost (pf) ophthalmic (eye) dropperette 0.0015 %</i> | 1 | QL (30 per 30 days) |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 %</i> | 1 | |
| <i>travoprost ophthalmic (eye) drops 0.004 %</i> | 1 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 3 | NDS; QL (5 per 30 days) |
| Replacement Preparations | | |
| Replacement Preparations | | |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | 1 | PA BvD; HI |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | 1 | PA BvD; HI |
| <i>electrolyte-148 intravenous parenteral solution</i> | 1 | |
| ISOLYTE S IV SOLUTION-EXCEL SINGLE USE | 3 | PA BvD; HI; NDS |
| ISOLYTE S PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | 3 | PA BvD; HI; NDS |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | 3 | PA BvD; HI; NDS |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> | 1 | |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> | 1 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> | 1 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | 3 | NDS |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | 1 | |
| PLASMA-LYTE 148 INTRAVENOUS PARENTERAL SOLUTION | 3 | PA BvD; HI; NDS |
| PLASMA-LYTE A INTRAVENOUS PARENTERAL SOLUTION | 3 | PA BvD; HI; NDS |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml)</i> | 1 | PA BvD; HI |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | 1 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|------------------------------|
| <i>potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | |
| <i>potassium chloride oral tablet, er particles/crystals 10 meq, 15 meq, 20 meq</i> | 1 | |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | 1 | PA BvD; HI |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg), 15 meq, 5 meq (540 mg)</i> | 1 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 1 | |
| <i>sodium chloride 0.9 % intravenous piggyback</i> | 1 | PA BvD; HI |
| TPN ELECTROLYTES II INTRAVENOUS SOLUTION 18-18-5-4.5-35 MEQ/20 ML | 3 | PA BvD; NDS |
| TPN ELECTROLYTES INTRAVENOUS SOLUTION 35-20-5 MEQ/20 ML | 3 | PA BvD; NDS |
| Respiratory Tract Agents | | |
| Anti-Inflammatories, Inhaled Corticosteroids | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION | 3 | NDS; QL (12 per 30 days) |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | 2 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE | 3 | NDS; QL (60 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml</i> | 1 | PA BvD; QL (120 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 1 mg/2 ml</i> | 1 | PA BvD; QL (60 per 30 days) |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 160-4.5 mcg/actuation</i> | 1 | QL (30.6 per 30 days) |
| <i>budesonide-formoterol inhalation hfa aerosol inhaler 80-4.5 mcg/actuation</i> | 1 | QL (30 per 30 days) |
| FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 50 MCG/ACTUATION | 3 | NDS; QL (60 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 250 MCG/ACTUATION | 3 | NDS; QL (120 per 30 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION | 3 | NDS; QL (12 per 30 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 220 MCG/ACTUATION | 3 | NDS; QL (24 per 30 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 44 MCG/ACTUATION | 3 | NDS; QL (21.2 per 30 days) |
| <i>fluticasone furoate-vilanterol inhalation blister with device 100-25 mcg/dose, 200-25 mcg/dose</i> | 1 | QL (60 per 30 days) |
| <i>fluticasone propionate inhalation blister with device 100 mcg/actuation, 50 mcg/actuation</i> | 1 | QL (60 per 30 days) |
| <i>fluticasone propionate inhalation blister with device 250 mcg/actuation</i> | 1 | QL (120 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation, 220 mcg/actuation, 44 mcg/actuation</i> | 1 | |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation</i> | 1 | QL (1 per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 1 | QL (60 per 30 days) |
| <i>fluticasone propion-salmeterol inhalation hfa aerosol inhaler 115-21 mcg/actuation, 230-21 mcg/actuation, 45-21 mcg/actuation</i> | 1 | QL (12 per 30 days) |
| SYMBICORT INHALATION HFA AEROSOL INHALER 160-4.5 MCG/ACTUATION, 80-4.5 MCG/ACTUATION | 3 | NDS; QL (30.6 per 30 days) |
| <i>wixela inhub inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 1 | QL (60 per 30 days) |
| Antileukotrienes | | |
| <i>montelukast oral tablet 10 mg</i> | 1 | |
| <i>montelukast oral tablet, chewable 4 mg, 5 mg</i> | 1 | |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 1 | |
| Bronchodilators | | |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i> | 1 | QL (17 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------------|
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | 1 | QL (13.4 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | 1 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %)</i> | 1 | PA BvD; QL (360 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 2.5 mg/0.5 ml</i> | 1 | PA BvD; QL (120 per 30 days) |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 1 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 1 | |
| <i>albuterol sulfate oral tablet extended release 12 hr 4 mg, 8 mg</i> | 1 | |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION | 2 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 3 | NDS; QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 2 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 2 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 1 | PA BvD; QL (312.5 per 30 days) |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 1 | PA BvD; QL (540 per 30 days) |
| <i>levalbuterol tartrate inhalation hfa aerosol inhaler 45 mcg/actuation</i> | 1 | |
| PROAIR RESPICLICK INHALATION AEROSOL POWDR BREATH ACTIVATED 90 MCG/ACTUATION | 3 | NDS; QL (2 per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 2 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 2 | QL (4 per 30 days) |
| SPIRIVA WITH HANDHALER INHALATION CAPSULE, W/INHALATION DEVICE 18 MCG | 3 | NDS; QL (30 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 2 | QL (4 per 30 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 2 | QL (4 per 28 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 1 | |
| <i>terbutaline subcutaneous solution 1 mg/ml</i> | 4 | NDS |
| <i>theophylline oral solution 80 mg/15 ml</i> | 1 | |
| <i>theophylline oral tablet extended release 12 hr 300 mg, 450 mg</i> | 1 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 1 | |
| <i>tiotropium bromide inhalation capsule, w/inhalation device 18 mcg</i> | 1 | QL (30 per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG | 2 | QL (60 per 30 days) |
| Respiratory Tract Agents, Other | | |
| <i>acetylcysteine intravenous solution 200 mg/ml (20 %)</i> | 1 | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 1 | PA BvD |
| BRONCHITOL INHALATION CAPSULE, W/INHALATION DEVICE 40 MG | 4 | PA; LA; NDS |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 1 | PA BvD |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 4 | PA; LA; NDS; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML | 4 | PA; LA; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG | 4 | NDS |
| KALYDECO ORAL GRANULES IN PACKET 25 MG, 50 MG, 75 MG | 4 | PA; LA; NDS; QL (56 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 5.8 MG | 4 | PA; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 4 | PA; LA; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 4 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 4 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 4 | PA; LA; NDS; QL (3 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 4 | PA; LA; NDS; QL (0.4 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG | 4 | PA; LA; NDS; QL (56 per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 4 | PA; LA; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> | 4 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> | 4 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg, 801 mg</i> | 4 | PA; NDS; QL (90 per 30 days) |
| PROLASTIN C 1,000 MG/20 ML VL PRICE/ONE MG,SUV | 4 | PA BvD; LA; NDS |
| PROLASTIN-C INTRAVENOUS RECON SOLN 1,000 MG | 4 | PA BvD; LA; NDS |
| <i>roflumilast oral tablet 250 mcg, 500 mcg</i> | 1 | QL (30 per 30 days) |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) | 4 | PA; LA; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 4 | NDS |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 4 | PA; LA; NDS; QL (84 per 28 days) |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 4 | PA; LA; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML | 4 | PA; LA; NDS |
| Skeletal Muscle Relaxants | | |
| Skeletal Muscle Relaxants | | |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | |
| <i>chlorzoxazone oral tablet 250 mg</i> | 4 | NDS |
| <i>chlorzoxazone oral tablet 500 mg</i> | 1 | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>dantrolene oral capsule 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 1 | |
| <i>tizanidine oral tablet 2 mg, 4 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| Sleep Disorder Agents | | |
| Sleep Disorder Agents | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 1 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 2 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | 1 | QL (30 per 30 days) |
| HETLIOZ LQ ORAL SUSPENSION 4 MG/ML | 4 | PA; LA; NDS; QL (150 per 30 days) |
| HETLIOZ ORAL CAPSULE 20 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> | 1 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> | 1 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> | 4 | PA; LA; NDS; QL (540 per 30 days) |
| SUNOSI ORAL TABLET 150 MG, 75 MG | 3 | PA; NDS; QL (30 per 30 days) |
| <i>tasimelteon oral capsule 20 mg</i> | 4 | PA; NDS; QL (30 per 30 days) |
| XYREM ORAL SOLUTION 500 MG/ML | 4 | PA; LA; NDS; QL (540 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>zolpidem oral tablet,ext release multiphase 12.5 mg, 6.25 mg</i> | 1 | QL (30 per 30 days) |
| Vasodilating Agents | | |
| Vasodilating Agents | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 4 | PA; LA; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> | 1 | PA; QL (60 per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 4 | PA; LA; NDS; QL (30 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 4 | PA; LA; NDS; QL (60 per 30 days) |
| <i>epoprostenol intravenous recon soln 0.5 mg, 1.5 mg</i> | 4 | PA; NDS |
| OPSUMIT ORAL TABLET 10 MG | 4 | PA; LA; NDS; QL (30 per 30 days) |
| <i>sildenafil (pulm.hypertension) intravenous solution 10 mg/12.5 ml</i> | 4 | PA; NDS; QL (37.5 per 1 day) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> | 1 | PA; QL (360 per 30 days) |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i> | 5 | EX; CB (8 EA per 30 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> | 1 | PA; QL (60 per 30 days) |
| <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 1 | PA; QL (30 per 30 days) |
| TRACLEER ORAL TABLET FOR SUSPENSION 32 MG | 4 | PA; LA; NDS; QL (112 per 28 days) |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| <i>treprostinil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml</i> | 4 | PA; NDS |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) | 4 | PA; NDS |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 4 | PA; LA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 4 | PA; LA; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 4 | PA; LA; NDS |
| Vitamins And Minerals | | |
| Vitamins And Minerals | | |
| <i>bal-care dha combo pack 27-1-430 mg</i> | 1 | |
| <i>bal-care dha essential pack 27 mg iron-1 mg -374 mg</i> | 1 | |
| <i>c-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>completenate tablet chew 29 mg iron- 1 mg</i> | 1 | |
| <i>cyanocobalamin (vitamin b-12) injection solution</i> | 5 | EX |
| <i>dodex injection solution 1,000 mcg/ml</i> | 5 | EX |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> | 5 | EX |
| <i>folic acid oral tablet 1 mg</i> | 5 | EX |
| <i>folivane-ob capsule 85-1 mg</i> | 1 | |
| <i>kosher prenatal plus iron tab 30 mg iron- 1 mg</i> | 1 | |
| <i>marnatal-f capsule 60 mg iron-1 mg</i> | 1 | |
| <i>m-natal plus tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>mynatal advance oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal capsule 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal plus captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal-z captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynate 90 plus oral tablet extended release 90 mg iron-1 mg</i> | 1 | |
| <i>newgen tablet 32-1,000 mg-mcg</i> | 1 | |
| <i>niva-plus tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>obstetrix dha combo pack 29 mg iron- 1,700 mcg dfe</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>obstetrix dha oral combo pack,tablet and cap,dr 29 mg iron-1 mg -50 mg</i> | 1 | |
| <i>o-cal prenatal tablet 15 mg iron- 1,000 mcg</i> | 1 | |
| <i>pnv 29-1 tablet (rx) 29 mg iron- 1 mg</i> | 1 | |
| <i>pnv prenatal plus multivit tab gluten-free (rx) 27 mg iron- 1 mg</i> | 1 | |
| <i>pnv-dha + docusate oral capsule 27-1.25-55-300 mg</i> | 1 | |
| <i>pnv-omega softgel 28-1-300 mg</i> | 1 | |
| <i>pr natal 400 combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 400 ec combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 430 combo pack 29 mg iron-1 mg - 430 mg</i> | 1 | |
| <i>pr natal 430 ec combo pack 29-1-430 mg</i> | 1 | |
| <i>prena1 true combo pack 30 mg iron- 1.4 mg-300 mg</i> | 1 | |
| <i>prenaissance oral capsule 29-1.25-55-325 mg</i> | 1 | |
| <i>prenaissance plus oral capsule 28-1-50-250 mg</i> | 1 | |
| <i>prenatabs fa tablet 29-1 mg</i> | 1 | |
| <i>prenatal 19 (with docusate) oral tablet 29 mg iron- 1 mg-25 mg</i> | 1 | |
| <i>prenatal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>prenatal low iron tablet (rx) 27 mg iron- 1 mg</i> | 1 | |
| <i>prenatal plus iron tablet (rx) 29 mg iron- 1 mg</i> | 1 | |
| <i>prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>prenatal-u capsule 106.5-1 mg</i> | 1 | |
| <i>preplus ca-fe 27 mg-fa 1 mg tb (rx) 27 mg iron- 1 mg</i> | 1 | |
| <i>pretab 29 mg-1 mg tablet (rx) 29-1 mg</i> | 1 | |
| <i>r-natal ob softgel 20 mg iron- 1 mg-320 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>se-natal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>taron-c dha capsule 35-1-200 mg</i> | 1 | |
| <i>taron-prex prenatal-dha oral capsule 30 mg iron-1.2 mg-55 mg-265 mg</i> | 1 | |
| <i>triveen-duo dha combo pack 29-1-400 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>vinate care oral tablet, chewable 40 mg iron-1 mg</i> | 1 | |
| <i>virt-c dha softgel (rx) 35-1-200 mg</i> | 1 | |
| <i>virt-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>virt-pn dha softgel (rx) 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>virt-pn plus softgel (rx) 28-1-300 mg</i> | 1 | |
| <i>vitafol gummies 3.33 mg iron- 0.33 mg</i> | 1 | |
| <i>vitafol nano tablet 18 mg iron- 1 mg</i> | 1 | |
| <i>vitafol-ob+dha combo pack 65-1-250 mg</i> | 1 | |
| <i>vp-ch-pnv oral capsule 30 mg iron-1 mg -50 mg-260 mg</i> | 1 | |
| <i>vp-pnv-dha softgel (rx) 28 mg iron- 1 mg-200 mg</i> | 1 | |
| <i>zatean-pn dha capsule 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>zatean-pn plus softgel 28-1-300 mg</i> | 1 | |
| <i>zingiber tablet 1.2 mg-40 mg- 124.1 mg-100 mg</i> | 1 | |

03/19/2024

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document. (Page 6)

| | | |
|---|---|--|
| <i>amoxicillin-pot clavulanate</i> 19, 20 | <i>atovaquone</i> 47 | BD AUTOSHIELD DUO PEN NEEDLE 89 |
| <i>amphotericin b</i> 42 | <i>atovaquone-proguanil</i> 47 | BD ECLIPSE LUER-LOK .. 89 |
| <i>amphotericin b liposome</i> ... 42 | <i>atropine</i> 122 | BD INSULIN SYRINGE 89 |
| <i>ampicillin</i> 20 | ATROVENT HFA 151 | BD INSULIN SYRINGE (HALF UNIT)..... 89 |
| <i>ampicillin sodium</i> 20 | AUBAGIO..... 71 | BD INSULIN SYRINGE SLIP TIP 89 |
| <i>ampicillin-sulbactam</i> 20 | <i>aubra eq</i> 75 | BD INSULIN SYRINGE U-500..... 89 |
| <i>anagrelide</i> 61 | AUGTYRO 22 | BD INSULIN SYRINGE ULTRA-FINE..... 89 |
| <i>anastrozole</i> 22 | <i>aurovela 1.5/30 (21)</i> 75 | BD NANO 2ND GEN PEN NEEDLE 89 |
| ANORO ELLIPTA..... 151 | <i>aurovela 1/20 (21)</i> 75 | BD SAFETYGLIDE INSULIN SYRINGE 89, 90 |
| <i>apomorphine</i> 48 | <i>aurovela 24 fe</i> 75 | BD SAFETYGLIDE SYRINGE 89 |
| <i>apraclonidine</i> 122 | <i>aurovela fe 1.5/30 (28)</i> 75 | BD ULTRA-FINE MICRO PEN NEEDLE 90 |
| <i>aprepitant</i> 46 | <i>aurovela fe 1-20 (28)</i> 75 | BD ULTRA-FINE MINI PEN NEEDLE 90 |
| <i>apri</i> 75 | AUSTEDO..... 71 | BD ULTRA-FINE NANO PEN NEEDLE 90 |
| APTIOM 31 | AUSTEDO XR..... 71 | BD ULTRA-FINE ORIG PEN NEEDLE 90 |
| APTIVUS..... 54 | AUSTEDO XR TITRATION KT(WK1-4)..... 71 | BD ULTRA-FINE SHORT PEN NEEDLE 90 |
| AQINJECT PEN NEEDLE. 88 | AUVELITY 35 | BD VEO INSULIN SYR (HALF UNIT)..... 90 |
| <i>aranelle (28)</i> 75 | <i>aviane</i> 75 | BD VEO INSULIN SYRINGE UF 90 |
| ARCALYST 135 | <i>avita</i> 86 | BELSOMRA 154 |
| <i>aripiprazole</i> 49 | AVONEX 72 | <i>benazepril</i> 64 |
| ARISTADA 50 | AVSOLA..... 135 | <i>benazepril-hydrochlorothiazide</i> 64 |
| ARISTADA INITIO..... 50 | <i>ayuna</i> 75 | <i>bendamustine</i> 22 |
| <i>armodafinil</i> 154 | AYVAKIT 22 | BENDAMUSTINE 22 |
| ARNUITY ELLIPTA 149 | <i>azacitidine</i> 22 | BENDEKA 22 |
| <i>ascomp with codeine</i> 10 | <i>azathioprine</i> 135 | BENLYSTA 135 |
| <i>asenapine maleate</i> 50 | <i>azathioprine sodium</i> 135 | <i>benzonatate</i> 81 |
| <i>ashlyna</i> 75 | <i>azelastine</i> 122 | <i>benztropine</i> 48 |
| <i>aspirin-dipyridamole</i> 61 | <i>azithromycin</i> 18, 19 | |
| ASSURE ID DUO PRO SFTY PEN NDL 88 | <i>aztreonam</i> 19 | |
| ASSURE ID DUO-SHIELD 88 | <i>azurette (28)</i> 75 | |
| ASSURE ID INSULIN SAFETY..... 88 | B | |
| ASSURE ID PEN NEEDLE 88 | <i>bacitracin</i> 122 | |
| ASSURE ID PRO PEN NEEDLE 88 | <i>bacitracin-polymyxin b</i> 122 | |
| ASTAGRAF XL 135 | <i>baclofen</i> 153 | |
| <i>atazanavir</i> 54 | <i>bal-care dha</i> 155 | |
| <i>atenolol</i> 65 | <i>bal-care dha essential</i> 155 | |
| <i>atenolol-chlorthalidone</i> 65 | <i>balsalazide</i> 143 | |
| <i>atomoxetine</i> 71 | BALVERSA 22 | |
| <i>atorvastatin</i> 69 | <i>balziva (28)</i> 75 | |
| | BCG VACCINE, LIVE (PF) 140 | |
| | BD ALCOHOL SWABS 82 | |

| | | | | | |
|-------------------------------------|---------|---------------------------------------|----------|-------------------------------------|--------|
| <i>bepotastine besilate</i> | 122 | <i>bromocriptine</i> | 48 | CAPLYTA | 50 |
| BERINERT | 59 | BROMSITE | 124 | CAPRELSA | 23 |
| BESREMI | 135 | BRONCHITOL | 152 | <i>captupil</i> | 64 |
| <i>betaine</i> | 145 | BRUKINSA | 23 | <i>captupil-hydrochlorothiazide</i> | |
| <i>betamethasone acet, sod</i> | | <i>budesonide</i> | 144, 149 | | 64 |
| <i>phos</i> | 131 | <i>budesonide-formoterol</i> | 149 | <i>carbamazepine</i> | 31 |
| <i>betamethasone dipropionate</i> | | <i>bumetanide</i> | 68 | <i>carbidopa</i> | 48 |
| | 84 | <i>buprenorphine</i> | 10 | <i>carbidopa-levodopa</i> | 48 |
| <i>betamethasone valerate</i> | 84 | <i>buprenorphine hcl</i> | 10, 14 | <i>carbidopa-levodopa-</i> | |
| <i>betamethasone, augmented</i> | | <i>buprenorphine-naloxone</i> ... | 14 | <i>entacapone</i> | 48 |
| | 84 | <i>bupropion hcl</i> | 35, 36 | <i>carbinoxamine maleate</i> | 44 |
| BETASERON | 72 | <i>bupropion hcl (smoking</i> | | CAREFINE PEN NEEDLE 90 | |
| <i>betaxolol</i> | 65, 147 | <i>deter</i>) | 15 | CARETOUCH ALCOHOL | |
| <i>bethanechol chloride</i> | 128 | <i>bupirone</i> | 145 | PREP PAD | 82 |
| <i>bexarotene</i> | 22 | <i>butalbital-acetaminop-caf-cod</i> | | CARETOUCH INSULIN | |
| BEXSERO | 140 | | 10 | SYRINGE | 91 |
| <i>bicalutamide</i> | 22 | <i>butalbital-acetaminophen</i> .. | 10 | CARETOUCH PEN NEEDLE | |
| BICILLIN L-A | 20 | <i>butalbital-acetaminophen-caff</i> | | | 91 |
| BIKTARVY | 54 | | 10 | <i>carglumic acid</i> | 126 |
| <i>bimatoprost</i> | 147 | <i>butalbital-aspirin-caffeine</i> .. | 10 | CAROSPIR | 71 |
| <i>bisoprolol fumarate</i> | 65 | <i>butorphanol</i> | 10 | <i>carteolol</i> | 147 |
| <i>bisoprolol-</i> | | BYLVAY | 126 | <i>cartia xt</i> | 66 |
| <i>hydrochlorothiazide</i> | 65 | C | | <i>carvedilol</i> | 65 |
| <i>bleomycin</i> | 22 | CABENUVA | 54 | <i>casprofungin</i> | 42 |
| <i>blisovi 24 fe</i> | 76 | <i>cabergoline</i> | 48 | CAYSTON | 19 |
| <i>blisovi fe 1.5/30 (28)</i> | 76 | CABLIVI | 61 | <i>caziant (28)</i> | 76 |
| <i>blisovi fe 1/20 (28)</i> | 76 | CABOMETYX | 23 | <i>cefaclor</i> | 17 |
| BOOSTRIX TDAP | 141 | <i>cabotegravir</i> | 54 | <i>cefadroxil</i> | 17, 18 |
| BORDERED GAUZE | 90 | <i>caffeine citrate</i> | 72 | <i>cefazolin</i> | 18 |
| <i>bortezomib</i> | 22 | <i>calcipotriene</i> | 82 | <i>cefdinir</i> | 18 |
| <i>bosentan</i> | 154 | <i>calcitonin (salmon)</i> | 144 | <i>cefepime</i> | 18 |
| BOSULIF | 22 | <i>calcitriol</i> | 144 | <i>cefixime</i> | 18 |
| BRAFTOVI | 22, 23 | <i>calcium acetate(phospat</i> | | <i>cefoxitin</i> | 18 |
| BREO ELLIPTA | 149 | <i>bind</i>) | 128 | <i>cefpodoxime</i> | 18 |
| BREZTRI AEROSPHERE | 151 | CALQUENCE | 23 | <i>cefprozil</i> | 18 |
| <i>briellyn</i> | 76 | CALQUENCE | | <i>ceftazidime</i> | 18 |
| BRILINTA | 61 | (ACALABRUTINIB MAL) | 23 | <i>ceftriaxone</i> | 18 |
| <i>brimonidine</i> | 147 | <i>camila</i> | 76 | <i>cefuroxime axetil</i> | 18 |
| <i>brimonidine-timolol</i> | 147 | <i>camrese</i> | 76 | <i>cefuroxime sodium</i> | 18 |
| <i>brinzolamide</i> | 147 | <i>candesartan</i> | 63 | <i>celecoxib</i> | 12 |
| BRIVIACT | 31 | <i>candesartan-</i> | | CELONTIN | 31 |
| <i>bromfenac</i> | 124 | <i>hydrochlorothiazid</i> | 63 | <i>cephalexin</i> | 18 |

| | | | | | |
|--------------------------------------|---------|--|--------|------------------------------------|---------------|
| CEQUA | 124 | <i>clindamycin-benzoyl peroxide</i> | | COMETRIQ | 23 |
| CERDELGA | 121 | | 83 | COMFORT EZ INSULIN | |
| <i>cevimeline</i> | 81 | CLINIMIX 5%/D15W | | SYRINGE | 91, 92, 93 |
| <i>chateal eq (28)</i> | 76 | SULFITE FREE | 61 | COMFORT EZ PEN | |
| <i>chlordiazepoxide hcl</i> | 15 | CLINIMIX 4.25%/D10W | | NEEDLES | 92 |
| <i>chlorhexidine gluconate</i> | 81 | SULF FREE..... | 62 | COMFORT EZ PRO | |
| <i>chloroquine phosphate</i> | 47 | CLINIMIX 4.25%/D5W | | SAFETY PEN NDL | 92 |
| <i>chlorpromazine</i> | 50 | SULFIT FREE..... | 62 | COMFORT TOUCH PEN | |
| <i>chlorthalidone</i> | 68 | CLINIMIX 5%- | | NEEDLE | 93 |
| <i>chlorzoxazone</i> | 153 | D20W(SULFITE-FREE). 62 | | COMPLERA | 54 |
| <i>cholestyramine (with sugar)</i> | | CLINIMIX E 2.75%/D5W | | <i>completenate</i> | 155 |
| | 69 | SULF FREE | 62 | <i>compro</i> | 46 |
| <i>cholestyramine light</i> | 69 | CLINIMIX E 4.25%/D10W | | <i>constulose</i> | 126 |
| <i>ciclopirox</i> | 42 | SUL FREE | 62 | COPAXONE | 72 |
| <i>cilostazol</i> | 61 | CLINIMIX E 4.25%/D5W | | COPIKTRA | 23 |
| CIMDUO..... | 54 | SULF FREE..... | 62 | CORLANOR | 67 |
| <i>cimetidine</i> | 125 | CLINIMIX E 5%/D15W | | CORTROPHIN GEL | 132 |
| <i>cimetidine hcl</i> | 125 | SULFIT FREE..... | 62 | COSENTYX | 135, 145 |
| CIMZIA..... | 135 | CLINIMIX E 5%/D20W | | COSENTYX (2 SYRINGES) | |
| CIMZIA POWDER FOR | | SULFIT FREE..... | 62 | | 135 |
| RECONST | 135 | <i>clobazam</i> | 31 | COSENTYX PEN (2 PENS) | |
| <i>cinacalcet</i> | 144 | <i>clobetasol</i> | 84, 85 | | 135 |
| CINRYZE | 60 | <i>clobetasol-emollient</i> | 85 | COSENTYX UNOREADY | |
| <i>ciprofloxacin</i> | 20 | <i>clomipramine</i> | 36 | PEN | 135 |
| <i>ciprofloxacin hcl</i> | 20, 122 | <i>clonazepam</i> | 15 | COTELLIC..... | 23 |
| <i>ciprofloxacin in 5 % dextrose</i> | | <i>clonidine</i> | 63 | CREON | 121 |
| | 20 | <i>clonidine hcl</i> | 63, 72 | <i>cromolyn</i> | 122, 126, 152 |
| <i>ciprofloxacin-dexamethasone</i> | | <i>clopidogrel</i> | 61 | <i>cryselle (28)</i> | 76 |
| | 122 | <i>clorazepate dipotassium</i> | 15 | CURAD GAUZE PAD..... | 93 |
| <i>citalopram</i> | 36 | <i>clotrimazole</i> | 42 | CURITY ALCOHOL SWABS | |
| <i>claravis</i> | 82 | <i>clotrimazole-betamethasone</i> | | | 82 |
| <i>clarithromycin</i> | 19 | | 43 | CURITY GAUZE..... | 93 |
| <i>clemastine</i> | 44 | <i>clozapine</i> | 50 | <i>cyanocobalamin (vitamin b-</i> | |
| CLENPIQ | 127 | <i>c-nate dha</i> | 155 | 12) | 155 |
| CLICKFINE PEN NEEDLE | 91 | COARTEM | 47 | <i>cyclobenzaprine</i> | 153 |
| <i>clindamycin hcl</i> | 16 | <i>codeine sulfate</i> | 10 | <i>cyclopentolate</i> | 122 |
| <i>clindamycin in 5 % dextrose</i> | | <i>codeine-butalbital-asa-caff</i> | 10 | <i>cyclophosphamide</i> | 23 |
| | 16 | <i>colchicine</i> | 44 | <i>cyclosporine</i> | 124, 136 |
| <i>clindamycin pediatric</i> | 16 | <i>colesevelam</i> | 69 | <i>cyclosporine modified</i> | 136 |
| <i>clindamycin phosphate</i> | 17, | <i>colestipol</i> | 69 | CYLTEZO(CF)..... | 136 |
| 44, 83 | | <i>colistin (colistimethate na)</i> . 17 | | CYLTEZO(CF) PEN | 136 |
| | | COMBIVENT RESPIMAT | 151 | | |

| | | |
|--------------------------------------|------------|--|
| CYLTEZO(CF) PEN | | |
| CROHN'S-UC-HS..... | 136 | |
| CYLTEZO(CF) PEN | | |
| PSORIASIS-UV..... | 136 | |
| <i>cyproheptadine</i> | 44 | |
| <i>cyred eq</i> | 76 | |
| CYSTADROPS..... | 122 | |
| CYSTARAN..... | 122 | |
| D | | |
| <i>d5 % and 0.9 % sodium</i> | | |
| <i>chloride</i> | 148 | |
| <i>d5 %-0.45 % sodium chloride</i> | | |
| | 148 | |
| <i>dabigatran etexilate</i> | 58 | |
| <i>dalfampridine</i> | 72 | |
| <i>danazol</i> | 129 | |
| <i>dantrolene</i> | 153 | |
| <i>dapaglifloz propaned-</i> | | |
| <i>metformin</i> | 38 | |
| <i>dapagliflozin propanediol</i> .. | 38 | |
| <i>dapsone</i> | 46 | |
| DAPTACEL (DTAP | | |
| PEDIATRIC) (PF)..... | 141 | |
| <i>daptomycin</i> | 17 | |
| <i>darunavir</i> | 54 | |
| <i>dasetta 1/35 (28)</i> | 76 | |
| <i>dasetta 7/7/7 (28)</i> | 76 | |
| DAURISMO..... | 23 | |
| DAYBUE..... | 145 | |
| <i>daysee</i> | 76 | |
| <i>deblitane</i> | 76 | |
| <i>deferasirox</i> | 129 | |
| <i>deferiprone</i> | 129 | |
| <i>deferoxamine</i> | 129 | |
| DELSTRIGO..... | 54 | |
| <i>demeclocycline</i> | 21 | |
| DEPO-SUBQ PROVERA | 104 | |
| | 133 | |
| DERMACEA..... | 93, 94 | |
| DERMACEA NON-WOVEN | | |
| | 94 | |
| DESCOVY..... | 54 | |
| <i>desipramine</i> | 36 | |
| <i>desmopressin</i> | 132 | |
| <i>desog-e.estradiol/e.estradiol</i> | | |
| | 76 | |
| <i>desogestrel-ethinyl estradiol</i> | | |
| | 76 | |
| <i>desonide</i> | 85 | |
| <i>desoximetasone</i> | 85 | |
| <i>desvenlafaxine succinate</i> .. | 36 | |
| <i>dexamethasone</i> | 131 | |
| <i>dexamethasone sodium</i> | | |
| <i>phosphate</i> | 124 | |
| <i>dexmethylphenidate</i> | 72 | |
| <i>dextroamphetamine sulfat</i> e72 | | |
| <i>dextroamphetamine-</i> | | |
| <i>amphetamine</i> | 72 | |
| <i>dextrose 10 % in water</i> | | |
| (<i>d10w</i>)..... | 62 | |
| <i>dextrose 5 % in water (d5w)</i> | | |
| | 62 | |
| DIACOMIT..... | 31, 32 | |
| <i>diazepam</i> | 15, 16, 32 | |
| <i>diazepam intensol</i> | 16 | |
| <i>diazoxide</i> | 145 | |
| <i>diclofenac potassium</i> | 12 | |
| <i>diclofenac sodium</i> 12, 13, 124 | | |
| <i>diclofenac-misoprostol</i> | 13 | |
| <i>dicloxacillin</i> | 20 | |
| <i>dicyclomine</i> | 126 | |
| <i>didanosine</i> | 54 | |
| DIFICID..... | 19 | |
| <i>diflorasone</i> | 85 | |
| <i>diflunisal</i> | 13 | |
| <i>difluprednate</i> | 124 | |
| <i>digitek</i> | 67 | |
| <i>digox</i> | 67 | |
| <i>digoxin</i> | 67 | |
| <i>dihydroergotamine</i> | 45 | |
| DILANTIN..... | 32 | |
| <i>diltiazem hcl</i> | 66 | |
| <i>dilt-xr</i> | 66 | |
| <i>dimethyl fumarate</i> | 72, 73 | |
| DIPENTUM..... | 144 | |
| <i>diphenhydramine hcl</i> | 44 | |
| <i>diphenoxylate-atropine</i> ... | 126 | |
| <i>dipyridamole</i> | 61 | |
| <i>disopyramide phosphate</i> ... | 65 | |
| <i>disulfiram</i> | 15 | |
| <i>divalproex</i> | 32 | |
| <i>dodex</i> | 155 | |
| <i>dofetilide</i> | 65 | |
| <i>donepezil</i> | 35 | |
| DOPTELET (10 TAB PACK) | | |
| | 60 | |
| DOPTELET (15 TAB PACK) | | |
| | 60 | |
| DOPTELET (30 TAB PACK) | | |
| | 60 | |
| <i>dorzolamide</i> | 147 | |
| <i>dorzolamide-timolol</i> | 147 | |
| <i>dorzolamide-timolol (pf)</i> ... | 147 | |
| <i>dotti</i> | 130 | |
| DOVATO..... | 54 | |
| <i>doxazosin</i> | 63 | |
| <i>doxepin</i> | 36 | |
| <i>doxercalciferol</i> | 144 | |
| <i>doxorubicin, peg-liposomal</i> 23 | | |
| <i>doxy-100</i> | 21 | |
| <i>doxycycline hyclate</i> | 21 | |
| <i>doxycycline monohydrate</i> .. | 21 | |
| DRIZALMA SPRINKLE | 36 | |
| <i>dronabinol</i> | 46 | |
| DROPLET INSULIN | | |
| SYR(HALF UNIT)..... | 94 | |
| DROPLET INSULIN | | |
| SYRINGE..... | 94 | |
| DROPLET MICRON PEN | | |
| NEEDLE..... | 95 | |
| DROPLET PEN NEEDLE.. | 95 | |
| DROPSAFE ALCOHOL | | |
| PREP PADS..... | 82 | |
| DROPSAFE INSULIN | | |
| SYRINGE..... | 95 | |

| | | | |
|---------------------------------------|------------|-------------------------------------|---------|
| DROPSAFE PEN NEEDLE | | ENDARI..... | 145 |
| | 95, 96 | <i>endocet</i> | 10 |
| <i>drospirenone-ethinyl estradiol</i> | | ENGERIX-B (PF)..... | 141 |
| | 76 | ENGERIX-B PEDIATRIC | |
| DROXIA | 61 | (PF)..... | 141 |
| <i>droxidopa</i> | 63 | <i>enilloring</i> | 76 |
| DUAVEE | 130 | <i>enoxaparin</i> | 58, 59 |
| <i>duloxetine</i> | 36 | <i>enpresse</i> | 76 |
| DUPIXENT PEN..... | 136 | <i>enskyce</i> | 76 |
| DUPIXENT SYRINGE..... | 136 | ENSPRYNG | 73 |
| <i>dutasteride</i> | 129 | <i>entacapone</i> | 48 |
| <i>dutasteride-tamsulosin</i> | 129 | ENTADFI..... | 129 |
| E | | <i>entecavir</i> | 58 |
| EASY COMFORT ALCOHOL | | ENTRESTO..... | 63 |
| PAD | 82 | <i>enulose</i> | 126 |
| EASY COMFORT INSULIN | | EPCLUSA | 57 |
| SYRINGE | 96, 97 | EPIDIOLEX | 32 |
| EASY COMFORT PEN | | <i>epinastine</i> | 122 |
| NEEDLES..... | 96, 97 | <i>epinephrine</i> | 67 |
| EASY COMFORT SAFETY | | <i>epitol</i> | 32 |
| PEN NEEDLE..... | 96 | <i>eplerenone</i> | 71 |
| EASY GLIDE INSULIN | | <i>epoprostenol</i> | 154 |
| SYRINGE | 97 | EPRONTIA..... | 32 |
| EASY GLIDE PEN NEEDLE | | <i>eprosartan</i> | 63 |
| | 97 | <i>ergocalciferol (vitamin d2)</i> | 155 |
| EASY TOUCH..... | 98 | <i>ergoloid</i> | 35 |
| EASY TOUCH ALCOHOL | | ERIVEDGE..... | 24 |
| PREP PADS | 82 | ERLEADA | 24 |
| EASY TOUCH FLIPLOCK | | <i>erlotinib</i> | 24 |
| INSULIN | 98 | <i>errin</i> | 76 |
| EASY TOUCH FLIPLOCK | | <i>ertapenem</i> | 19 |
| SYRINGE | 97 | <i>ery pads</i> | 83 |
| EASY TOUCH INSULIN | | <i>erythromycin</i> | 19, 123 |
| SAFETY SYR..... | 97 | <i>erythromycin ethylsuccinate</i> | |
| EASY TOUCH INSULIN | | | 19 |
| SYRINGE | 97, 98, 99 | <i>erythromycin with ethanol</i> .. | 83 |
| EASY TOUCH LUER LOCK | | <i>erythromycin-benzoyl</i> | |
| INSULIN | 98 | <i>peroxide</i> | 84 |
| EASY TOUCH PEN NEEDLE | | <i>escitalopram oxalate</i> | 36 |
| | 98 | <i>esomeprazole magnesium</i> | |
| EASY TOUCH SAFETY PEN | | | 125 |
| NEEDLE | 98, 99 | <i>estarylla</i> | 76 |
| | | | |
| EASY TOUCH | | | |
| SHEATHLOCK INSULIN | | | |
| | 97, 98 | | |
| EASY TOUCH UNI-SLIP ... | 99 | | |
| <i>ec-naproxen</i> | 13 | | |
| <i>econazole</i> | 43 | | |
| EDARBI..... | 63 | | |
| EDARBYCLOR | 63 | | |
| EDURANT..... | 54 | | |
| <i>efavirenz</i> | 54 | | |
| <i>efavirenz-emtricitabin-tenofov</i> | | | |
| | 54 | | |
| <i>efavirenz-lamivu-tenofov</i> | | | |
| <i>disop</i> | 55 | | |
| EGRIFTA SV..... | 132 | | |
| <i>electrolyte-148</i> | 148 | | |
| ELIGARD | 24 | | |
| ELIGARD (3 MONTH)..... | 23 | | |
| ELIGARD (4 MONTH)..... | 23 | | |
| ELIGARD (6 MONTH)..... | 24 | | |
| <i>elinest</i> | 76 | | |
| ELIQUIS | 58 | | |
| ELIQUIS DVT-PE TREAT | | | |
| 30D START | 58 | | |
| ELLA | 76 | | |
| ELMIRON..... | 145 | | |
| <i>eluryng</i> | 76 | | |
| EMBRACE PEN NEEDLE..... | 99 | | |
| EMCYT..... | 24 | | |
| EMEND | 46 | | |
| EMGALITY PEN..... | 45 | | |
| EMGALITY SYRINGE | 45 | | |
| EMSAM | 36 | | |
| <i>emtricitabine</i> | 55 | | |
| <i>emtricitabine-tenofovir (tdf)</i> | 55 | | |
| EMTRIVA | 55 | | |
| <i>enalapril maleate</i> | 64 | | |
| <i>enalapril-hydrochlorothiazide</i> | | | |
| | 64 | | |
| ENBREL..... | 136 | | |
| ENBREL MINI | 136 | | |
| ENBREL SURECLICK ... | 136 | | |

| | | | | | |
|---------------------------------------|-----|---------------------------------------|----------|---------------------------------------|-----|
| <i>estazolam</i> | 16 | <i>fenofibrate micronized</i> | 69 | <i>fluoxetine</i> | 36 |
| <i>estradiol</i> | 130 | <i>fenofibrate nanocrystallized</i> | | <i>fluphenazine decanoate</i> ... | 50 |
| <i>estradiol valerate</i> | 130 | | 70 | <i>fluphenazine hcl</i> | 50 |
| <i>estradiol-norethindrone acet</i> | | <i>fenofibric acid (choline)</i> | 70 | <i>flurbiprofen</i> | 13 |
| | 130 | <i>fenoprofen</i> | 13 | <i>flurbiprofen sodium</i> | 124 |
| <i>eszopiclone</i> | 154 | <i>fentanyl</i> | 11 | <i>fluticasone furoate-vilanterol</i> | |
| <i>ethambutol</i> | 46 | <i>fentanyl citrate</i> | 10, 11 | | 150 |
| <i>ethosuximide</i> | 32 | FERRIPROX..... | 129 | <i>fluticasone propionate</i> | 85, |
| <i>ethynodiol diac-eth estradiol</i> | | FERRIPROX (2 TIMES A | | 124, 150 | |
| | 76 | DAY)..... | 129 | <i>fluticasone propion-</i> | |
| <i>etodolac</i> | 13 | <i>fesoterodine</i> | 128 | <i>salmeterol</i> | 150 |
| <i>etonogestrel-ethinyl estradiol</i> | | FETZIMA..... | 36 | <i>fluvastatin</i> | 70 |
| | 76 | FIASP FLEXTOUCH U-100 | | <i>fluvoxamine</i> | 36 |
| <i>etravirine</i> | 55 | INSULIN..... | 40 | <i>folic acid</i> | 155 |
| EUCRISA..... | 85 | FIASP PENFILL U-100 | | <i>folivane-ob</i> | 155 |
| EVENITY..... | 144 | INSULIN..... | 40 | <i>fondaparinux</i> | 59 |
| <i>everolimus (antineoplastic)</i> 24 | | FIASP U-100 INSULIN..... | 40 | FORTEO..... | 145 |
| <i>everolimus</i> | | FILSPARI..... | 146 | <i>fosamprenavir</i> | 55 |
| (<i>immunosuppressive</i>) .. | 136 | <i>finasteride</i> | 129 | <i>fosaprepitant</i> | 46 |
| EVOTAZ..... | 55 | <i> fingolimod</i> | 73 | <i>fosfomycin tromethamine</i> .. | 17 |
| EVRYSDI..... | 146 | FINTEPLA..... | 32 | <i>fosinopril</i> | 64 |
| EXEL INSULIN..... | 99 | FIRMAGON KIT W DILUENT | | <i>fosinopril-hydrochlorothiazide</i> | |
| <i>exemestane</i> | 24 | SYRINGE..... | 24 | | 64 |
| EXKIVITY..... | 24 | FIRVANQ..... | 17 | FOTIVDA..... | 24 |
| EYSUVIS..... | 124 | <i>flavoxate</i> | 128 | FREESTYLE PRECISION | |
| EZALLOR SPRINKLE..... | 69 | FLEBOGAMMA DIF..... | 136 | | 100 |
| <i>ezetimibe</i> | 69 | <i>flecainide</i> | 65 | FRUZAQLA..... | 24 |
| <i>ezetimibe-simvastatin</i> | 69 | FLOVENT DISKUS . | 149, 150 | FULPHILA..... | 60 |
| F | | FLOVENT HFA..... | 150 | <i>furosemide</i> | 68 |
| <i>falmina (28)</i> | 77 | <i>fluconazole</i> | 43 | FUZEON..... | 55 |
| <i>famciclovir</i> | 58 | <i>fluconazole in nacl (iso-osm)</i> | | <i>fyavolv</i> | 130 |
| <i>famotidine</i> | 125 | | 43 | FYCOMPA..... | 32 |
| FANAPT..... | 50 | <i>flucytosine</i> | 43 | FYLNETRA..... | 60 |
| FARXIGA..... | 38 | <i>fludrocortisone</i> | 131 | G | |
| FARYDAK..... | 24 | <i>flunisolide</i> | 124 | <i>gabapentin</i> | 32 |
| FASENRA..... | 152 | <i>fluocinolone</i> | 85 | GALAFOLD..... | 121 |
| FASENRA PEN..... | 152 | <i>fluocinolone acetonide oil</i> | 124 | <i>galantamine</i> | 35 |
| <i>febuxostat</i> | 44 | <i>fluocinonide</i> | 85 | GAMMAGARD LIQUID ... | 136 |
| <i>felbamate</i> | 32 | <i>fluocinonide-emollient</i> | 85 | GAMMAGARD S-D (IGA < 1 | |
| <i>felodipine</i> | 68 | <i>fluoride (sodium)</i> | 81 | MCG/ML)..... | 137 |
| FEMRING..... | 130 | <i>fluorometholone</i> | 124 | GAMMAPLEX..... | 137 |
| <i>fenofibrate</i> | 70 | <i>fluorouracil</i> | 82, 83 | | |

| | | | | | |
|--|-------------|--------------------------------------|----------|---|-----|
| GAMMAPLEX (WITH SORBITOL) | 137 | GVOKE PFS 2-PACK SYRINGE | 146 | HUMIRA(CF) PEDI CROHNS STARTER | 137 |
| GAMUNEX-C | 137 | H | | HUMIRA(CF) PEN | 138 |
| GARDASIL 9 (PF) | 141 | HADLIMA | 137 | HUMIRA(CF) PEN CROHNS-UC-HS | 138 |
| <i>gatifloxacin</i> | 123 | HADLIMA PUSHTOUCH | 137 | HUMIRA(CF) PEN PEDIATRIC UC | 138 |
| GATTEX 30-VIAL | 126 | HADLIMA(CF) | 137 | HUMIRA(CF) PEN PSOR-UV-ADOL HS | 138 |
| GAUZE PAD | 100 | HADLIMA(CF) PUSHTOUCH | 137 | HUMULIN R U-500 (CONC) INSULIN | 40 |
| <i>gavilyte-c</i> | 127 | HAEGARDA | 60 | HUMULIN R U-500 (CONC) KWIKPEN | 40 |
| <i>gavilyte-g</i> | 127 | <i>hailey</i> | 77 | <i>hydralazine</i> | 67 |
| GAVRETO | 24 | <i>hailey 24 fe</i> | 77 | <i>hydrochlorothiazide</i> | 68 |
| <i>gefitinib</i> | 24 | <i>hailey fe 1.5/30 (28)</i> | 77 | <i>hydrocodone-acetaminophen</i> | 11 |
| <i>gemfibrozil</i> | 70 | <i>hailey fe 1/20 (28)</i> | 77 | <i>hydrocodone-ibuprofen</i> | 11 |
| <i>gemmily</i> | 77 | <i>halobetasol propionate</i> | 85 | <i>hydrocortisone</i> 85, 86, 131, 144 | |
| <i>generlac</i> | 126 | <i>haloette</i> | 77 | <i>hydrocortisone butyrate</i> 85 | |
| <i>gengraf</i> | 137 | <i>haloperidol</i> | 51 | <i>hydrocortisone valerate</i> 86 | |
| <i>gentamicin</i> | 16, 84, 123 | <i>haloperidol decanoate</i> | 51 | <i>hydrocortisone-acetic acid</i> | 123 |
| GENVOYA | 55 | <i>haloperidol lactate</i> | 51 | <i>hydrocortisone-min oil-wht pet</i> | 86 |
| GILENYA | 73 | HARVONI | 57 | <i>hydromorphone</i> | 11 |
| GILOTRIF | 24 | HAVRIX (PF) | 141 | <i>hydromorphone (pf)</i> | 11 |
| <i>glatiramer</i> | 73 | HEALTHWISE INSULIN SYRINGE | 100 | <i>hydroxychloroquine</i> | 47 |
| <i>glatopa</i> | 73 | HEALTHWISE PEN NEEDLE | 100, 101 | <i>hydroxyurea</i> | 24 |
| GLEOSTINE | 24 | HEALTHY ACCENTS UNIFINE PENTIP | 101 | <i>hydroxyzine hcl</i> | 44 |
| <i>glimepiride</i> | 42 | <i>heather</i> | 77 | <i>hydroxyzine pamoate</i> | 146 |
| <i>glipizide</i> | 42 | HEMADY | 131 | HYRIMOZ PEN CROHN'S-UC STARTER | 138 |
| <i>glipizide-metformin</i> | 42 | <i>heparin (porcine)</i> | 59 | HYRIMOZ PEN PSORIASIS STARTER | 138 |
| <i>glyburide</i> | 42 | HEPLISAV-B (PF) | 141 | HYRIMOZ(CF) | 138 |
| <i>glyburide micronized</i> | 42 | HETLIOZ | 154 | HYRIMOZ(CF) PEDI CROHN STARTER | 138 |
| <i>glyburide-metformin</i> | 42 | HETLIOZ LQ | 154 | HYRIMOZ(CF) PEN | 138 |
| <i>glycopyrrolate</i> | 126 | HIBERIX (PF) | 141 | I | |
| <i>glydo</i> | 14 | HULIO(CF) | 137 | <i>ibandronate</i> | 145 |
| GLYXAMBI | 38 | HULIO(CF) PEN | 137 | | |
| <i>granisetron (pf)</i> | 47 | HUMIRA | 137 | | |
| <i>granisetron hcl</i> | 47 | HUMIRA PEN | 137 | | |
| GRANIX | 60 | HUMIRA PEN CROHNS-UC-HS START | 137 | | |
| <i>griseofulvin microsize</i> | 43 | HUMIRA PEN PSOR-UVEITS-ADOL HS | 137 | | |
| <i>griseofulvin ultramicrosize</i> | 43 | HUMIRA(CF) | 138 | | |
| <i>guanfacine</i> | 63, 73 | | | | |
| GVOKE | 146 | | | | |
| GVOKE HYPOPEN 2-PACK | 146 | | | | |
| GVOKE PFS 1-PACK SYRINGE | 146 | | | | |

| | | | | |
|-----------------------------------|--------|---------------------------------------|-------------------------------------|--------|
| IBRANCE | 24, 25 | <i>insulin asp prt-insulin aspart</i> | <i>isosorbide dinitrate</i> | 71 |
| <i>ibu</i> | 13 | | <i>isosorbide mononitrate</i> | 71 |
| <i>ibuprofen</i> | 13 | <i>insulin aspart u-100</i> | <i>isosorbide-hydralazine</i> | 71 |
| <i>ibuprofen-famotidine</i> | 13 | <i>insulin degludec</i> | <i>isotretinoin</i> | 83 |
| <i>icatibant</i> | 67 | <i>insulin glargine</i> | <i>isradipine</i> | 68 |
| <i>iclevia</i> | 77 | <i>insulin glargine u-300 conc</i> | <i>itraconazole</i> | 43 |
| ICLUSIG | 25 | <i>insulin glargine-yfgn</i> | IV PREP WIPES | 83 |
| <i>icosapent ethyl</i> | 70 | <i>insulin lispro</i> | <i>ivermectin</i> | 47 |
| IDHIFA | 25 | <i>insulin lispro protamin-lispro</i> | IWILFIN | 25 |
| <i>ifosfamide</i> | 25 | | IXIARO (PF) | 141 |
| ILEVRO | 124 | INSULIN SYR/NDL U100 | J | |
| ILUMYA | 138 | HALF MARK | <i>jaimiess</i> | 77 |
| <i>imatinib</i> | 25 | INSULIN SYRINGE | JAKAFI | 25 |
| IMBRUVICA | 25 | INSULIN SYRINGE | <i>jantoven</i> | 59 |
| <i>imipenem-cilastatin</i> | 19 | MICROFINE | JARDIANCE | 38 |
| <i>imipramine hcl</i> | 36 | INSULIN SYRINGE | <i>jasmiel (28)</i> | 77 |
| <i>imipramine pamoate</i> | 37 | NEEDLELESS | <i>javygtor</i> | 121 |
| <i>imiquimod</i> | 83 | INSULIN SYRINGE-NEEDLE | JAYPIRCA | 25 |
| IMOVAX RABIES VACCINE | | U-100 89, 90, 99, 100, 101, | <i>jencycla</i> | 77 |
| (PF) | 141 | 102, 108, 112 | JENTADUETO | 38 |
| IMPAVIDO | 47 | INSUPEN PEN NEEDLE. | JENTADUETO XR | 38 |
| INBRIJA | 48 | INTELENCE | <i>jinteli</i> | 130 |
| <i>incassia</i> | 77 | INTRALIPID | <i>jolessa</i> | 77 |
| INCONTROL ALCOHOL | | INVEGA HAFYERA | <i>juleber</i> | 77 |
| PADS | 83 | INVEGA SUSTENNA | JULUCA | 55 |
| INCONTROL PEN NEEDLE | | INVEGA TRINZA | <i>junel 1.5/30 (21)</i> | 77 |
| | 101 | INVELTYS | <i>junel 1/20 (21)</i> | 77 |
| INCRELEX | 132 | IPOL | <i>junel fe 1.5/30 (28)</i> | 77 |
| <i>indapamide</i> | 68 | <i>ipratropium bromide</i> | <i>junel fe 1/20 (28)</i> | 77 |
| <i>indomethacin</i> | 13 | <i>ipratropium-albuterol</i> | <i>junel fe 24</i> | 77 |
| INFANRIX (DTAP) (PF) .. | 141 | <i>irbesartan</i> | JUXTAPID | 70 |
| <i>infliximab</i> | 138 | <i>irbesartan-</i> | JYNARQUE | 68, 69 |
| INGREZZA | 73 | <i>hydrochlorothiazide</i> | JYNNEOS (PF) | 141 |
| INGREZZA INITIATION | | IRESSA | K | |
| PACK | 73 | ISENTRESS | <i>kalliga</i> | 77 |
| INLYTA | 25 | ISENTRESS HD | KALYDECO | 152 |
| INPEN (FOR HUMALOG) | | <i>isibloom</i> | <i>kariva (28)</i> | 77 |
| BLUE | 101 | ISOLYTE S PH 7.4 | KATERZIA | 68 |
| INPEN (NOVOLOG OR | | ISOLYTE-P IN 5 % | <i>kelnor 1/35 (28)</i> | 77 |
| FIASP) BLUE | 101 | DEXTROSE | <i>kelnor 1-50 (28)</i> | 77 |
| INQOVI | 25 | ISOLYTE-S | KERENDIA | 71 |
| INREBIC | 25 | <i>isoniazid</i> | KESIMPTA PEN | 73 |

| | | | | | |
|--|---------|--|--------|--|-------------|
| <i>ketoconazole</i> | 43 | LATUDA | 51 | LISCO | 102 |
| <i>ketoprofen</i> | 13 | <i>ledipasvir-sofosbuvir</i> | 57 | <i>lisinopril</i> | 64 |
| <i>ketorolac</i> | 13, 125 | <i>leena 28</i> | 78 | <i>lisinopril-hydrochlorothiazide</i> | 64 |
| KEVZARA | 138 | <i>leflunomide</i> | 138 | LITE TOUCH INSULIN PEN NEEDLES | 102, 103 |
| KINERET..... | 138 | <i>lenalidomide</i> | 26 | LITE TOUCH INSULIN SYRINGE | 102, 103 |
| KINRIX (PF) | 141 | LENVIMA | 26 | <i>lithium carbonate</i> | 73 |
| KISQALI | 25, 26 | <i>lessina</i> | 78 | <i>lithium citrate</i> | 73 |
| KISQALI FEMARA CO-PACK | 25 | <i>letrozole</i> | 26 | LIVALO..... | 70 |
| KLISYRI | 83 | <i>leucovorin calcium</i> | 146 | <i>lojaimiess</i> | 78 |
| <i>klor-con m10</i> | 148 | LEUKERAN | 26 | LOKELMA | 127 |
| <i>klor-con m15</i> | 148 | LEUKINE..... | 60 | LONSURF | 26 |
| <i>klor-con m20</i> | 148 | <i>leuprolide</i> | 26 | <i>loperamide</i> | 127 |
| KLOXXADO | 15 | <i>leuprolide (3 month)</i> | 26 | <i>lopinavir-ritonavir</i> | 55 |
| KORLYM..... | 38 | <i>levalbuterol tartrate</i> | 151 | <i>lorazepam</i> | 16 |
| KOSELUGO | 26 | <i>levetiracetam</i> | 33 | <i>lorazepam intensol</i> | 16 |
| <i>kosher prenatal plus iron</i> . | 155 | <i>levobunolol</i> | 147 | LORBRENA | 26 |
| KOURZEQ | 82 | <i>levocarnitine</i> | 146 | <i>loryna (28)</i> | 78 |
| KRAZATI..... | 26 | <i>levocarnitine (with sugar)</i> 146 | | <i>losartan</i> | 63 |
| KRINTAFEL | 48 | <i>levocetirizine</i> | 44 | <i>losartan-hydrochlorothiazide</i> | 63 |
| <i>kurvelo (28)</i> | 77 | <i>levofloxacin</i> . 20, 21, 122, 123 | | LOTEMAX..... | 125 |
| KYNMOBI..... | 48 | <i>levofloxacin in d5w</i> | 20 | LOTEMAX SM..... | 125 |
| L | | <i>levoleucovorin calcium</i> | 146 | <i>loteprednol etabonate</i> | 125 |
| <i>l norgest/e.estradiol-e.estrad</i> | 78 | <i>levonest (28)</i> | 78 | <i>lovastatin</i> | 70 |
| <i>labetalol</i> | 65 | <i>levonorgest-eth.estradiol-iron</i> | 78 | <i>low-ogestrel (28)</i> | 78 |
| <i>lacosamide</i> | 32 | <i>levonorgestrel-ethinyl estrad</i> | 78 | <i>loxapine succinate</i> | 51 |
| <i>lactulose</i> | 126 | <i>levonorg-eth estrad triphasic</i> | 78 | <i>lo-zumandimine (28)</i> | 78 |
| <i>lagevrio (eua)</i> | 58 | <i>levora-28</i> | 78 | <i>lubiprostone</i> | 127 |
| <i>lamivudine</i> | 55 | <i>levothyroxine</i> | 134 | LUMAKRAS | 26 |
| <i>lamivudine-zidovudine</i> | 55 | LEVOXYL..... | 134 | LUMIGAN..... | 147 |
| <i>lamotrigine</i> | 32, 33 | LEXIVA..... | 55 | LUPRON DEPOT | 132 |
| <i>lanreotide</i> | 132 | <i>lidocaine</i> | 14 | LUPRON DEPOT (3 MONTH) | 26, 132 |
| <i>lansoprazole</i> | 126 | <i>lidocaine (pf)</i> | 14, 65 | LUPRON DEPOT (4 MONTH) | 26 |
| <i>lanthanum</i> | 128 | <i>lidocaine hcl</i> | 14 | LUPRON DEPOT (6 MONTH) | 26 |
| <i>lapatinib</i> | 26 | <i>lidocaine viscous</i> | 14 | LUPRON DEPOT-PED .. | 132, 133 |
| <i>larin 1.5/30 (21)</i> | 78 | <i>lidocaine-prilocaine</i> | 14 | | |
| <i>larin 1/20 (21)</i> | 78 | <i>linezolid</i> | 17 | | |
| <i>larin 24 fe</i> | 78 | <i>linezolid in dextrose 5%</i> | 17 | | |
| <i>larin fe 1.5/30 (28)</i> | 78 | LINZESS | 126 | | |
| <i>larin fe 1/20 (28)</i> | 78 | <i>liothyronine</i> | 134 | | |
| <i>latanoprost</i> | 147 | | | | |

| | | | | | |
|-------------------------------------|-----|--------------------------------------|----------|---|------------|
| LUPRON DEPOT-PED (3 MONTH) | 132 | MAXI-COMFORT INSULIN SYRINGE | 104 | <i>methsuximide</i> | 33 |
| <i>lurasidone</i> | 51 | MAXI-COMFORT INSULIN SYRINGE | 104 | <i>methyl dopa</i> | 63 |
| <i>lutea (28)</i> | 78 | MAXICOMFORT SAFETY PEN NEEDLE | 104 | <i>methylphenidate hcl</i> | 74 |
| LYBALVI | 51 | MAYZENT | 73, 74 | <i>methylprednisolone</i> | 131 |
| <i>lyleq</i> | 78 | MAYZENT STARTER(FOR 1MG MAINT) | 74 | <i>methylprednisolone acetate</i> | 131 |
| <i>lyllana</i> | 130 | MAYZENT STARTER(FOR 2MG MAINT) | 74 | <i>methylprednisolone sodium succ</i> | 131 |
| LYNPARZA | 26 | <i>meclizine</i> | 47 | <i>metoclopramide hcl</i> | 127 |
| LYSODREN | 26 | <i>medroxyprogesterone</i> ... | 133, 134 | <i>metolazone</i> | 69 |
| LYTGOBI..... | 27 | <i>mefenamic acid</i> | 13 | <i>metoprolol succinate</i> | 65 |
| <i>lyza</i> | 78 | <i>mefloquine</i> | 48 | <i>metoprolol ta-hydrochlorothiaz</i> | 66 |
| M | | <i>megestrol</i> | 27, 134 | <i>metoprolol tartrate</i> | 66 |
| MAGELLAN INSULIN SAFETY SYRNG | 103 | MEKINIST | 27 | <i>metronidazole</i> | 17, 45, 84 |
| MAGELLAN SYRINGE ... | 103 | MEKTOVI..... | 27 | <i>metronidazole in nacl (iso-os)</i> | 17 |
| <i>magnesium sulfate</i> | 148 | <i>meloxicam</i> | 13 | <i>metyrosine</i> | 67 |
| <i>malathion</i> | 87 | <i>memantine</i> | 35 | <i>mexiletine</i> | 65 |
| <i>maraviroc</i> | 55 | MENACTRA (PF) | 141 | <i>miconazole-3</i> | 43 |
| <i>marlissa (28)</i> | 78 | MENQUADFI (PF)..... | 142 | MICRODOT INSULIN PEN NEEDLE | 104 |
| <i>marnatal-f</i> | 155 | MENVEO A-C-Y-W-135-DIP (PF)..... | 142 | <i>microgestin 1.5/30 (21)</i> | 78 |
| MARPLAN..... | 37 | <i>mercaptopurine</i> | 27 | <i>microgestin 1/20 (21)</i> | 79 |
| MATULANE..... | 27 | <i>meropenem</i> | 19 | <i>microgestin 24 fe</i> | 79 |
| <i>matzim la</i> | 66 | <i>merzee</i> | 78 | <i>microgestin fe 1.5/30 (28)</i> .. | 79 |
| MAVENCLAD (10 TABLET PACK)..... | 73 | <i>mesalamine</i> | 144 | <i>microgestin fe 1/20 (28)</i> | 79 |
| MAVENCLAD (4 TABLET PACK)..... | 73 | MESNEX..... | 146 | <i>midazolam</i> | 16 |
| MAVENCLAD (5 TABLET PACK)..... | 73 | <i>metadate er</i> | 74 | <i>midodrine</i> | 63 |
| MAVENCLAD (6 TABLET PACK)..... | 73 | <i>metformin</i> | 38, 39 | <i>miglitol</i> | 39 |
| MAVENCLAD (7 TABLET PACK)..... | 73 | <i>methadone</i> | 11 | <i>miglustat</i> | 121 |
| MAVENCLAD (8 TABLET PACK)..... | 73 | <i>methadose</i> | 11 | <i>mili</i> | 79 |
| MAVENCLAD (9 TABLET PACK)..... | 73 | <i>methazolamide</i> | 147 | MILLIPRED | 131 |
| MAVYRET..... | 58 | <i>methenamine hippurate</i> | 17 | MILLIPRED DP | 131 |
| MAXICOMFORT II PEN NEEDLE | 103 | <i>methimazole</i> | 134 | <i>mimvey</i> | 131 |
| MAXICOMFORT INSULIN SYRINGE | 104 | <i>methocarbamol</i> | 153 | MINI ULTRA-THIN II | 104 |
| | | <i>methotrexate sodium</i> | 27 | <i>minocycline</i> | 21 |
| | | <i>methotrexate sodium (pf)</i> .. | 27 | <i>minoxidil</i> | 71 |
| | | <i>methoxsalen</i> | 83 | <i>mirtazapine</i> | 37 |
| | | <i>methscopolamine</i> | 127 | <i>misoprostol</i> | 126 |
| | | | | M-M-R II (PF) | 142 |
| | | | | <i>m-natal plus</i> | 155 |

| | | | | | |
|---------------------------------------|----------|------------------------------------|-----|---------------------------------------|---------|
| <i>modafinil</i> | 154 | <i>naloxone</i> | 15 | <i>nitrofurantoin macrocrystal</i> | 17 |
| <i>moexipril</i> | 64 | <i>naltrexone</i> | 15 | <i>nitrofurantoin monohyd/m-</i> | |
| <i>molindone</i> | 52 | NAMZARIC | 35 | <i>cryst</i> | 17 |
| <i>mometasone</i> | 86, 125 | <i>naproxen</i> | 14 | <i>nitroglycerin</i> | 71 |
| <i>mondoxyne nl</i> | 21 | <i>naratriptan</i> | 45 | <i>niva-plus</i> | 155 |
| MONOJECT INSULIN | | NATAACYN | 123 | NIVESTYM..... | 60 |
| SAFETY SYRING..... | 105 | <i>nateglinide</i> | 39 | <i>nizatidine</i> | 126 |
| MONOJECT INSULIN | | NATPARA | 145 | <i>nora-be</i> | 79 |
| SYRINGE | 104, 105 | NAYZILAM | 33 | NORDITROPIN FLEXPRO | |
| MONOJECT SYRINGE ... | 104 | <i>nebivolol</i> | 66 | | 133 |
| MONOJECT ULTRA | | <i>necon 0.5/35 (28)</i> | 79 | <i>norelgestromin-ethin.estradiol</i> | |
| COMFORT INSULIN ... | 116 | <i>nefazodone</i> | 37 | | 79 |
| <i>mono-lynyah</i> | 79 | <i>neomycin</i> | 16 | <i>norethindrone (contraceptive)</i> | |
| <i>montelukast</i> | 150 | <i>neomycin-bacitracin-poly-hc</i> | | | 79 |
| <i>morphine</i> | 11 | | 123 | <i>norethindrone acetate</i> | 134 |
| MORPHINE..... | 11 | <i>neomycin-bacitracin-</i> | | <i>norethindrone ac-eth</i> | |
| <i>morphine concentrate</i> | 11 | <i>polymyxin</i> | 123 | <i>estradiol</i> | 79, 131 |
| MOUNJARO..... | 39 | <i>neomycin-polymyxin b-</i> | | <i>norethindrone-e.estradiol-iron</i> | |
| MOVANTIK | 127 | <i>dexameth</i> | 123 | | 79 |
| <i>moxifloxacin</i> | 21, 123 | <i>neomycin-polymyxin-</i> | | <i>norgestimate-ethinyl estradiol</i> | |
| <i>moxifloxacin-sod.ace,sul-</i> | | <i>gramicidin</i> | 123 | | 79 |
| <i>water</i> | 21 | <i>neomycin-polymyxin-hc</i> ... | 123 | <i>nortrel 0.5/35 (28)</i> | 79 |
| <i>moxifloxacin-sod.chloride(iso)</i> | | <i>neo-polycin</i> | 123 | <i>nortrel 1/35 (21)</i> | 79 |
| | 21 | <i>neo-polycin hc</i> | 123 | <i>nortrel 1/35 (28)</i> | 79 |
| MULTAQ | 65 | NERLYNX | 27 | <i>nortrel 7/7/7 (28)</i> | 79 |
| <i>mupirocin</i> | 84 | <i>neuac</i> | 84 | <i>nortriptyline</i> | 37 |
| <i>mycophenolate mofetil</i> | 139 | NEULASTA | 60 | NORVIR | 56 |
| <i>mycophenolate mofetil (hcl)</i> | | NEUPRO..... | 49 | NOVOFINE 30..... | 105 |
| | 139 | <i>nevirapine</i> | 55 | NOVOFINE 32..... | 105 |
| <i>mycophenolate sodium</i> ... | 139 | <i>newgen</i> | 155 | NOVOFINE PLUS | 105 |
| <i>mynatal</i> | 155 | NEXLETOL | 70 | NOVOLIN 70/30 U-100 | |
| <i>mynatal advance</i> | 155 | NEXLIZET | 70 | INSULIN | 41 |
| <i>mynatal plus</i> | 155 | <i>niacin</i> | 70 | NOVOLIN 70-30 FLEXPEN | |
| <i>mynatal-z</i> | 155 | <i>niacor</i> | 70 | U-100..... | 41 |
| <i>mynate 90 plus</i> | 155 | <i>nicardipine</i> | 68 | NOVOLIN N FLEXPEN | 41 |
| MYRBETRIQ..... | 128 | NICOTROL..... | 15 | NOVOLIN N NPH U-100 | |
| N | | <i>nifedipine</i> | 68 | INSULIN | 41 |
| <i>nabumetone</i> | 13 | <i>nikki (28)</i> | 79 | NOVOLIN R FLEXPEN | 41 |
| <i>nadolol</i> | 66 | <i>nilutamide</i> | 27 | NOVOLIN R REGULAR | |
| <i>nafcillin</i> | 20 | NINLARO | 27 | U100 INSULIN..... | 41 |
| <i>nafcillin in dextrose iso-osm</i> | | <i>nitazoxanide</i> | 48 | NOVOTWIST | 105 |
| | 20 | <i>nitisinone</i> | 121 | NOXAFIL..... | 43 |

| | | | | | |
|--|----------|--------------------------------------|-----|---|-----|
| NUBEQA..... | 27 | OMNIPOD 5 G6 PODS (GEN 5) | 106 | <i>pantoprazole</i> | 126 |
| NUCALA..... | 152, 153 | OMNIPOD CLASSIC PODS (GEN 3) | 106 | <i>paricalcitol</i> | 145 |
| NUPLAZID | 52 | OMNIPOD DASH INTRO KIT (GEN 4) | 106 | <i>paroex oral rinse</i> | 82 |
| NURTEC ODT..... | 45 | OMNIPOD DASH PDM KIT (GEN 4) | 106 | <i>paromomycin</i> | 48 |
| NUTRILIPID | 62 | OMNIPOD DASH PODS (GEN 4) | 106 | <i>paroxetine hcl</i> | 37 |
| <i>nyamyc</i> | 43 | <i>ondansetron</i> | 47 | PAXLOVID | 57 |
| <i>nylia 1/35 (28)</i> | 79 | <i>ondansetron hcl</i> | 47 | <i>pazopanib</i> | 27 |
| <i>nylia 7/7/7 (28)</i> | 79 | <i>ondansetron hcl (pf)</i> | 47 | PEDIARIX (PF)..... | 142 |
| <i>nymyo</i> | 79 | ONGENTYS | 49 | PEDVAX HIB (PF)..... | 142 |
| <i>nystatin</i> | 43 | ONUREG | 27 | <i>peg 3350-electrolytes</i> | 127 |
| <i>nystatin-triamcinolone</i> | 43 | OPSUMIT..... | 154 | PEGASYS | 58 |
| <i>nystop</i> | 44 | <i>oralone</i> | 82 | <i>peg-electrolyte soln</i> | 127 |
| NYVEPRIA..... | 60 | ORENCIA..... | 139 | PEMAZYRE | 27 |
| O | | ORENCIA CLICKJECT ... | 139 | PEN NEEDLE . 100, 106, 108 | |
| <i>obstetrix dha</i> | 156 | ORFADIN | 121 | PEN NEEDLE, DIABETIC 93, 104, 106, 108 | |
| <i>obstetrix dha prenatal duo</i> | 155 | ORGOVYX | 133 | PEN NEEDLE, DIABETIC, SAFETY..... | 109 |
| <i>o-cal prenatal</i> | 156 | ORILISSA..... | 133 | PENBRAYA (PF)..... | 142 |
| OICALIVA..... | 127 | ORKAMBI..... | 153 | <i>penciclovir</i> | 83 |
| <i>ocella</i> | 79 | ORSERDU | 27 | <i>penicillamine</i> | 129 |
| OCTAGAM..... | 139 | <i>oseltamivir</i> | 57 | <i>penicillin g potassium</i> | 20 |
| <i>octreotide acetate</i> | 133 | OSMOLEX ER | 49 | <i>penicillin g procaine</i> | 20 |
| ODEFSEY | 56 | OTEZLA | 139 | <i>penicillin v potassium</i> | 20 |
| ODOMZO | 27 | OTEZLA STARTER | 139 | PENTACEL (PF) | 142 |
| OFEV | 153 | <i>oxandrolone</i> | 129 | <i>pentamidine</i> | 48 |
| <i>ofloxacin</i> | 123 | <i>oxazepam</i> | 16 | PENTIPS..... | 106 |
| OGSIVEO..... | 27 | <i>oxcarbazepine</i> | 33 | <i>pentoxifylline</i> | 61 |
| OJJAARA | 27 | <i>oxybutynin chloride</i> | 128 | <i>perindopril erbumine</i> | 64 |
| <i>olanzapine</i> | 52 | <i>oxycodone</i> | 11 | <i>perlogard</i> | 82 |
| <i>olmesartan</i> | 63 | <i>oxycodone-acetaminophen</i> | 12 | <i>permethrin</i> | 87 |
| <i>olmesartan-amlodipin-hcthiiazid</i> | 63 | OXYCONTIN..... | 12 | <i>perphenazine</i> | 52 |
| <i>olmesartan-hydrochlorothiazide</i> | 63 | <i>oxymorphone</i> | 12 | <i>perphenazine-amitriptyline</i> | 37 |
| <i>olopatadine</i> | 122 | OZEMPIC..... | 39 | PERSERIS | 52 |
| OLUMIANT..... | 139 | P | | <i>pfizerpen-g</i> | 20 |
| <i>omega-3 acid ethyl esters</i> | 70 | <i>pacerone</i> | 65 | <i>phenelzine</i> | 37 |
| <i>omeprazole</i> | 126 | <i>paliperidone</i> | 52 | <i>phenobarbital</i> | 33 |
| <i>omeprazole-sodium bicarbonate</i> | 126 | PALYNZIQ | 121 | <i>phenylephrine hcl</i> | 63 |
| OMNIPOD 5 G6 INTRO KIT (GEN 5) | 105 | PANRETIN | 83 | <i>phenytoin</i> | 33 |
| | | | | <i>phenytoin sodium extended</i> | 33 |
| | | | | <i>philith</i> | 79 |

| | | | | | |
|--------------------------------------|----------|---------------------------------------|---------------|------------------------------------|--------|
| PHOSLYRA..... | 128 | <i>pravastatin</i> | 70 | PRIVIGEN..... | 139 |
| PIFELTRO..... | 56 | <i>prazosin</i> | 63 | PRO COMFORT ALCOHOL | |
| <i>pilocarpine hcl</i> | 82, 147 | <i>prednicarbate</i> | 86 | PADS..... | 83 |
| <i>pimecrolimus</i> | 86 | <i>prednisolone</i> | 131 | PRO COMFORT INSULIN | |
| <i>pimozide</i> | 52 | <i>prednisolone acetate</i> | 125 | SYRINGE | 107 |
| <i>pimtree (28)</i> | 80 | <i>prednisolone sodium</i> | | PRO COMFORT PEN | |
| <i>pindolol</i> | 66 | <i>phosphate</i> | 125, 131, 132 | NEEDLE | 107 |
| <i>pioglitazone</i> | 39 | <i>prednisone</i> | 132 | PROAIR RESPICLICK ... | 151 |
| <i>pioglitazone-metformin</i> | 39 | PREDNISONE INTENSOL | | <i>probenecid</i> | 44 |
| PIP PEN NEEDLE..... | 107 | | 132 | <i>probenecid-colchicine</i> | 44 |
| <i>piperacillin-tazobactam</i> | 20 | <i>pregabalin</i> | 33 | <i>procainamide</i> | 65 |
| PIQRAY | 27, 28 | PREHEVBRIO (PF)..... | 142 | <i>prochlorperazine</i> | 47 |
| <i>pirfenidone</i> | 153 | PREMARIN | 131 | <i>prochlorperazine maleate</i> .. | 47 |
| <i>pirmella</i> | 80 | PREMPHASE..... | 131 | <i>procto-med hc</i> | 86 |
| <i>piroxicam</i> | 14 | PREMPRO | 131 | <i>proctosol hc</i> | 86 |
| <i>pitavastatin calcium</i> | 70 | <i>prena1 true</i> | 156 | <i>proctozone-hc</i> | 86 |
| PLASMA-LYTE 148 | 148 | <i>prenaissance</i> | 156 | PRODIGY INSULIN | |
| PLASMA-LYTE A..... | 148 | <i>prenaissance plus</i> | 156 | SYRINGE | 107 |
| PLEGRIDY | 74 | <i>prenatabs fa</i> | 156 | <i>progesterone</i> | 134 |
| <i>pnv 29-1</i> | 156 | <i>prenatal 19</i> | 156 | <i>progesterone micronized</i> .. | 134 |
| <i>pnv-dha + docusate</i> | 156 | <i>prenatal 19 (with docusate)</i> | | PROGRAF | 139 |
| <i>pnv-omega</i> | 156 | | 156 | PROLASTIN-C | 153 |
| <i>podofilox</i> | 83 | <i>prenatal low iron</i> | 156 | PROLENSA..... | 125 |
| <i>polycin</i> | 123 | <i>prenatal plus</i> | 156 | PROLIA | 145 |
| <i>polymyxin b sulfate</i> | 17 | <i>prenatal plus (calcium carb)</i> | | PROMACTA..... | 60 |
| <i>polymyxin b sulf-trimethoprim</i> | | | 156 | <i>promethazine</i> | 44, 47 |
| | 123 | <i>prenatal vitamin plus low iron</i> | | <i>promethegan</i> | 47 |
| POMALYST..... | 28 | | 156 | <i>propafenone</i> | 65 |
| <i>portia 28</i> | 80 | <i>prenatal-u</i> | 156 | <i>proparacaine</i> | 122 |
| <i>posaconazole</i> | 44 | <i>preplus</i> | 156 | <i>propranolol</i> | 66 |
| <i>potassium chloride</i> .. | 148, 149 | <i>pretab</i> | 156 | <i>propranolol-</i> | |
| <i>potassium chloride-0.45 %</i> | | PRETOMANID | 46 | <i>hydrochlorothiazid</i> | 66 |
| <i>nacl</i> | 149 | <i>prevalite</i> | 70 | <i>propylthiouracil</i> | 134 |
| <i>potassium citrate</i> | 149 | PREVENT DROPSAFE PEN | | PROQUAD (PF)..... | 142 |
| <i>pr natal 400</i> | 156 | NEEDLE | 107 | PROSOL 20 % | 62 |
| <i>pr natal 400 ec</i> | 156 | PREVYMIS..... | 57 | <i>protiptyline</i> | 37 |
| <i>pr natal 430</i> | 156 | PREZCOBIX | 56 | PULMOZYME | 121 |
| <i>pr natal 430 ec</i> | 156 | PREZISTA..... | 56 | PURE COMFORT ALCOHOL | |
| PRADAXA..... | 59 | PRIFTIN | 46 | PADS..... | 83 |
| PRALUENT PEN..... | 70 | PRIMAQUINE | 48 | PURE COMFORT PEN | |
| <i>pramipexole</i> | 49 | <i>primidone</i> | 33 | NEEDLE | 108 |
| <i>prasugrel</i> | 61 | PRIORIX (PF) | 142 | | |

| | | | | |
|--------------------------------------|------------------------------------|----------|---------------------------------------|-----|
| PURE COMFORT SAFETY | RETEVMO | 28 | SANTYL | 83 |
| PEN NEEDLE..... | REVCovi | 121 | <i>sapropterin</i> | 121 |
| PURIXAN | REXULTI | 52 | SAVELLA | 75 |
| <i>pyrazinamide</i> | REYATAZ..... | 56 | SCEMBLIX | 28 |
| <i>pyridostigmine bromide</i> ... | REZLIDHIA | 28 | <i>scopolamine base</i> | 47 |
| <i>pyrimethamine</i> | REZUROCK | 139 | SECUADO | 53 |
| Q | RHOPRESSA..... | 147 | SECURESAFE INSULIN | |
| QINLOCK | <i>ribavirin</i> | 58 | SYRINGE | 109 |
| QUADRACEL (PF)..... | RIDAURA..... | 139 | SECURESAFE PEN | |
| <i>quetiapine</i> | <i>rifabutin</i> | 46 | NEEDLE | 109 |
| <i>quinapril</i> | <i>rifampin</i> | 46 | <i>select-ob</i> | 156 |
| <i>quinapril-hydrochlorothiazide</i> | <i>rilpivirine</i> | 56 | <i>select-ob (folic acid)</i> | 156 |
| | <i>riluzole</i> | 74 | <i>selegiline hcl</i> | 49 |
| <i>quinidine gluconate</i> | <i>rimantadine</i> | 57 | <i>selenium sulfide</i> | 84 |
| <i>quinidine sulfate</i> | RINVOQ | 139 | SELZENTRY | 56 |
| <i>quinine sulfate</i> | <i>risedronate</i> | 145 | SEMGLEE(INSULIN | |
| QULIPTA..... | RISPERDAL CONSTA | 52 | GLARGINE-YFGN)..... | 41 |
| R | <i>risperidone</i> | 52, 53 | SEMGLEE(INSULIN | |
| RABAVERT (PF)..... | <i>ritonavir</i> | 56 | GLARG-YFGN)PEN | 41 |
| <i>rabeprazole</i> | <i>rivastigmine</i> | 35 | <i>se-natal 19 chewable</i> | 156 |
| RADICAVA..... | <i>rivastigmine tartrate</i> | 35 | SEREVENT DISKUS..... | 151 |
| <i>raloxifene</i> | <i>rizatriptan</i> | 45 | SEROSTIM | 133 |
| <i>ramipril</i> | <i>r-natal ob</i> | 156 | <i>sertraline</i> | 37 |
| <i>ranolazine</i> | ROCKLATAN | 147 | <i>setlakin</i> | 80 |
| <i>rasagiline</i> | <i>roflumilast</i> | 153 | <i>sevelamer carbonate</i> | 128 |
| RASUVO (PF)..... | <i>ropinirole</i> | 49 | <i>sevelamer hcl</i> | 128 |
| RAVICTI | <i>rosadan</i> | 84 | <i>sharobel</i> | 80 |
| RAYALDEE | <i>rosuvastatin</i> | 70 | SHINGRIX (PF)..... | 143 |
| <i>reclipsen (28)</i> | ROTARIX | 142 | SIGNIFOR..... | 133 |
| RECOMBIVAX HB (PF) .. | ROTATEQ VACCINE | 143 | SIKLOS | 61 |
| RECTIV | ROZLYTREK..... | 28 | <i>sildenafil</i> | 154 |
| REGRANEX | RUBRACA..... | 28 | <i>sildenafil (pulm.hypertension)</i> | |
| RELENZA DISKHALER | <i>rufinamide</i> | 33 | | 154 |
| RELEUKO..... | RUKOBIA..... | 56 | <i>silodosin</i> | 129 |
| RELION NEEDLES | RYBELSUS | 39 | <i>silver sulfadiazine</i> | 84 |
| RELION PEN NEEDLES. | RYDAPT..... | 28 | SIMBRINZA..... | 147 |
| RELISTOR | S | | <i>simliya (28)</i> | 80 |
| <i>repaglinide</i> | SAFESNAP INSULIN | | <i>simpesse</i> | 80 |
| REPATHA PUSHTRONEX70 | SYRINGE | 108, 109 | <i>simvastatin</i> | 71 |
| REPATHA SURECLICK.... | SAFETY PEN NEEDLE... 109 | | <i>sirolimus</i> | 139 |
| REPATHA SYRINGE | SAIZEN | 133 | SIRTURO | 46 |
| RETACRIT | <i>sajazir</i> | 67 | | |

| | | | | | |
|---|----------|---|----------|--|---------|
| SKY SAFETY PEN NEEDLE | 109 | STRIVERDI RESPIMAT .. | 152 | SYMBICORT | 150 |
| SKYRIZI | 139, 140 | SUBLOCADE | 15 | SYMDEKO | 153 |
| SLYND | 80 | <i>subvenite</i> | 34 | SYMJEPI | 67 |
| <i>sodium chloride 0.45 %</i> ... | 149 | <i>sucalfate</i> | 126 | SYMLINPEN 120 | 39 |
| <i>sodium chloride 0.9 %</i> | 149 | <i>sulfacetamide sodium</i> | 123, 124 | SYMLINPEN 60 | 39 |
| <i>sodium fluoride-pot nitrate</i> .. | 82 | <i>sulfacetamide sodium (acne)</i> .. | 84 | SYMPAZAN | 34 |
| <i>sodium oxybate</i> | 154 | <i>sulfacetamide-prednisolone</i> .. | 124 | SYMTUZA | 56 |
| <i>sodium phenylbutyrate</i> | 127 | <i>sulfadiazine</i> | 21 | SYNAREL | 133 |
| <i>sodium polystyrene sulfonate</i> .. | 127 | <i>sulfamethoxazole-trimethoprim</i> .. | 21 | SYNJARDY | 39 |
| <i>sodium, potassium, magnesium sulfates</i> .. | 128 | <i>sulfasalazine</i> | 144 | SYNJARDY XR | 39 |
| <i>solifenacin</i> | 128 | <i>sulfatrim</i> | 21 | SYNRIBO | 28 |
| SOLIQUA 100/33 | 41 | <i>sulindac</i> | 14 | SYNTHROID | 134 |
| SOLTAMOX | 28 | <i>sumatriptan</i> | 45 | SYRINGE WITH NEEDLE, SAFETY .. | 109 |
| SOMATULINE DEPOT ... | 133 | <i>sumatriptan succinate</i> | 45 | T | |
| SOMAVERT | 133 | <i>sumatriptan-naproxen</i> | 46 | TABLOID | 28 |
| <i>sorafenib</i> | 28 | <i>sunitinib malate</i> | 28 | TABRECTA | 28 |
| <i>sorine</i> | 66 | SUNLENCA | 56 | <i>tacrolimus</i> | 86, 140 |
| <i>sotalol</i> | 66 | SUNOSI | 154 | <i>tadalafil</i> | 154 |
| <i>sotalol af</i> | 66 | SUPREP BOWEL PREP KIT | 128 | <i>tadalafil (pulm. hypertension)</i> .. | 154 |
| SPIRIVA RESPIMAT | 151 | SURE COMFORT ALCOHOL PREP PADS .. | 83 | TAFINLAR | 28, 29 |
| SPIRIVA WITH HANDIHALER | 151 | SURE COMFORT INS. SYR. U-100 .. | 109 | <i>tafluprost (pf)</i> | 147 |
| <i>spironolactone</i> | 69 | SURE COMFORT INSULIN SYRINGE .. | 109, 110 | TAGRISSE | 29 |
| <i>spironolactone-hydrochlorothiaz</i> .. | 69 | SURE COMFORT PEN NEEDLE | 110 | TAKHZYRO | 146 |
| SPRAVATO | 37 | SURE COMFORT SAFETY PEN NEEDLE .. | 109 | TALTZ AUTOINJECTOR .. | 140 |
| <i>sprintec (28)</i> | 80 | SURE-FINE PEN NEEDLES | 110 | TALTZ SYRINGE | 140 |
| SPRITAM | 33, 34 | SURE-JECT INSULIN SYRINGE | 110 | TALZENNA | 29 |
| SPRYCEL | 28 | SURE-PREP ALCOHOL PREP PADS .. | 83 | <i>tamoxifen</i> | 29 |
| <i>sps (with sorbitol)</i> | 127 | SUTAB | 128 | <i>tamsulosin</i> | 129 |
| <i>sronyx</i> | 80 | <i>syeda</i> | 80 | <i>tarina 24 fe</i> | 80 |
| <i>ssd</i> | 84 | | | <i>tarina fe 1-20 eq (28)</i> | 80 |
| <i>stavudine</i> | 56 | | | <i>taron-c dha</i> | 156 |
| STELARA | 140 | | | <i>taron-prex prenatal-dha</i> .. | 156 |
| STERILE PADS | 109 | | | TASCENSO ODT | 75 |
| STIOLTO RESPIMAT | 151 | | | TASIGNA | 29 |
| STIVARGA | 28 | | | <i>tasimelteon</i> | 154 |
| <i>streptomycin</i> | 16 | | | TAVALISSE | 61 |
| STRIBILD | 56 | | | <i>taysofy</i> | 80 |
| | | | | <i>tazarotene</i> | 86 |
| | | | | <i>tazicef</i> | 18 |
| | | | | TAZORAC | 86 |

| | | | | | |
|--------------------------------------|----------|--------------------------------------|--------------|--|--------|
| <i>taztia xt</i> | 67 | <i>tiagabine</i> | 34 | <i>trazodone</i> | 37 |
| TAZVERIK..... | 29 | TIBSOVO | 29 | TRECATOR | 46 |
| TDVAX | 143 | TICE BCG | 29 | TRELEGY ELLIPTA | 152 |
| TECHLITE INSULIN | | TICOVAC | 143 | TRELSTAR | 29 |
| SYRINGE | 111 | <i>tigecycline</i> | 21 | TREMFYA..... | 140 |
| TECHLITE INSULN | | <i>tilia fe</i> | 80 | <i>treprostinil sodium</i> | 155 |
| SYR(HALF UNIT) 110, 111 | | <i>timolol maleate</i> .. | 66, 147, 148 | <i>tretinoin</i> | 86 |
| TECHLITE PEN NEEDLE | | <i>tinidazole</i> | 48 | <i>tretinoin (antineoplastic)</i> | 29 |
| | 111, 112 | <i>tiopronin</i> | 129 | <i>triamcinolone acetonide</i> ... | 82, |
| TEFLARO..... | 18 | <i>tiotropium bromide</i> | 152 | 86, 132 | |
| <i>telmisartan</i> | 64 | TIVICAY | 56 | <i>triamterene-</i> | |
| <i>telmisartan-amlodipine</i> | 64 | TIVICAY PD | 56 | <i>hydrochlorothiazid</i> | 69 |
| <i>telmisartan-</i> | | <i>tizanidine</i> | 153 | <i>trianex</i> | 86 |
| <i>hydrochlorothiazid</i> | 64 | TOBI PODHALER..... | 16 | <i>triazolam</i> | 16 |
| <i>temazepam</i> | 16 | <i>tobramycin</i> | 16, 124 | <i>triderm</i> | 86 |
| TEMIXYS | 56 | <i>tobramycin in 0.225 % nacl</i> 16 | | <i>trientine</i> | 129 |
| <i>tencon</i> | 12 | <i>tobramycin sulfate</i> | 16 | <i>tri-estarylla</i> | 80 |
| TENIVAC (PF)..... | 143 | <i>tobramycin-dexamethasone</i> | | <i>trifluoperazine</i> | 53 |
| <i>tenofovir disoproxil fumarate</i> | | | 124 | <i>trifluridine</i> | 124 |
| | 56 | <i>tolterodine</i> | 128, 129 | <i>trihexyphenidyl</i> | 49 |
| TEPMETKO | 29 | TOPCARE CLICKFINE ... | 112 | TRIJARDY XR..... | 39, 40 |
| <i>terazosin</i> | 129 | TOPCARE ULTRA | | TRIKAFTA..... | 153 |
| <i>terbinafine hcl</i> | 44 | COMFORT | 112 | <i>tri-legest fe</i> | 80 |
| <i>terbutaline</i> | 152 | <i>topiramate</i> | 34 | <i>tri-linyah</i> | 80 |
| <i>terconazole</i> | 45 | <i>toremifene</i> | 29 | <i>tri-lo-estarylla</i> | 80 |
| <i>teriflunomide</i> | 75 | <i>torse mide</i> | 69 | <i>tri-lo-marzia</i> | 80 |
| TERUMO INSULIN | | TOUJEO MAX U-300 | | <i>tri-lo-mili</i> | 80 |
| SYRINGE | 112 | SOLOSTAR..... | 42 | <i>tri-lo-sprintec</i> | 80 |
| <i>testosterone</i> | 130 | TOUJEO SOLOSTAR U-300 | | <i>trimethoprim</i> | 17 |
| <i>testosterone cypionate</i> | 129 | INSULIN | 42 | <i>tri-mili</i> | 80 |
| <i>testosterone enanthate</i> ... | 130 | TPN ELECTROLYTES.... | 149 | <i>trimipramine</i> | 37 |
| TETANUS,DIPHThERIA | | TPN ELECTROLYTES II. | 149 | TRINTELLIX..... | 37 |
| TOX PED(PF)..... | 143 | TRACLEER | 154 | <i>tri-nymyo</i> | 81 |
| <i>tetrabenazine</i> | 75 | TRADJENTA | 39 | <i>tri-sprintec (28)</i> | 81 |
| <i>tetracycline</i> | 21 | <i>tramadol</i> | 12 | TRIUMEQ..... | 56 |
| THALOMID..... | 146 | <i>tramadol-acetaminophen</i> ... 12 | | TRIUMEQ PD..... | 56 |
| <i>theophylline</i> | 152 | <i>trandolapril</i> | 64 | <i>triveen-duo dha</i> | 156 |
| THINPRO INSULIN | | <i>trandolapril-verapamil</i> | 65 | <i>trivora (28)</i> | 81 |
| SYRINGE | 112 | <i>tranexamic acid</i> | 61 | <i>tri-vylibra</i> | 81 |
| <i>thioridazine</i> | 53 | <i>tranylcypromine</i> | 37 | <i>tri-vylibra lo</i> | 81 |
| <i>thiothixene</i> | 53 | TRAVASOL 10 % | 62 | TRIZIVIR | 56 |
| <i>tiadylt er</i> | 67 | <i>travoprost</i> | 148 | TROPHAMINE 10 % | 62 |

| | | | | | |
|---|----------|--|--------------|--|----------|
| <i>trosipium</i> | 129 | ULTICARE SAFETY PEN NEEDLE | 115 | UNIFINE PENTIPS PLUS MAXFLOW | 119 |
| TRUE COMFORT ALCOHOL PADS..... | 83 | ULTIGUARD SAFEPAK- INSULIN SYR | 115, 116 | UNIFINE PROTECT..... | 119 |
| TRUE COMFORT INSULIN SYRINGE | 113 | ULTIGUARD SAFEPAK- PEN NEEDLE..... | 115, 116 | UNIFINE SAFECONTROL | 119 |
| TRUE COMFORT PEN NEEDLE | 113 | ULTILET ALCOHOL SWAB | 83 | UNIFINE ULTRA PEN NEEDLE | 119, 120 |
| TRUE COMFORT PRO ALCOHOL PADS..... | 83 | ULTILET INSULIN SYRINGE | 102, 116 | UPTRAVI..... | 155 |
| TRUE COMFORT PRO INS SYRINGE | 112, 113 | ULTILET PEN NEEDLE .. | 116 | <i>ursodiol</i> | 127 |
| TRUE COMFORT SAFETY PEN NEEDLE..... | 113 | ULTRA CMFT INS SYR (HALF UNIT)..... | 100, 109 | UZEDY | 53 |
| TRUEPLUS INSULIN..... | 114 | ULTRA COMFORT INSULIN SYRINGE | 96, 100, 116 | V | |
| TRUEPLUS PEN NEEDLE | 114 | ULTRA FLO INSUL SYR(HALF UNIT) 116, 117 | | <i>valacyclovir</i> | 58 |
| TRULICITY..... | 40 | ULTRA FLO INSULIN SYRINGE | 117 | VALCHLOR..... | 83 |
| TRUMENBA..... | 143 | ULTRA FLO PEN NEEDLE | 117 | <i>valganciclovir</i> | 58 |
| TRUQAP | 29 | ULTRA THIN PEN NEEDLE | 117 | <i>valproic acid</i> | 34 |
| TUKYSA..... | 29 | ULTRACARE INSULIN SYRINGE | 117 | <i>valproic acid (as sodium salt)</i> | 34 |
| <i>tulana</i> | 81 | ULTRACARE PEN NEEDLE | 117, 118 | <i>valsartan</i> | 64 |
| TURALIO..... | 29 | ULTRA-THIN II (SHORT) INS SYR..... | 118 | <i>valsartan-hydrochlorothiazide</i> | 64 |
| <i>turqoz (28)</i> | 81 | ULTRA-THIN II (SHORT) PEN NDL | 118 | VALTOCO | 34 |
| TWINRIX (PF)..... | 143 | ULTRA-THIN II INS PEN NEEDLES..... | 118 | <i>vancomycin</i> | 17 |
| <i>tyblume</i> | 81 | ULTRA-THIN II INSULIN SYRINGE | 118 | VANFLYTA..... | 29 |
| TYBOST..... | 146 | UNIFINE PEN NEEDLE .. | 118 | VANISHPOINT INSULIN SYRINGE | 120 |
| TYMLOS | 145 | UNIFINE PENTIPS 106, 118, 119 | | VANISHPOINT SYRINGE | 120 |
| TYPHIM VI | 143 | UNIFINE PENTIPS MAXFLOW | 119 | VAQTA (PF) | 143 |
| TYVASO..... | 155 | UNIFINE PENTIPS PLUS | 119 | <i>varenicline</i> | 15 |
| U | | | | VARIVAX (PF)..... | 143 |
| UBRELVY | 46 | | | <i>velivet triphasic regimen (28)</i> | 81 |
| UCERIS | 144 | | | VELPHORO | 128 |
| UDENYCA..... | 61 | | | VELTASSA..... | 127 |
| UDENYCA AUTOINJECTOR | 61 | | | VEMLIDY | 57 |
| ULTICARE | 115 | | | VENCLEXTA..... | 29 |
| ULTICARE INSULIN SYRINGE | 114 | | | VENCLEXTA STARTING PACK..... | 30 |
| ULTICARE INSULN SYR(HALF UNIT) | 114 | | | <i>venlafaxine</i> | 37, 38 |
| ULTICARE PEN NEEDLE | 115 | | | <i>venlafaxine besylate</i> | 37 |
| | | | | <i>verapamil</i> | 67 |

| | | | |
|------------------------------|---------------------------|--------|-----------------------------------|
| VERIFINE INSULIN | <i>vp-pnv-dha</i> | 157 | Y |
| SYRINGE | VRAYLAR | 53 | <i>yargesa</i> |
| VERIFINE PEN NEEDLE | VUMERITY | 75 | YF-VAX (PF) |
| VERIFINE PLUS PEN | <i>vyfemla (28)</i> | 81 | YONSA |
| NEEDLE | <i>vylibra</i> | 81 | YUSIMRY(CF) PEN |
| VERIFINE PLUS PEN | VYZULTA | 148 | <i>yuvaferm</i> |
| NEEDLE-SHARP | W | | Z |
| VERQUVO | <i>warfarin</i> | 59 | <i>zafemy</i> |
| VERSACLOZ | WEBCOL | 83 | <i>zafirlukast</i> |
| VERSALON | WELIREG | 30 | <i>zaleplon</i> |
| VERZENIO | <i>wera (28)</i> | 81 | <i>zarah</i> |
| <i>vestura (28)</i> | <i>wixela inhub</i> | 150 | ZARXIO |
| V-GO 20 | X | | <i>zatean-pn dha</i> |
| V-GO 30 | XADAGO | 49 | <i>zatean-pn plus</i> |
| V-GO 40 | XALKORI | 30 | <i>zebutal</i> |
| <i>vienna</i> | XARELTO | 59 | ZEGALOGUE |
| <i>vigabatrin</i> | XARELTO DVT-PE TREAT | | AUTOINJECTOR |
| <i>vigadrone</i> | 30D START | 59 | ZEGALOGUE SYRINGE |
| <i>vigpoder</i> | XATMEP | 30 | ZEJULA |
| VIIBRYD | XCOPRI | 34 | ZELBORAF |
| <i>vilazodone</i> | XCOPRI MAINTENANCE | | <i>zenatane</i> |
| <i>vinate care</i> | PACK | 34 | ZENPEP |
| <i>viorele (28)</i> | XCOPRI TITRATION PACK | | <i>zidovudine</i> |
| VIRACEPT | | 34 | ZIEXTENZO |
| VIREAD | XELJANZ | 140 | <i>zingiber</i> |
| <i>virt-c dha</i> | XELJANZ XR | 140 | <i>ziprasidone hcl</i> |
| <i>virt-nate dha</i> | XERMELO | 127 | <i>ziprasidone mesylate</i> |
| <i>virt-pn dha</i> | XGEVA | 145 | ZIRGAN |
| <i>virt-pn plus</i> | XHANCE | 125 | ZOLADEX |
| <i>vitafol gummies</i> | XIFAXAN | 17 | <i>zoledronic acid-mannitol-</i> |
| <i>vitafol nano</i> | XIGDUO XR | 40 | <i>water</i> |
| <i>vitafol-ob+dha</i> | XIIDRA | 125 | ZOLINZA |
| VITRAKVI | XOFLUZA | 57 | <i>zolmitriptan</i> |
| VIZIMPRO | XOLAIR | 153 | <i>zolpidem</i> |
| VOCABRIA | XOSPATA | 30 | ZOMACTON |
| <i>volnea (28)</i> | XPOVIO | 30 | ZONISADE |
| VONJO | XTAMPZA ER | 12 | <i>zonisamide</i> |
| <i>voriconazole</i> | XTANDI | 30, 31 | <i>zovia 1-35 (28)</i> |
| VOSEVI | <i>xulane</i> | 81 | ZTALMY |
| VOTRIENT | XULTOPHY 100/3.6 | 42 | ZTLIDO |
| VOWST | XYOSTED | 130 | <i>zumandimine (28)</i> |
| <i>vp-ch-pnv</i> | XYREM | 154 | ZURZUVAE |

ZYDELIG..... 31
ZYKADIA..... 31

ZYLET 124
ZYPREXA RELPREVV 54

Multi-Language Insert

Multi-Language Interpreter Services

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-844-969-5366. Someone who speaks English/Language can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-844-969-5366. Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-844-969-5366。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-844-969-5366。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggagamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa 1-844-969-5366. Maaari kayong tulungan ng isang nakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-844-969-5366. Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-844-969-5366 sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-844-969-5366. Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 답해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-844-969-5366 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-844-969-5366. Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: لدينا خدمات ترجمة فورية مجانية للإجابة على أي أسئلة قد تكون لديكم حول خطتنا الصحية أو الدوائية. للحصول على مترجم فوري، ما عليك سوى الاتصال بنا على 1-844-969-5366 يمكن لشخص يتحدث الإنجليزية / اللغة مساعدتك. هذه خدمة مجانية.



Multi-Language Insert

Multi-Language Interpreter Services

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं। एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-844-969-5366 पर फोन करें। कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है। यह एक मुफ्त सेवा है।

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-844-969-5366. Un nostro incaricato che parla Italianovi fornirà l'assistenza necessaria. È un servizio gratuito.

Portuguese: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-844-969-5366. Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-844-969-5366. Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-844-969-5366. Ta usługa jest bezpłatna.

Japanese: 当社の健康 健康保険と薬品 処方薬プランに関するご質問にお答えするために、無料の通訳サービスがあります。通訳をご用命になるには 1-844-969-5366 にお電話ください。日本語を話す人者が支援いたします。これは無料のサービスです。





This formulary was updated on 03/19/2024.
For more recent information or other questions, please contact Leon Health's Member Services Department at the toll-free number (844) 969-5366, or our local number (305) 541-5366. (TTY users should call 711). Hours of operation are from 8 a.m. to 8 p.m., seven days a week from October 1st through March 31st, and Monday through Friday the rest of the year, or visit www.leonhealth.com.